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Chapter 1
Introduction
The highly sophisticated network of cooperating neurons within the central nervous
system (CNS) requires stringent homeostasis of its environment for proper function.
This homeostasis is maintained by the endothelial blood-brain barrier (BBB), which
protects the CNS from the changing milieu of the bloodstream by strictly limiting
passage of molecules and cells. However, another highly sophisticated network of
cells, which composes the immune system, requires trafficking of its cellular compo-
nents through the whole organism to guarantee immunosurveillance. Trafficking of
lymphocytes from the bloodstream into tissues is not random, but strictly regulated.
Taken together, the necessity of stringent regulation of the CNS micromilieu on the
one hand and immunosurveillance on the other hand suggests unique mechanisms
for lymphocyte recruitment across the endothelial BBB into the CNS.
1.1 The blood-brain barrier
Normal function of neurons within the brain and spinal cord requires a homeostatic
microenvironment, which is maintained by the blood-brain barrier. However, the
high metabolic needs of CNS tissue demand a close connection to the bloodstream
to mediate transport of nutrients into the CNS and toxic metabolites out of the
CNS.
The barrier between the blood and the brain was discovered in the early 20th
century. Paul Ehrlich described the way in which intravenously injected dyes could
be detected in all organs but the CNS (Ehrlich, 1904). However, while he inter-
preted these findings as a lack of affinity of the CNS for these dyes, his fellow
1
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researcher Goldmann modified the experiment and injected the same dyes into the
cerebrospinal fluid. In that way, CNS tissue was stained while peripheral organs
kept unstained (Goldmann, 1913). Goldmann concluded that there must be a dye-
impermeable blood-brain barrier, which also serves as a functional brain-blood bar-
rier. Although this compartmentalization of the brain was described that early,
decades passed before Reese and Karnovsky could structurally describe the BBB
(Reese and Karnovsky, 1967). Enhancing the procedures established by Ehrlich
and Goldmann, they injected horseradish peroxidase intravenously, which could be
visualized by electron microscopy. Diffusion of horseradish peroxidase from the
bloodstream into the CNS was limited by special endothelial cell-to-cell contacts,
the tight junctions (TJ). Therefore, interendothelial TJ are the morphological cor-
relate of the BBB. In addition, BBB endothelial cells contain few if any pinocytotic
vesicles, thereby strictly limiting diffusion of hydrophilic substances from the blood-
stream to the CNS parenchyma and vice versa, which results in a high transelectrical
resistance (Crone and Olesen, 1982). However, specialized transport mechanisms
guarantee specific exchange of metabolites between the bloodstream and the CNS
parenchyma.
TJ at the blood-brain barrier endothelium have been demonstrated to be more
complex than TJ of other endothelial cells in the body. While complexity of the
strands is one feature of the tight junctional network, association of the TJ particles
with the protoplasmic leaflet (P-face) or the exoplasmic leaflet (E-face) of the mem-
brane is another criterion to correlate their morphology and physiology. TJ particles
of BBB endothelial cells remain mostly at the P-face, in contrast to other endothelial
cells (Wolburg et al., 1994). This suggests a special cytoplasmic anchorage of TJ as-
sociated proteins to the cytoskeleton. Occludin and claudins seem to be specifically
located within TJ particles (Tsukita and Furuse, 1998; Morita et al., 1999). Of the
to-date more than 20 members of the claudin gene-family, claudin-3 and claudin-5
are localized within human and mouse endothelial cells within the CNS (Wolburg
et al., 2003). Functionally, loss of claudin-5 has recently been shown to result in
size-selective loosening of the BBB in vivo, suggesting a loss of TJ consistency (Nitta
et al., 2003).
Development of the cerebral vascular system begins by vasculogenesis when meso-
dermally originating angioblasts enter the head region and form the perineural
3Figure 1.1.1: Cellular components of the blood-brain barrier (modified from Engelhardt et al.,
1997)
plexus. Perineural plexus-derived vascular sprouts grow into the developing neu-
roectoderm, which is called angiogenesis (Risau and Wolburg, 1990). Therefore,
BBB endothelial cells are mesodermally and not neuroectodermally derived. Trans-
plantation studies have demonstrated, that vessels derived from the coelomic cavity,
when growing in an embryonic ectopic brain transplant, gain BBB characteristics
(Stewart and Wiley, 1981). Thus, development of BBB characteristics in endothe-
lial cells is not pre-determined but rather induced by surrounding neuroectoderm.
Additionally, culture of BBB endothelial cells in vitro results in loss of specific BBB
properties. Therefore, an interaction between endothelial cells and surrounding CNS
parenchyma is necessary for BBB maintenance (Figure 1.1.1). Despite these find-
ings, factors which are involved in either BBB development or maintenance could
not be identified yet. Also remaining unsolved is the question of which cell type
or combination of cell types within the neuroectoderm induces BBB characteris-
tics in endothelium. There are several potential candidates. BBB endothelial cells
are surrounded by a basal membrane containing a large number of pericytes most
likely being required for vessel maturation (Sims, 1986; Lindahl et al., 1997). Ad-
ditionally, this basal membrane is nearly completely covered by astrocytic endfeet.
This close proximity as well as the temporal correlation of astrocytic vascular sheet
formation and BBB permeability development suggests an important role of astro-
cytes in BBB development. This is underlined by the fact that coculture models
of endothelial cells and astrocytes in vitro improve blood-brain barrier character-
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istics compared to endothelial monocultures (Cecchelli et al., 1999). Furthermore,
microglial cells or macrophages located within the perivascular space (Hickey and
Kimura, 1988) have been reported to be able to phagocytose and present antigen
after activation (Rieske et al., 1989). Therefore, they have been suggested to form
a second line of defense within the CNS, while a possible role in differentiation and
maintenance of the BBB characteristics has not been elucidated yet. In conclusion,
the BBB is formed by endothelial cells. However, although their interactions with
the surrounding parenchyma is required for its development and maintenance, open
questions remain about the molecular means of these interactions.
1.2 Multiple sclerosis and experimental autoim-
mune encephalomyelitis
Because of the presence of the BBB, the absence of lymphatic vessels and the lack
of antigen-presentation, the CNS is considered as an immunoprivileged organ. The
first to describe this functionality was Sir Peter Medawar, who showed that allo-
genic, ectopic tissue transplants were not rejected for long periods of time after
transplantation into the CNS, while they were rejected quickly after transplantation
into other organs (Medawar, 1948). Under physiological conditions, lymphocyte
entry across the BBB into the CNS is low, but has been described for activated
T cells which are able to access the CNS parenchyma in Lewis rats disregarding
their antigen specificity in vivo (Wekerle et al., 1986; Hickey et al., 1991). During
viral infection of cells within the CNS, recruitment of mononuclear cells into the
CNS has been described (Griffin et al., 1992). Therefore, immune cells readily gain
access to the CNS under pathological conditions, which can also be seen during
inflammatory diseases of the CNS, such as multiple sclerosis (MS).
MS is an inflammatory demyelinating disease of the CNS during which mononu-
clear cells gain access to the CNS parenchyma (Martin and McFarland, 1995). Al-
though MS was first described around 1835 (Cruveilhier, 1830 – 1842), its etiology is
still unknown. It has been suggested that specific genetic predisposition and a viral
infection during childhood are a prerequisite to trigger disease during adulthood by
additional infections and environmental factors (Sibley et al., 1985; Poser, 1994). MS
disease courses are classified to be either relapsing-remitting, progressive-remitting,
5secondary-progressive or primary-progressive. MS therapy either targets symptoms
to increase life quality or to globally modulate immune functions with either corti-
coids, interferon-β or copolymer 1 (Beck et al., 1992; Jacobs et al., 1995; Johnson
et al., 1995). Besides these treatments with general immunomodulatory effects,
there is hope that future therapeutics will more directly modulate MS pathogenesis.
Clinical trials with humanized antibodies against α4-integrin are currently ongoing
(Miller et al., 2003). Such reagents could be developed using the animal model for
MS best known today, experimental autoimmune encephalomyelitis (EAE).
EAE is an inflammatory disease of the CNS causing focal areas of inflamma-
tion within the CNS, which are called perivascular infiltrates or inflammatory cuffs
(Levine, 1974). The disease is accompanied by edema formation and demyelina-
tion of the CNS resulting in an ascending paralysis (Martin and McFarland, 1995).
EAE was first described in the late 19th century, when Louis Pasteur used inac-
tivated rabies virus particles purified from rabbit brains to develop a vaccination
therapy against rabies, which resulted in lethal neuroparalytic complications (Pas-
teur, 1885). The same disease could be induced by injecting brain preparations from
healthy rabbits into monkeys (Rivers et al., 1933), thereby proving that brain tissue
contaminations in the rabies virus particle purifications were able to induce EAE.
Addition of adjuvant removed the necessity for multiple injections and markedly
reduced the time till onset of disease (Kabat et al., 1947). Later on, analysis of
different fractions of spinal cord homogenate allowed identification of myelin basic
protein (MBP) as the first autoantigen being usable for induction of EAE (Laatsch
et al., 1962). Additionally, myelin oligodendrocytic glycoprotein (MOG) as well as
proteolipid protein (PLP) were identified to be encephalitogenic (Zamvil and Stein-
man, 1990; Linington et al., 1993). Specific peptides of these proteins were identified
as the encephalitogenic agents (Tuohy et al., 1989; Adelmann et al., 1995). Whereas
all these molecules are constituents of the myelin sheets being formed by oligoden-
drocytes, injection of astrocytic S100β protein did also result in a disease resembling
EAE (Kojima et al., 1994). While active immunization of animals with encephal-
itogenic autoantigens causes active EAE (aEAE), transfer of T lymphocytes from
EAE afflicted rats into untreated syngeneic animals caused transfer EAE (tEAE),
but serumtransfusion did not propagate the disease (Paterson, 1960). Later experi-
ments established MBP antigen specific T cell lines from rat in vitro, which could be
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used to induce EAE in healthy syngeneic animals (Ben-Nun et al., 1981). Therefore,
EAE is mediated by T cells, which were further characterized to be CD4+ CD8−
TH1 lymphoblasts. EAE can only be induced in specific susceptible animal strains,
indicating the necessity for a specific genetic background. While basic mechanisms
of EAE in different susceptible animal strains are the same, there are specific dif-
ferences as well. On the one hand, in C57Bl/6 mice, EAE is induced by a peptide
of myelin oligodendrocytic glycoprotein (MOG35−55) leading to massive demyelina-
tion and resulting in a chronic relapsing/remitting disease course. On the other
hand, in SJL/N mice, induction of EAE with a short peptide of proteolipid pro-
tein (PLP139−151) results in little demyelination and a mostly monophasic clinical
behavior. It has been hypothesized that these different EAE models resemble dif-
ferent features of MS (Wekerle et al., 1994), making each model a useful tool for
investigation of the disease.
Only freshly in vitro activated T lymphoblasts are able to induce tEAE. The
question, where T lymphocytes are activated in vivo, could not be answered yet.
As inflammatory processes during EAE are limited to the CNS, it is suggestive,
that antigen-presentation is performed by BBB endothelial cells themselves, so that
T lymphocytes are locally activated and can migrate from the bloodstream across
the endothelial BBB into the CNS parenchyma. However, although BBB endothelial
cells are competent to present antigen, they are unable to fully activate T lympho-
cytes (Risau et al., 1990). Therefore, firsthand involvement of antigen presentation
in recruitment of T cells across the endothelial BBB is improbable. More likely,
specific adhesion and signaling molecules at the endothelial BBB are meaningful for
the recruitment of lymphoblasts from the bloodstream across the endothelial BBB
into the CNS parenchyma. Additionally, TJ molecules, such as claudins, may be
relevant for leukocyte recruitment into the CNS, as claudin-3 is lost from endothelial
TJ during EAE pathogenesis (Wolburg et al., 2003). However, as encephalitogenic
T cells appear to migrate instead through the endothelial cells, they should therefore
not require TJ modifications (Wolburg et al., 2003 - in press -). Nevertheless, TJ
modifications might be involved in the recruitment of secondary inflammatory cells
such as macrophages.
7Figure 1.3.1: Schematic description of the multistep model. A: Steps involved in leukocyte-
endothelial interactions. B: Molecules involved in the cascade (modified from Butcher, 1991;
Springer, 1994)
1.3 Multi-step model
Lymphocytes extravasate from the bloodstream mainly across postcapillary venules
into parenchymal tissue. This extravasation is not random but rather well-regulated
by a successive cascade of molecular interactions described as the multi-step model
(Butcher, 1991; Springer, 1994). Therefore, only if leukocytes and endothelial cells
have the correct combination of ligands and receptors on their respective surfaces,
a full cascade of leukocyte-endothelial interactions can take place in four sequential
steps: Tethering/Rolling, Activation, Adhesion and Transmigration, resulting in re-
cruitment of the leukocyte from the bloodstream into the parenchyma (Figure 1.3.1).
Initial transient contact of circulating leukocytes with the vascular wall is gen-
erally mediated by adhesion molecules of the selectin family and their respective
carbohydrate ligands, which are located on microvilli / cell protrusions on the
surface of the leukocytes. Selectins are able to interact via their lectin domain
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with their respective ligands on the endothelial surface and consequently deceler-
ate the leukocytes, resulting in rolling of the leukocyte along the vascular wall.
Leukocyte-selectin (L-selectin) is expressed by leukocytes, while endothelial- and
platelet-selectin (E- and P-selectin) can be expressed on inflamed endothelial cells.
Next, chemokines being presented on the endothelial cells can bind to their respec-
tive seven-transmembrane spanning receptors / serpentine receptors / G protein
coupled receptors on the leukocytes. This interaction is followed by pertussis toxin
sensitive Gαi-mediated inside-out signaling, which results in activation of the inte-
grins on the leukocyte surface by increase of their affinity to their ligands due to
conformational changes and potentially additional increase in integrin avidity by
clustering (Takagi et al., 2002). Integrins are heterodimers consisting of an α- and
β-subunit. Once activated, integrins mediate firm adhesion of the leukocyte to their
immunoglobulin (Ig)-superfamily ligands located on the endothelial cells. After firm
adhesion, leukocytes can transmigrate through the vessel wall into the parenchymal
tissue. This transmigration is as well mediated by integrins and Ig superfamily
ligands, like ICAM-1, PECAM-1, JAM-1 or CD99.
1.4 Chemokines and chemokine receptors
The first chemokine to be functionally described was interleukin-8 (IL-8) which is
secreted by monocytes and has chemotactic activity on neutrophilic granulocytes
(Walz et al., 1987; Yoshimura et al., 1987; Schroder et al., 1987). Therefore, this
molecule was termed a chemotactic cytokine or in short, chemokine. Later on, more
and more chemokines were identified by their chemotactic activity. Chemokines
are about 8 – 12 kDa in size consisting of about 90 – 130 amino acids. Molecular
cloning of these proteins helped to identify a common structural motif. Four highly
conserved cysteine residues form two disulfide bridges between the first and third as
well as the second and fourth cysteine respectively. The number of amino acids in
between the first and second cysteine defines chemokine subfamilies (Figure 1.4.1).
Identification of chemokines by their functional, chemotactic properties led to several
names for certain chemokines. This generated a lot of confusion and urged the need
of getting a consistent nomenclature. Therefore, chemokines were named according
to their subfamilies either CXC, CC, XC or CX3C supplemented with an L for
9Figure 1.4.1: Schematic description of two exemplary members of the CXC and CC chemokine
subfamilies (modified from Hughes and Yeager, 1999)
ligand and a number according to the timepoint when the human homolog was
cloned (Table 1.4.1).
CXCL8 / IL-8 belongs to the CXC- or α-chemokine subfamily which contains
exactly one amino acid in between the first and second cystein residue (Figure 1.4.1).
Additionally, most CXC chemokines contain an N-terminal ELR motif, consisting
of glutaminic acid (E), leucin (L) and arginine (R). These ELR motif containing
chemokines like CXCL8 and CXCL1 / Groα preferentially chemoattract neutrophilic
granulocytes (Moser et al., 1990; Schroder et al., 1990). In contrast, non-ELR motif
containing CXC chemokines mainly attract activated T cells. Expression of such
a chemokine, CXCL10 / interferon-γ-inducible protein 10 (IP-10) was described to
be detectable in fibroblasts, mononuclear cells, endothelial cells and lymphocytes in
vitro (Luster et al., 1985). Additional studies reported it to be expressed in kidney,
liver and spleen after systemic application of IFN-γ in vivo. Besides CXCL10,
CXCL9 / monokine-induced by interferon-γ (IFN-γ; MIG) is another non-ELR motif
containing chemokine (Farber, 1990). It is functionally related to CXCL10, as it
binds to the same chemokine receptor (Loetscher et al., 1996). A third non-ELR
chemokine, CXCL12 / stromal cell derived factor 1 (SDF-1), chemoattracts T cells
as well; however, it appears to be rather unusual, as it has been described to be
constitutively expressed in many organs (Tashiro et al., 1993; Bleul et al., 1996).
The first and second cysteine residues of the CC- or β-chemokine subfamily
members are directly linked (Figure 1.4.1). CCL2 / monocyte chemoattractant pro-
tein 1 (MCP-1) chemoattracts monocytes, CD4+ and CD8+ T cells, but does not
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systematic name human ligand mouse ligand receptors
CXCL1 GROα/MGSA-α GRO/KC? CXCR2 > CXCR1
CXCL2 GROβ/MGSA-β/MIP-2 GRO/KC? CXCR2
CXCL3 GROγ/MGSA-γ GRO/KC? CXCR2
CXCL4 PF4 PF4 unknown
CXCL5 ENA-78 LIX? CXCR2
CXCL6 GCP-2 CKα-3 CXCR1, CXCR2
CXCL7 NAP-2 unknown CXCR2
CXCL8 IL-8 unknown CXCR1, CXCR2
CXCL9 MIG MIG CXCR3
CXCL10 IP-10 IP-10 CXCR3
CXCL11 I-TAC unknown CXCR3
CXCL12 SDF-1α/β SDF-1 CXCR4
CXCL13 BLC/BCA-1 BLC/BCA-1 CXCR5
CXCL14 BRAK/bolekine BRAK unknown
(CXCL15) unknown Lungkine unknown
CCL1 I-309 TCA-3, P500 CCR8
CCL2 MCP-1/MCAF JE? CCR2
CCL3 MIP-1α/LD78α MIP-1α CCR1, CCR5
CCL4 MIP-1β MIP-1β CCR5
CCL5 RANTES RANTES CCR1, CCR3, CCR5
(CCL6) unknown C10, MRP-1 unknown
CCL7 MCP-3 MARC? CCR1, CCR2, CCR3
CCL8 MCP-2 MCP-2? CCR3
(CCL9/10) MRP-2, CCF18 MIP-1γ unknown
CCL11 Eotaxin Eotaxin CCR3
(CCL12) unknown MCP-5 CCR2
CCL13 MCP-4 unknown CCR2, CCR3
CCL14 HCC-1 unknown CCR1
CCL15 HCC-2/Lkn-1/MIP-1d unknown CCR1, CCR3
CCL16 HCC-4/LEC LCC-1 CCR1
CCL17 TARC TARC CCR4
CCL18 DC-CK1/PARC AMAC-1 unknown unknown
CCL19 MIP-3β/ELC/exodus-3 MIP-3β/ELC/exodus-3 CCR7
CCL20 MIP-3α/LARC/exodus-1 MIP-3α/LARC/exodus-1 CCR6
CCL21 6Ckine/SLC/exodus-2 6Ckine/SLC/exodus-2/TCA-4 CCR7
CCL22 MDC/STCP-1 ABCD-1 CCR4
CCL23 MPIF-1 unknown CCR1
CCL24 MPIF-2/Eotaxin-2 unknown CCR3
CCL25 TECK TECK CCR9
CCL26 Eotaxin-3 unknown CCR3
CCL27 CTACK/ILC ALP/CTACK/ILC ESkine CCR10
XCL1 Lymphotactin/SCM-1α/ATAC Lymphotactin XCR1
XCL2 SCM-1β unknown XCR1
CX3CL1 Fractalkine Neurotactin CX3CR1
Table 1.4.1: Systematic nomenclature for CXC, CC, C and CX3C chemokines. Listed are sys-
temic names and names which have been used for a particular chemokine before. Question marks
indicate if listed mouse chemokines may not correspond to the listed human ligand. Additionally,
main receptors for each chemokine are listed. Systematic names in brackets indicates that no
human homolog has been identified. (modified from Zlotnik and Yoshie, 2000).
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chemoattract neutrophilic granulocytes or B cells (Valente et al., 1988; Carr et al.,
1994). Additionally, it has been described to increase integrin affinity on T lym-
phocytes (Carr et al., 1996). CCL3 / macrophage inflammatory protein 1α (MIP-
1α) and CCL4 / macrophage inflammatory protein 1β (MIP-1β) were isolated from
lipopolysaccharide (LPS) treated monocytes (Wolpe et al., 1988; Sherry et al., 1988).
CCL3 is a more potent chemoattractant and preferentially chemoattracts CD4+
T cells as compared to CCL4 which mainly chemoattracts CD8+ T lymphocytes (Fa-
hey et al., 1992; Taub et al., 1993). CCL5 / regulated upon activation normal T cell
expressed and secreted (RANTES) is expressed by T cells and eosinophils (Schall
et al., 1988; Lim et al., 1996) and chemoattracts CD4+ and CD8+ T lymphocytes,
eosinophilic and basophilic granulocytes and Natural Killer (NK) cells (Roth et al.,
1995; Rot et al., 1992; Kuna et al., 1992; Taub et al., 1995). CCL6 / C10 expres-
sion was described in differentiated hematopoietic progenitor cells, macrophages and
T cells in vitro and to chemoattract macrophages (Kleinerman et al., 1984; Orlofsky
et al., 1991, 1994; Berger et al., 1996). CCL11 / eotaxin chemoattracts eosinophilic
granulocytes and TH2 lymphocytes (Griffiths-Johnson et al., 1993; Sallusto et al.,
1997). CCL19 / Epstein-Barr-induced 1 ligand chemokine (ELC) is expressed by
lymph node dendritic cells within the T cell zones and then transported to the
high endothelial venules, where it chemoattracts na¨ıve T cells (Yoshida et al., 1997;
Ngo et al., 1998; Baekkevold et al., 2001). CCL21 / secondary lymphoid chemokine
(SLC) / 6CKine / thymus-derived chemotactic agent 4 (TCA-4) recruits na¨ıve T cells
to the lymph nodes as well; however, it is expressed and presented by endothelial
cells themselves (Gunn et al., 1998). While both, CCL19 and CCL21 bind to the
same chemokine receptor, CCR7, this binding has been described to result in dif-
ferent effects, as CCL19 binding, but not CCL21 binding, results in internalization
of CCR7 (Bardi et al., 2001). Additionally, murine CCL21 binds to the chemo-
kine receptor CXCR3 (Soto et al., 1998). CCL22 / macrophage derived chemokine
(MDC) / activated B cell derived chemokine (ABCD-1) has been described to be ex-
pressed by macrophages and chemoattract dendritic cells, macrophages and NK cells
in vitro (Godiska et al., 1997) while the mouse homolog appears to chemoattract
activated T cells (Schaniel et al., 1998, 1999a,b).
XCL1 / lymphotactin, which is a potent chemoattractant for lymphocytes, does
not fit into either of these two subfamilies, as it only contains two cysteine residues
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representing the second and fourth cysteine as compared to CXC- or CC-chemokines
(Houck and Chang, 1977; Kelner et al., 1994). Therefore, XCL1 constitutes the C-
or γ-chemokine subfamily.
Another very special chemokine is CX3CL1 / fractalkine / neurotactin (Bazan
et al., 1997; Pan et al., 1997). As its first and second cysteine residue are separated
by three amino acids, it is assigned to the CX3C- or δ-chemokine subfamily. Fur-
thermore, CX3CL1 is membrane-bound via a mucin stalk and can be shed off the
membrane to become soluble.
While this classification in CXC-, CC-, C- and CX3C-subfamilies is based on the
structural properties of chemokines, they can also be divided into functional groups.
There are so-called lymphoid, constitutive or homeostatic chemokines, like CXCL12,
CCL19, CCL21, which are constitutively expressed in lymphoid organs. In contrast,
inducible or inflammatory chemokines are induced during inflammation.
IL-8 and platelet-factor 4 (PF4) were the first chemokines to be structurally
analyzed. Monomeric chemokines consist of an N-terminal loop, three antiparallel
β-sheets and a C-terminal α-helix. IL-8 forms homodimers and PF4 tetramers,
which resemble a dimeric IL-8 dimer (Clore et al., 1990; Baldwin et al., 1991). The
question of whether monomers, dimers or tetramers are biologically active, remains
controversial. While physiologic chemokine concentrations are in nanomolar ranges
(Burrows et al., 1994), chemokine dimer dissociation constants are in micromolar
ranges, suggesting chemokine monomers to be the physiologically relevant form.
This is emphasized as modified IL-8, which is no longer able to dimerize, maintains
its chemotactic activity in vitro (Rajarathnam et al., 1994). However, recently
it was described that dimerization of chemokines as well as their ability to bind
proteoglycans is required to maintain their biologic activity in vivo (Proudfoot et al.,
2003). Therefore, it has been suggested that chemokine binding to proteoglycans
locally increases chemokine concentration and thereby results in dimerization.
Besides their chemotactic activity, chemokines have been suggested to be in-
volved in additional biological effector functions, like TH1/TH2 development, an-
giogenesis/angiostasis, metastasis, cell recruitment, inflammation, lymphoid organ
development, lymphoid trafficking and wound healing (reviewed in Rossi and Zlot-
nik, 2000).
Chemokines bind to chemokine receptors, which are named CXCR1 – CXCR5,
13
CCR1 – CCR10, XCR1 and CX3CR1 according to their ligand subfamilies. Chemo-
kine – chemokine receptor binding is very promiscuous, as chemokines may bind to
different receptors and chemokine receptors bind different chemokines. Therefore, it
is often not possible to assign distinct receptor ligand pairs. In general, chemokine
binding to its receptor results in a Gαi-mediated, pertussis-toxin sensitive signaling
pathway which leads to Ca2+ influx and chemotaxis (Rollins et al., 1991). On the
other hand, via arrestin signaling pathways, chemokine receptor internalization is
induced to limit chemokine signaling.
Besides known chemokine receptors, there are a lot of orphan receptors with a
high homology to chemokine receptors. However, their ligands have not been iden-
tified yet, so they are not termed chemokine receptors. Two very special chemokine
receptors are Duffy antigen / receptor for chemokines (DARC) and D6. These are
two atypical chemokine receptors, as they unspecifically bind chemokines of the
CXC- and CC-subfamilies and additionally lack the typical chemokine receptor in-
tracellular signal transducing domains. Therefore they do not induce functional
responses like Ca2+-influx or chemotaxis. DARC is a blood group antigen and
therefore largely expressed on erythrocytes. Additionally, upregulation of DARC on
BBB endothelial cells during EAE pathogenesis was first observed by us (Alt, 1999),
strongly suggesting a special role during EAE pathogenesis. DARC might act as a
sink to remove chemokines from the bloodstream, it might present chemokines on
the luminal surface of the endothelium and thereby facilitate ligand binding or it
might be involved in active transcytosis of chemokines from the CNS parenchymal
tissue across the endothelial BBB onto the luminal surface of the endothelial cells.
1.5 Chemokine involvement in EAE
Several chemokines have been described to be expressed in CNS tissue of EAE af-
flicted animals. Godiska et al. performed reverse transcription - polymerase chain
reactions (RT-PCR) and Northern hybridizations, thereby reporting expression of
CXCL1, CXCL10, CCL1, CCL2, CCL3, CCL4, CCL5 and CCL7 in spinal cord
preparations of SJL mice afflicted with EAE (Godiska et al., 1995). They described
CXCL12 to be expressed in spinal cord preparations of healthy and EAE afflicted
mice, while they could detect neither CCL6 nor CXCL2. Expression of CXCL10
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and CCL2 was reported in astrocytes of SJL mice afflicted with EAE (Ransohoff
et al., 1993), while expression of CCL3 and CCL4 was described in inflammatory
cells, microglial cells and astrocytes of Lewis rats afflicted with EAE (Miyagishi
et al., 1997). Thus, different chemokines have been reported to be expressed during
EAE in the CNS; however, none of them has been shown to be expressed by the
BBB endothelial cells themselves. Karpus et al. reported that pretreatment with
polyclonal CCL3 but not CCL2 antisera protected SJL mice from transfer EAE and
reduced the number of inflammatory cells within the spinal cord, while administra-
tion of this antiserum additionally ameliorated an ongoing disease (Karpus et al.,
1995). However, whereas application of polyclonal antiserum against CCL2 but not
CCL5 could ameliorate the EAE relapse in SJL mice, it had no effect on the acute
phase of disease (Kennedy et al., 1998). Although these studies suggest an impor-
tant role of CCL2 and CCL3 in the pathogenesis of EAE, their exact mechanistic
role in EAE pathogenesis is not clear. CNS specific expression of CCL6 was shown
to induce leukocyte infiltration into the CNS (Asensio et al., 1999). In contrast to
this, absence of CCL2 was shown to lead to amelioration of EAE, while absence of
its receptor CCR2 inhibits onset of the disease (Fife et al., 2000; Izikson et al., 2000;
Huang et al., 2001). Lack of CCR1, which is a receptor for both, CCL5 and CCL7,
has been described to result in less severe EAE (Rottman et al., 2000). However,
absence of CCR5, an additional receptor for CCL5 was shown to have no influence
EAE pathogenesis (Tran et al., 2000). This suggests that lack of CCR5 can be com-
pensated by CCL5 binding to CCR1, while lack of CCR1 results in lack of CCL5
and CCL7 binding which cannot be compensated. Although several of these studies
describe an important role of chemokines during EAE pathogenesis, it has not been
investigated yet, if these chemokines are involved in recruitment of encephalitogenic
T cells from the bloodstream across the endothelial blood-brain barrier into the CNS
parenchyma or if they have different effector functions. None of these chemokines
has been reported to be expressed by BBB endothelial cells themselves.
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1.6 The aim of this study
Aim of this study was the identification of chemokines which are involved in lympho-
cyte recruitment from the bloodstream across the endothelial BBB into the brain
parenchyma. For chemokines to be involved in this process, they have to be ei-
ther expressed by BBB endothelial cells themselves or would require a yet unknown
transport mechanism from the brain parenchyma across the endothelial BBB to the
luminal surface of the endothelial cells. Preliminary results from earlier studies had
pointed out the possibility that CCL21 and therefore lymphoid chemokines might be
involved in this process (Alt, 1999). Hence, expression of lymphoid chemokines and
inflammatory chemokines which had been reported to be involved in EAE pathogen-
esis or lymphocyte recruitment, was analyzed by in situ hybridization. Chemokines
which could be detected as being expressed by BBB endothelial cells themselves
were to be analyzed in more detail by immunohistochemistry and immunoblot. Ad-
ditional studies had to evaluate chemokine receptor expression on encephalitogenic
T cells, while functional relevance of the findings was subject to transmigration and
frozen-section assays in vitro. Application of intravital fluorescence videomicroscopy
in cooperation with Dr. Peter Vajkoczy (Klinikum Mannheim, University of Heidel-
berg) should prove involvement of these chemokines in T lymphoblast recruitment
across the endothelial BBB in vivo.
Furthermore, involvement of so far not known chemokines and receptors pos-
sibly being involved in lymphocyte recruitment across the endothelial BBB was
addressed by three different technical approaches targeting two different tissues in
cooperation with Astra-Zeneca (So¨derta¨lje, Sweden). Gene array, subtractive sup-
pression hybridization and proteomics analysis were applied either to compare cere-
bral microvessels from EAE-afflicted mice with healthy control mice or to compare
encephalitogenic with non-encephalitogenic T cells. Results should be analyzed by
extensive gene bank searches to identify possible targets for further investigation.
The Duffy antigen / receptor for chemokines (DARC) is a potential transporter of
chemokines across the endothelial BBB. By use of DARC-deficient mice, which were
kindly provided by Antal Rot (Novartis, Vienna, Austria; Dawson et al. (2000)), a
potential involvement of DARC in lymphocyte recruitment across the endothelial
BBB should be analyzed in vitro and in vivo.
Chapter 2
Materials and Methods
2.0.1 Devices
ABI Prism 3700 DNA Analyzer. . . . . . . . Applied Biosystems, Darmstadt, Ger-
many)
β-scintillation counter LS 6500. . . . . . . . . Beckman-Coulter, Unterschleißheim, Ger-
many
Balance LC 4800 P . . . . . . . . . . . . . . . . . . . . Sartorius, Hamburg, Germany
Balance RC 210 D. . . . . . . . . . . . . . . . . . . . . Sartorius, Karlsruhe, Germany
Binocular KL 1500 electronic . . . . . . . . . . Zeiss, Oberkochen, Germany
Cell Harvester . . . . . . . . . . . . . . . . . . . . . . . . . Inotech, Dottikon, Switzerland
Centrifuge Biofuge Fresco. . . . . . . . . . . . . . Heraeus, Hanau, Germany
Centrifuge Biofuge Pico . . . . . . . . . . . . . . . Heraeus, Hanau, Germany
Centrifuge 5415 C . . . . . . . . . . . . . . . . . . . . . Eppendorf, Hamburg, Germany
Centrifuge 4K15 . . . . . . . . . . . . . . . . . . . . . . . Sigma-Zentrifugen, Osterode, Germany
Centrifuge 4K15 C . . . . . . . . . . . . . . . . . . . . Sigma-Zentrifugen, Osterode, Germany
CO2 incubator IR Autoflow. . . . . . . . . . . . Nuaire; Zapf, Sarstedt, Germany
Developing machine M35 X-OMAT . . . . Kodak, Stuttgart, Germany
Electrophoresis apparatus . . . . . . . . . . . . . Peqlab, Erlangen, Germany
Gel chamber Mini-Sub Cell GT . . . . . . . . Bio-Rad, Munich, Germany
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Gel chamber Sub-Cell GT . . . . . . . . . . . . . Bio-Rad, Munich, Germany
Gel chamber Mini-Sub Cell Model 192 . Bio-Rad, Munich, Germany
Gel Dryer Model 583 . . . . . . . . . . . . . . . . . . Bio-Rad, Munich, Germany
Gene Amp PCR System 9700. . . . . . . . . . Applied Biosystems, Darmstadt, Germany
Heating Block thermomixer 5436 . . . . . . Eppendorf, Hamburg, Germany
Heating Plate . . . . . . . . . . . . . . . . . . . . . . . . . Medax, Kiel, Germany
Hybridization oven . . . . . . . . . . . . . . . . . . . . Bachofer, Reutlingen, Germany
Incubator B5060E . . . . . . . . . . . . . . . . . . . . . Heraeus, Hanau, Germany
Laminar flow cabinet 425-400E . . . . . . . . Nuaire; Zapf, Sarstedt, Germany
Disperser Ultra-Turrax T25. . . . . . . . . . . . IKA Labortechnik, Staufen, Germany
Microscope Axiophot . . . . . . . . . . . . . . . . . . Zeiss, Oberkochen, Germany
Microtome HM 500 OM . . . . . . . . . . . . . . . Microm, Walldorf, Germany
Microwave oven Inverter . . . . . . . . . . . . . . . Panasonic, Hamburg, Germany
Multi stepping pipet . . . . . . . . . . . . . . . . . . . Eppendorf, Hamburg, Germany
pH meter pH 192 . . . . . . . . . . . . . . . . . . . . . . WTW, Weilheim, Germany
Phosphoimager BAS-2500 . . . . . . . . . . . . . Fujifilm, Raytest, Straubenhardt, Ger-
many
Pipetboy acu . . . . . . . . . . . . . . . . . . . . . . . . . . Integra Biosciences, Fernwald, Germany
Electronic pipettor Impact2 . . . . . . . . . . . Matrix, Wehrheim, Germany
Power supply E 450 . . . . . . . . . . . . . . . . . . . Consort, Turnhout, Belgium
Power supply E 455 . . . . . . . . . . . . . . . . . . . Consort, Turnhout, Belgium
Shaking Incubator . . . . . . . . . . . . . . . . . . . . . HT Infors, Bottmingen, Switzerland
UV-Systeme . . . . . . . . . . . . . . . . . . . . . . . . . . . Intas, Go¨ttingen, Germany
UV Screen 312 nm . . . . . . . . . . . . . . . . . . . . Bachofer, Reutlingen, Germany
UV/VIS Spectrometer Lambda Bio . . . . Perkin-Elmer, Munich-Neuried, Germany
Vortex-Genie 2 . . . . . . . . . . . . . . . . . . . . . . . . Scientific Industries, Bohemia, NY, USA
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Water bath Julabo 7 A . . . . . . . . . . . . . . . . Julabo, Seebach, Germany
Water bath Julabo SW 20 C. . . . . . . . . . . Julabo, Seebach, Germany
2.0.2 Expendable materials
Reaction tubes, 0.5 – 2.0 ml . . . . . . . . . . . . Eppendorf, Hamburg, Germany
15 ml, 50 ml tubes. . . . . . . . . . . . . . . . . . . . . . Greiner, Nu¨rtingen, Germany
Tissue culture flasks . . . . . . . . . . . . . . . . . . . . Costar, Bodenheim, Germany; Greiner,
Nu¨rtingen, Germany
Pipet tips . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Greiner, Nu¨rtingen, Germany
Sterile filters. . . . . . . . . . . . . . . . . . . . . . . . . . . . Millipore, Eschborn, Germany; Pall,
Dreieich, Germany
Photofilm EPY64T . . . . . . . . . . . . . . . . . . . . . Kodak, Stuttgart, Germany
2.0.3 Chemicals
Chemicals were obtained in purity p. a. from BDBiosciences, Heidelberg, Germany;
Invitrogen, Karlsruhe, Germany; J. T. Baker, Deventer, The Netherlands; Merck,
Darmstadt, Germany; Riedel-de-Haen, Seelze, Germany; Roth, Karlsruhe, Germany
and Sigma, Deisenhofen, Germany.
2.0.4 Buffers and Solutions
Standard solutions were prepared using deionized, ultrafiltered and autoclaved tap
water. If not explicitly noted, pH was adjusted using hydrochloric acid or sodium
hydroxide solution.
2.1 Tissue culture
2.1.1 Tissue culture media and solutions
Supplements for tissue culture were obtained from Invitrogen (Karlsruhe, Germany),
PAA (Co¨lbe, Germany), PAN (Aidenbach, Germany) or Sigma (Deisenhofen, Ger-
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many) unless otherwise noted. Supplements were either filtered sterile or autoclaved.
All sera were heated before use (30 min, 56◦C) to inactivate complement factors.
Cells were cultured under sterile conditions in a CO2 incubator (NUAire; Zapf,
Sarstedt, Germany) at 37◦C, 7 % – 10 % CO2 and 100 % humidity in tissue culture
dishes (BDBiosciences Falcon, Heidelberg, Germany) or flasks (Greiner, Nu¨rtingen,
Germany).
2.1.1.0.1 Concanavalin A (ConA) medium
Cytokine producing splenocytes were grown in DMEM (4500 g/l glucose) sup-
plemented with 1 % normal mouse serum (see 2.3.1.5), 4 mM L-glutamine, 1 mM
sodium pyruvate, 1 % (v/v) MEM non-essential amino acids (100×), 100 U/ml
penicillin, 100 µg/ml streptomycin and 0.05 mM β-mercaptoethanol.
2.1.1.0.2 Endothelioma medium
Endothelioma cell lines were cultured in DMEM (4500 g/l glucose) supplemented
with 10 % fetal calf serum, 4 mM L-glutamine, 1 mM sodium pyruvate, 1 % (v/v)
MEM non-essential amino acids (100×), 100 U/ml penicillin, 100 µg/ml strepto-
mycin and 0.05 mM β-mercaptoethanol.
2.1.1.0.3 Migration assay medium (MAM)
Migration and chemotaxis assays were performed in DMEM (4500 g/l glucose)
supplemented with 5 % calf serum, 4 mM L-glutamine and 25 mM HEPES.
2.1.1.0.4 Mouse brain endothelial (MBE) medium
Primary endothelial cells were grown in DMEM (4500 g/l glucose) supplemented
with 10 % calf serum, 4 mM L-glutamine, 1 mM sodium pyruvate, 1 % (v/v) MEM
non-essential amino acids (100×), 100 U/ml penicillin, 100 µg/ml streptomycin and
1 % retinal factor (see 2.1.4.6).
2.1.1.0.5 Phosphate-buffered saline (PBS)
PBS solution contained 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4 and
1.4 mM KH2PO4.
2.1.1.0.6 T cell (TC) medium
T cells were restimulated in RPMI-1640 supplemented with 10 % fetal calf
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serum, 4 mM L-glutamine, 1 mM sodium pyruvate, 1 % (v/v) MEM non-essential
amino acids (100×), 100 U/ml penicillin, 100 µg/ml streptomycin and 0.05 mM
β-mercaptoethanol.
2.1.1.0.7 T cell growth factor (TCGF) medium
T cells were propagated in RPMI-1640 supplemented with 10 % fetal calf
serum, 4 mM L-glutamine, 1 mM sodium pyruvate, 1 % (v/v) MEM non-essential
amino acids (100×), 100 U/ml penicillin, 100 µg/ml streptomycin, 0.05 mM β-
mercaptoethanol and 10 % – 20 % concanavalin A supernatant (see 2.1.3.8).
2.1.1.0.8 Washing buffer
Cells were washed in HBSS supplemented with 10 % FCS and 25 mM HEPES.
2.1.2 Primary cell preparation
2.1.2.1 Preparation of splenocytes
Mice were sacrificed by cervical dislocation. Spleens were taken out under sterile
conditions while thoroughly removing connective and fatty tissue. Spleens were
washed twice in washing buffer, cut up into small pieces and homogenized using a
Dounce homogenizer with a large clearance pestle (Bellco Glass, NJ, USA). The cell
suspension was filtered using a 100 µm nylon mesh and centrifuged (250 g, 10 min,
RT). Erythrocytes were lysed as described (Boyle, 1968) with a prewarmed mixture
of 9 volumes ACT I (155 mM NH4Cl) and 1 volume ACT II (170 mM Tris-HCl
pH 7.65) (2 × 107 cells/ml; 5 min, 37◦C). Erylysis was stopped by dilution with
washing buffer and centrifugation (250 g, 10 min, RT). Cells were filtered through
a 100 µm nylon mesh again, washed twice, counted and used for experiments.
2.1.2.2 Preparation of lymphocytes
Mesenteric or peripheral lymph nodes were prepared, while connective and fatty
tissue was thoroughly removed under sterile conditions. Lymph nodes were washed
twice in washing buffer, cut into small pieces and homogenized using a Dounce
homogenizer with a large clearance pestle (Bellco Glass, NJ, USA). Cell suspension
was filtered through a 100 µm nylon mesh, centrifuged (250 g, 10 min, RT), filtered
and washed again. Cells were counted and used for subsequent experiments.
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2.1.2.3 Preparation of peripheral blood cells
Mice were anesthetized with isoflurane and blood was collected intracardially using a
syringe, which contained 75 IU sodium-heparin in 100 µl PBS to avoid coagulation.
Blood samples were diluted 2-fold in PBS, carefully applied on top of 4 ml ficoll
gradient solution and centrifuged (1600 rpm, 20 min, RT, without brake). Cells were
washed three times in HBSS/25 mM HEPES, counted and used for experiments.
2.1.3 T cell culture
2.1.3.1 Preparation of primary PLP specific T cell lines
PLP specific T cell lines were established from SJL/N mice, as their genetic back-
ground allows them to develop EAE. 50 µg PLP139−151 (H2N - H - C - L - G -
K - W - L - G - H - P - D - K - F - COOH) solved in 50 µl PBS were emulsified
with 50 µl complete Freund’s adjuvant (CFA; incomplete Freund’s adjuvant, Invit-
rogen, Karlsruhe, Germany supplemented with 4 mg/ml heat-inactivated organisms
of Mycobacterium tuberculosis, BDBiosciences Difco, Heidelberg, Germany) by mix-
ing with two interconnected syringes. Female SJL/N mice (Taconics, Ry, Denmark)
were immunized with 100 µl emulgate by subcutaneous injection into the footpads.
At day 15 after injection, mice were sacrificed by cervical dislocation and peripheral
lymph nodes were prepared under sterile conditions. Lymph nodes were homoge-
nized and filtered through a 100 µm nylon mesh to obtain a single cell suspension.
5 × 107 lymphocytes were cultured per 60 mm dish in 5 ml TC medium, supple-
mented with 10 µg/ml PLP139−151. After three days, 1 ml TCGF medium was
added and cells were cultured for one more day. Highly activated T lymphoblasts
were then separated by density gradient centrifugation (see 2.1.3.3). In parallel,
antigen specificity was checked (see 2.1.3.7).
2.1.3.2 Preparation of primary MOG specific T cell lines
MOG specific T cell lines were prepared from spleens of C57Bl/6 mice (Harlan-
Winkelmann, Borchen, Germany). Mice were immunized with 200 µg MOG35−55
(H2N - M - E - V - G - W - Y - R - S - P - F - S - R - V - V - H - L - Y - R -
N - G - K - COOH) in 50 ml PBS emulsified with 50 µl CFA subcutaneously in
the footpads, hind legs and tail root. At day 15 after injection, mice were sacrificed
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by cervical dislocation and lymph nodes and spleens were prepared under sterile
conditions. Cells were homogenized and filtered through a 100 µm nylon mesh
to obtain a single cell suspension. 5 × 107 cells were cultured per 60 mm dish in
5 ml TC medium, supplemented with 40 µg/ml MOG35−55. After three days, 1 ml
TCGF medium was added and cells were cultured for one more day. Highly activated
T lymphoblasts were then separated by density gradient centrifugation (see 2.1.3.3).
In parallel, antigen specificity was checked (see 2.1.3.7).
2.1.3.3 T lymphoblast separation by density gradient centrifugation
Highly activated T lymphoblasts were separated from resting T lymphocytes and
cell debris by Ficoll density gradient centrifugation (Nycoprep; Nycomed, Oslo,
Norway). Therefore, cells from about 1 – 2 60 mm dishes were collected, centrifuged
(250 g, 10 min, RT) and resuspended in 3 ml HBSS / 25mM HEPES. This suspension
was carefully put on top of 5 ml Nycoprep 1.077 A solution (density: 1.077 g/ml at
20◦C; Nycomed, Oslo, Norway) and centrifuged (450 g, 20 min, RT, without brake).
T lymphoblasts were collected from the interphase and washed three times with
washing buffer. 3× 106 cells were resuspended in 10 ml TCGF medium and plated
per 100 mm dish.
2.1.3.4 Culture in IL-2 containing medium
T lymphoblasts were propagated in IL-2 containing TCGF medium for 8 – 10 days.
Therefore, they were regularly checked by microscopy and split or fed accordingly.
Freshly activated T lymphoblasts were typically large and shaped like a tennis racket,
while resting T lymphocytes were round and small. Once the majority of T cells had
entered the resting phase, they had to be restimulated with their respective antigen.
2.1.3.5 Restimulation of antigen specific T cell lines
Resting T cells were restimulated with antigen presenting cells and their respective
antigen. Therefore, syngeneic mice were sacrificed and their spleens were dissected
under sterile conditions. Spleens were homogenized and filtered through a 100 µm
nylon mesh to obtain a splenocyte single cell suspension. Cells were centrifuged
(250 g, 10 min, RT) and resuspended in Washing Buffer. They were then sublethally
irradiated (3000 rad, Strahlenzentrum University in Giessen / 45 Gy, University
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of Mu¨nster, Germany) to avoid cell division. Irradiated splenocytes were filtered
again through a 100 µm nylon mesh and washed in washing buffer. Per 60 mm
dish, 1.5 – 2×106 resting T lymphocytes were plated together with 2.5 – 4×107
antigen presenting cells in 5 ml TC medium containing either 10 µg/ml PLP139−151
or 50 µg/ml MOG35−55. After two days, 1 ml TCGF medium was added per dish
and after one more day, freshly activated T lymphoblasts were separated by density
gradient centrifugation (see 2.1.3.3). In parallel, specific antigen response was tested
(see 2.1.3.7).
2.1.3.6 Freezing and thawing of T cell lines
T cells were collected from about 3 – 5 tissue culture dishes and centrifuged (250 g,
10 min, RT). Pelleted cells were resuspended in 1.5 ml freezing medium (RPMI-
1640, 50 % (v/v) FCS, 10 % (v/v) DMSO), put into cryo tubes and slowly (about
1◦C per minute) cooled down to -80◦C in cryo freezing containers (Nalgene; Nunc,
Wiesbaden, Germany). Frozen cells were kept at -80◦C for two days and afterwards
stored in gaseous liquid nitrogen. Cells were thawed rapidly, immediately resus-
pended in washing buffer and plated on tissue culture dishes in TCGF medium.
Freezing and thawing advanced T cells into the resting phase.
2.1.3.7 T cell proliferation assay to detect antigen specificity
Antigen specific proliferation of encephalitogenic T cells was measured by 3H-
thymidin (3H-dT) incorporation in presence of antigen presenting cells and different
antigens. Therefore, 2× 104 T cells were cultured together with 5× 105 sublethally
irradiated splenocytes as antigen presenting cells per well in U-shaped 96-well plates.
Either 10 µg/ml PLP139−151 or 40 µg/ml MOG35−55 were added as specific antigen.
10 µg/ml purified protein derivate (PPD) from Mycobacterium tuberculosis or no
antigen were added to check for unspecific proliferation. 2.5 µg/ml concanavalin A
(Sigma, Deisenhofen, Germany) was added as a positive control. All values were
determined in triplicates. After 54 h, 1 µCi 3H-dT was added per well and cells were
incubated for another 16 hours. During this period, 3H-dT was incorporated into
proliferating cells. Cell suspensions were aspirated with a cell harvester (Inotech,
Dottikon, Switzerland) through glass fibre filters so that cells got stuck and were
subsequently lysed with ddH2O. Non-incorporated
3H-dT was removed by thorough
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washing. Glass fibre filters were dried (2 h, RT) and radioactivity was measured by
β-liquid scintillation counting.
2.1.3.8 Preparation of Concanavalin A supernatant (ConAS)
Interleukin-2 (IL-2) containing Concanavalin A supernatant was prepared as follows.
Spleens were dissected sterile from C3H mice (Harlan-Winkelmann, Borchen, Ger-
many), homogenized and filtered through a 100 µm nylon mesh to obtain a single
cell suspension. These cells were resuspended three times in Washing Buffer and
centrifuged (250 g, 10 min, RT). Subsequently, splenocytes (107 cells/ml) were cul-
tured in ConA medium for 24 hours. Supernatant was collected, stored at -20◦C and
its activity tested. Therefore, proliferation of 2 × 104 T cells / 200 µl TC medium
dependent on either 50 %, 25 %, 12.5 %, 6.25 %, 3.125 % or 0 % ConAS was com-
pared (see 2.1.3.7). A batch of tested ConAS was used as a control. All values were
determined in triplicates. As a result, ConAS was typically used in concentrations
ranging from 10 % – 20 %.
2.1.3.9 Fluorescent cell labeling
Cells were labeled using either 20 nM Cell Tracker Orange (CTrO; Molecular Probes,
Eugene, OR, USA) or 20 nM Cell Tracker Green (CTrG; Molecular Probes, Eugene,
OR, USA) in RPMI-1640 / 10 % FCS at 5× 106 cells/ml and incubated at 37◦C for
45 minutes as described (Hamann and Jonas, 1997). Cells were washed with 50 ml
RPMI-1640 / 10 % FCS, centrifuged (250 g, 10 min, RT), 5× 106 cells were plated
in 10 ml RPMI-1640 / 10 % FCS per 100 mm tissue culture dish and incubated
for 30 minutes at 37◦C. Cells were harvested and centrifuged (250 g, 10 min, RT).
Dead cells were removed by Nycodenz gradient centrifugation, applying 5 × 106
cells in 1 ml RPMI-1640 on top of 5 ml FCS which were on top of 3 ml Nycodenz.
After centrifugation (10 min, 1200 rpm, RT, without brake), cells were collected
and washed three times in washing buffer. Cells were counted and stored on ice for
experiments.
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2.1.4 Endothelial cell culture
2.1.4.1 Preparation of primary endothelial cells
2.1.4.1.1 by collagenase digestion
Brains of mice were prepared and stored on ice in buffer A (153 mM NaCl, 5.6 mM
KCl, 2.3 mM CaCl2, 2.6 mM MgCl2, 15 mM HEPES, 1 % (v/v) bovine serum al-
bumine (BSA), pH 7.4). Cerebellum and meninges were carefully removed. Cere-
bral hemispheres were washed twice with buffer A, cut into small pieces using two
scalpels, resuspended in buffer A and centrifuged (250 g, 5 min, RT). The pellet was
digested for 30 minutes at 37◦C by addition of 1 volume collagenase type II (0.75 %;
Biochrome, Berlin, Germany) and 1 volume buffer A (30 min, 37◦C, shaking). Di-
gestion was stopped by addition of 40 ml ice-cold buffer A and centrifugation (250 g,
10 min, 4◦C). The pellet was carefully resuspended in 20 ml 25 % BSA / PBS and
centrifuged (1000 g, 20 min, 4◦C) to separate myelin components. Myelin and BSA
were decanted and the centrifugation tube thoroughly dried. Pelleted microvessels
were carefully resuspended in PBS avoiding any backflow of BSA. Then, cells were
either plated on collagen-coated 35 mm tissue culture dishes (see 2.1.4.3) or washed
and shock-frozen for gene array (see 2.4.7) or proteomic analysis (see 2.5.7).
2.1.4.1.2 by mechanic separation
Brains of mice were dissected, stored in ice-cold PBS and cerebellum and meninges
were carefully removed. Tissue was washed twice with PBS and homogenized using
a Dounce homogenizer (Bellco Glass, NJ, USA) with a large clearance pestle. Cell
suspension was filtered through a 180 µm nylon mesh, which had been straddled over
a beaker and the nylon mesh was washed with PBS. The filtrate was homogenized
again, using a small clearance pestle, filtered through a 63 µm nylon mesh and
washed again with PBS. Thereby, microvessels got stuck on the nylon mesh and
were collected for further experiments.
2.1.4.2 Retroviral infection of primary endothelial cell lines
Primary endothelial cell lines were prepared as described above (see 2.1.4.1.1), cul-
tured over night and then transformed by infection with polyoma middle T oncogene
(pymT) transducing recombinant retrovirus. This virus was produced by GP+E86
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cells (see 2.1.5) and additionally contained a neomycin resistance gene locus. Virus
containing supernatant of these cells had been collected freshly, filter sterilized
(0.45 µm) and supplemented with 8 µg/ml polybrene (hexadimethin bromid; Sigma,
Deisenhofen, Germany). Endothelial cells were washed twice with PBS, and 2 ml
supernatant were added per 35 mm tissue culture dish. This procedure was repeated
after 24 hours. 48 hours after virus infection, cells were washed again with PBS and
MBE medium was added.
2.1.4.3 Culture of transfected endothelial cells
Transfected endothelial cells were grown on tissue culture dishes or flasks which had
been coated with collagen (1:20 in PBS from stock solution: 2.76 mg/ml) for at
least one hour and washed twice with PBS just before use. These cells were cul-
tured in MBE medium supplemented with 1 µg/ml G418 until pure endothelioma
cell lines were established. They were grown to confluency and then split 4-fold.
Therefore, they were washed with PBS/5mM EDTA and digested with 0.05 %
Trypsin/EDTA (Invitrogen, Karlsruhe, Germany). Subsequently, cells were cen-
trifuged (250 g, 10 min, RT). Pelleted cells were resuspended in MBE medium and
seeded onto new collagen dishes. Once pure endothelioma cultures were established,
cells were grown in endothelioma medium on uncoated tissue culture flasks.
2.1.4.4 Culture of endothelioma cell lines
Brain endothelioma cell line 5 (bEnd5) was used as a model system representing
wildtype endothelial cells, regarding its generic adhesion molecule expression pat-
tern (Reiss et al., 1998). It had been established by polyoma middle T oncogene
expression (pymT) in primary brain microvessels freshly prepared from BALB/c
mice (Kiefer et al., 1994; Wagner and Risau, 1994). bEnd5 cells were grown in
endothelioma medium to confluency and split 4-fold about every 2 – 3 weeks as
described above (see 2.1.4.3). Endothelioma cells were used in experiments during
passage 10 to 25.
2.1.4.5 Freezing and thawing of endothelioma cell lines
Endothelioma cells were detached and spun down as described (see 2.1.4.4). Cell
pellets were resuspended in freezing medium (DMEM / 30 % (v/v) FCS / 10 % (v/v)
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DMSO), put into cryo tubes (Greiner, Nu¨rtingen, Germany) and gently cooled down
in Cryo Freezing Containers (Nalgene; Nunc, Wiesbaden, Germany) about 1◦C/min
to -80◦C. They were stored for 2 days at -80◦C and then transferred to gaseous liquid
nitrogen storage conditions (-179◦C). Cells were thawed rapidly, washed in Washing
buffer and seeded in tissue culture flasks in endothelioma medium.
2.1.4.6 Preparation of retinal factor
Retinal factor containing endothelial growth factors was prepared as described
(D’Amore and Klagsbrun, 1984). Retinas were dissected from 25 bovine eyes
(slaughterhouse, Hamm-Uentrop, Germany) and incubated in 25 ml PBS at 4◦C
over night. After extraction, insoluble components were removed by two successive
centrifugation steps (5000 g, 30 min, RT; 30000 g, 30 min, RT). Supernatant was
stored in aliquots at -20◦C.
2.1.5 GP+E86 cell culture
Virus was produced by GP+E86 cells, which are modified 3T3 fibroblasts. This is a
retroviral packaging cell line containing parts of the polyoma virus on two different
plasmids (Markowitz et al., 1988). In this present study, the cell line GPE-pymT-neo
was used, which produced an ectopic retrovirus, containing the pymT gene as well as
a neomycin resistance gene (Williams et al., 1988, 1989). Transfection experiments
with established fibroblast cell lines could show, that pymT is the transforming gene
of polyoma virus (Treisman et al., 1981) and preferably transforms endothelial cells.
GPE-pymT-neo fibroblasts were grown to confluency in endothelioma medium, and
then split 5- to 10-fold. For production of virus containing supernatant, GPE-
pymT-neo were grown to subconfluency and supernatant was used as described (see
2.1.4.2).
2.1.6 Chemotaxis assay
Chemotaxis assays were performed slightly modified as described (Siveke and
Hamann, 1998). Transwell culture inserts (diameter 6.5 mm; pore size 5 µm; Costar,
Bodenheim, Germany) were put into a 24-well plate. These inserts were coated with
10 µg/ml fibronectin (Roche, Mannheim, Germany) for 1 hour at 37◦C in 7 % CO2
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and air-dried (2 h, RT). Chemokines were diluted in migration assay medium and
added in triplicates to the lower chamber in a final volume of 600 µl. 105 lym-
phocytes were added to the upper chamber in 100 µl MAM and chemotaxis assays
were incubated (2 h, 37◦C, 7 % CO2). Cells were analyzed by phase contrast mi-
croscopy. 500 µl cell suspension were collected from the lower chamber, 20-fold
diluted in CASYton (Scha¨rfe System, Reutlingen, Germany) and cell numbers were
determined using a CASY TT cell counter (Scha¨rfe System, Reutlingen, Germany).
2.1.7 Transmigration assay
Transmigration of lymphocytes was assayed as described (Rohnelt et al., 1997)
Therefore, a two-chamber system was used (see 2.1.6). Filters were coated with
100 µl laminin solution (50 µg/ml; Roche, Mannheim, Germany) for 30 min at
room temperature. Unbound laminin solution was aspirated and filter inserts were
air-dried (1 h, RT). Then, 4 × 104 endothelioma cells were plated onto the filter
inserts and cultured for two days until confluency. Optionally, endothelioma cells
were stimulated for 16 hours with TNF-α (5nM; Cell Concept, Freiburg, Germany).
Chemokines were added in 600 µl MAM into the lower chamber, 105 lymphocytes
were added in 100 µl MAM into the upper chamber and cells were incubated (4 h,
37◦C, 7 % CO2). During this time lymphocytes spontaneously migrated through
the endothelial monolayer. Afterwards, filter inserts were removed, 500 µl of the
cell suspension from the lower chamber were 20-fold diluted in CASYton and cell
numbers was measured using a CASY TT cell counter. Filter inserts were washed
with cold PBS, fixed for 2 hours in formalin gas phase, stained with 2.6 % (v/v)
Giemsa, air-dried over night and mounted. Endothelial monolayer confluency was
analyzed by light microscopy. All values were determined in triplicates.
2.1.8 Frozen section assay
Frozen section assays using a modified version of the original Stamper-Woodruff
protocol (Stamper and Woodruff, 1976) were performed as described before (Steffen
et al., 1994). Brain sections from mice afflicted with EAE were freshly cut and
air-dried (2 h, RT).
Meanwhile, T lymphocytes were either desensitized by preincubation with high
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chemokine concentrations (10 µg/ml; 30 min, 37◦C) or pretreated with pertussis
toxin (Sigma, Deisenhofen, Germany) followed by washing 3 times in washing buffer
as described (Warnock et al., 1998). 106 encephalitogenic T lymphocytes were ap-
plied per cryo section under rotation (30 min, RT). Alternatively, brain sections were
preincubated with blocking chemokine antibodies or normal goat IgG (100 µg/ml)
as a control for 30 minutes. 106 untreated encephalitogenic T lymphocytes were
applied per section (30 min, RT).
Slides were extremely gently put upside-down into 2.5 % glutaraldehyde on ice,
fixed for 2 hours, washed twice in PBS and counterstained (0.5 % toluidine blue,
20 % ethanol). Sections were analyzed by counting the number of T lymphocytes
specifically bound to cerebral vessels.
2.1.9 Cytospin
Cytospins of T lymphoblasts were performed in a Cytospin 3 (Thermo Shandon, PA,
USA). PLP-specific T lymphoblasts (2×105) were suspended in 50 µl RPMI-1640 /
20 % FCS, placed in one cytocentrifuge assembly funnel and centrifuged at 700 rpm
for 5 min exactly according to the manufacturer’s protocol. Slides were air-dried
over night, fixed with acetone and stained as described (see 2.3.3).
2.1.10 Flow cytometry
2.1.10.1 Analysis of cell surface epitopes by antibody binding
Flow cytometry was used for phenotypic analysis of endothelial cells and T cells.
Adhering cells were detached by incubation in HBSS / 25mM HEPES / 5mM EDTA,
resuspended in washing buffer and centrifuged (250 g, 10 min, RT). Suspension cells
were collected and centrifuged (250 g, 10 min, RT). Cells were then resuspended in
flow cytometry (FC) buffer (PBS / 2.5 % (v/v) CS / 0.1 % NaN3) and 10
5 cells
were added per well in a 96-well U-shaped microtiter plate on ice. Cells were washed
twice in FC buffer and incubated for 30 minutes in 100 µl primary antibody solution.
This was either hybridoma cell supernatant or purified antibodies diluted in PBS
(10 µg/ml). Then, cells were washed twice in 200 µl FC buffer and centrifuged (300 g,
3 min, 4◦C). Cells were incubated with phycoerythrin (PE)-conjugated goat-anti-
rat IgG (10 µg/ml; Jackson Laboratories; Dianova, Hamburg, Germany) which had
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been preincubated with 10 % NMS (see 2.3.1.5) to block unspecific binding. After
washing twice, like described before, cells were fixed in 1 % PFA/PBS and analyzed
by FACScan and CellQuest software (BDBiosciences, Heidelberg, Germany).
2.1.10.2 Analysis of cell surface sugar epitopes by lectin binding
Carbohydrate structures were detected by there binding to biotin-conjugated lectin
molecules (see 2.3.1.4). These were used instead of primary antibodies (see 2.1.10.1)
and were detected using PE-conjugated streptavidin (1:500; Jackson; Dianova, Ham-
burg, Germany).
2.1.10.3 Detection of fluorescently labeled cells
Cells which had been labeled with CellTrackerGreen (see 2.1.3.9) were detected by
flow cytometrical analysis. These cells were additionally stained as described (see
2.1.10.1). Therefore, a maximum of 107 cells were stained per ml antibody solution.
2.2 Animal models
2.2.1 Experimental autoimmune encephalomyelitis
2.2.1.1 active EAE in SJL/N mice
Induction of active EAE in SJL/N mice was essentially done as described in great
detail before (Engelhardt et al., 1998; Laschinger and Engelhardt, 2000). SJL/N
mice (Taconic, Ry, Denmark) were immunized subcutaneously into the footpads
with 50 µg PLP139−151 (Thermo Electron Corporation, Egelsbach, Germany) in
CFA. One and three days after immunization, 3× 109 heat-inactivated organisms of
Bordetella pertussis were injected intravenously (kindly provided by Dr. Blackolb,
Chiron-Behring, Marburg, Germany). Weight and clinical disease were checked daily
and scored as follows:
0.5 limp tail
1 hind leg weakness
2 hind leg paralysis
3 hind leg paraparesis and incontinence
4 death
A schematic overview is given in Figure 2.2.1.
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C57Bl/6 mouse strain
day 0
inject 200 µg MOG35-55 / CFA s. c.
day 1
inject 300 ng pertussis toxin i. p.
day 3
inject 300 ng pertussis toxin i. p.
SJL/N mouse strain
day 0
inject 50 µg PLP139-151 / CFA s. c.
day 1
inject 3•109 heat-inactivated
organisms of B. pertussis i. v.
day 3
inject 3•109 heat-inactivated
organisms of B. pertussis i. v.
approximately day 14
clinical disease
+/- tail weakness
+ hind leg paraparesis
++ hind leg paraplegia
+++ hind and fore leg paraplegia
++++ death
Figure 2.2.1: active EAE in C57Bl/6 and SJL/N mice
2.2.1.2 active EAE in C57Bl/6 mice
C57Bl/6 mice were immunized subcutaneously with 200 µg MOG35−55; Thermo
Electron Corporation, Egelsbach, Germany) in complete Freund’s adjuvant (see
2.2.1.1) subcutaneously in the footpads, hind legs and tailroot. One and three days
after immunization, 300 ng pertussis toxin were applied intraperitoneally (Sigma,
Deisenhofen, Germany). Weight and clinical disease were checked daily and scored
(see 2.2.1.1). A schematic overview is given in Figure 2.2.1.
2.2.1.3 transfer EAE
Established antigen specific T cell lines (see 2.1.3) were tested for their ability to
induce EAE in syngeneic recipient mice. Therefore, 3×106 freshly activated T lym-
phoblasts were in PBS and injected i. v. into 8 – 12 week old syngeneic recipient
mice (day 1). Weight and clinical disease score was measured daily and scored as de-
scribed above (see 2.2.1.1). Typically, first signs of clinical disease appeared around
day 5 – 7 after immunization.
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2.2.2 Intravital microscopy
2.2.2.1 Preparation of the spinal cord window
Preparation of the spinal cord window was done by Dr. Peter Vajkoczy (Klinikum
Mannheim at the University of Heidelberg, Germany) as described (Vajkoczy et al.,
2001). 15 – 20 week old female SJL/N mice were anesthetized by injection of
2.5 mg/kg ketamine and 7.5 mg/kg xylazine subcutaneously. A polyethylene
catheter (PE-10) was inserted into the right common carotid artery of a thermo-
controlled mouse placed on a heating pad, to allow systemic administration of flu-
orescent markers and injection of cells. Then, the animal was turned to the prone
position so that the head could be fixed in a stereotactic rodent head holder. After
a 3 – 4 cm midline skin incision, paravertebral musculature was detached from the
cervical spinous processes and retracted laterally, so that the vertebral laminae were
exposed. Microsurgical techniques were used to perform a laminectomy of C1 –
C7. The dura was opened over the dorsal spinal cord while taking care to avoid
trauma to the parenchyma and the spinal cord microvasculature. Dehydration was
prevented and ambient oxygen excluded by covering the site with an impermeable
transparent membrane. Mice which had been traumatized during surgery or devel-
oped signs of acute inflammation such as distorted vessels, hyperemia or stagnant
blood flow, were excluded from the experiments.
2.2.2.2 Intravital fluorescence videomicroscopy
The animals remained within the stereotactic head holder which was transferred to
the microscope stage to perform intravital fluorescence videomicroscopy. Therefore,
epiillumination techniques were applied using a modified Axiotech Vario microscope
(Attoarc; Zeiss, Oberkochen, Germany) with a 100 W mercury lamp emitting an
adjustable light intensity, being attached to a combined blue (450 – 490 nm) and
green (520 – 570 nm) filter block (Zeiss, Oberkochen, Germany). Observations were
made using 3.2× long-distance, 10× long-distance and 20× water immersion working
objectives (Zeiss, Oberkochen, Germany), which resulted in magnifications of 50×,
200× and 400×. Microscopic images were recorded using a low-light level charged
coupled device video camera with an optional image intensifier for weak fluorescence
(Kappa Opto-Electronics, Gleichen, Germany), which were transferred to an S-VHS
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videosystem (Panasonic, Hamburg, Germany) for slow-motion off-line evaluation.
100 µl 2 % FITC-conjugated dextrane (MW = 150,000; Sigma, Deisenhofen,
Germany) were injected to visualize spinal cord microvasculature by contrast en-
hancement using blue-light epiillumination. Approximately 1 min after injection,
FITC-conjugated dextrane was equally distributed within the vascular system. Si-
multaneously, CTrO-labeled T cell blasts (see 2.1.3.9) were injected and visual-
ized within the spinal cord microcirculation using greenlight epiillumination. By
combination of these two fluorescent markers with distinct excitation wavelengths,
CTrO-labeled T cell blasts could be localized with respect to FITC-stained vessel
luminae. After visualization of spinal cord microvasculature by FITC-conjugated
dextrane, 3× 106 CTrO-labeled PLP-specific T cell blasts were injected in aliquots
of 100 µl, containing 106 T cells each. Their interaction with the endothelium
was observed for 60 seconds within the spinal cord capillary bed and postcapil-
lary venules (20 – 60 µm) of three different regions of interest. In contrast to this,
T cell blast/endothelial interaction within precapillary arterioles could not be visual-
ized by intravital fluorescence videomicroscopy due to the architecture of the spinal
cord microvasculature, as precapillary arterioles are located deep in the spinal cord
parenchyma. Permanent T lymphoblast adhesion to spinal cord microvasculature
was assessed by scanning 10 minutes, 1 hour, and 2 hours after cell injection and is
expressed as the number of both adherent and plugging T lymphoblasts per region
of interest (mm2).
2.2.2.3 Intravital microscopic image analysis
Spinal cord microcirculation was quantitatively analyzed by measuring the diam-
eter d of postcapillary venules and the velocity v of nonadherent T lymphoblasts.
The highest cell velocity per vessel segment, vmax, was used to calculate the mean
blood flow velocity vmean as described previously: vmean = vmax/(2 − ²2) (µm/s)
(Ley and Gaehtgens, 1991). ² is the ratio of T lymphoblast diameter to vessel di-
ameter d. Using Hagen-Poiseuille’s law, the wall shear rate γ was estimated as
γ = 8 × vmean/d (s−1) (Ley and Gaehtgens, 1991). Shear stress (τ) was approx-
imated τ = λ × 0.025poise (dyn/cm2) (Von Andrian et al., 1992). Assuming
a parabolic velocity profile in the microvessel, nonpermanently adherent T lym-
phoblasts were further categorized (Ley and Gaehtgens, 1991). Therefore, the veloc-
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ity vcrit of an idealized noninteracting cell traveling at the vessel wall was calculated
as vcrit = vmean × ²× (2− ²). This means, that the normalized velocity vnorm of an
individual cell, which was defined as the ratio vnorm = v/vcrit is an indicator if an
individual cell was interacting with the vessel wall. If this ratio vnorm was smaller
than 1, the individual cell was traveling below vcrit and therefore regarded as a cell
interacting with the vessel wall. If vnorm was larger than 1, the individual cell was
traveling with a velocity higher than vcrit and therefore regarded as not interacting
with the vessel wall (Ley and Gaehtgens, 1991; Robert et al., 1999). Looking at the
capillary network, plugging T lymphoblasts were defined as cells that did not move
and obviously blocked the capillary lumen, as evident by induction blood flow stasis
in the corresponding vascular segment.
2.2.2.4 Detection of T lymphoblasts in the spinal cord by immunofluo-
rescence
T lymphoblasts were detected in the spinal cord by immunofluorescence to distin-
guish localization within or outside the blood vessels. Therefore, mice were perfused
with 1 % paraformaldehyde in PBS 6 hours after injection of the PLP-specific T cell
blasts. Spinal cords were prepared as described (see 2.3.2). Serial longitudinal 6 µm
cryosections of the spinal cords were cut, air-dried overnight and fixed in acetone
(10 min, -20◦C). CTrO-labeled T lymphoblasts were detected by immunofluorescence
microscopy. Localization of CTrO-labeled T lymphoblasts could only be judged af-
ter visualization of vessels by immunofluorescence with an endothelial cell specific
antibody. Therefore, the vessels were stained with the monoclonal antibody MJ7/18
(see 2.3.1.1), followed by a FITC-labeled goat-anti-rat antiserum (Jackson; Dianova,
Hamburg, Germany), mounted and immediately analyzed (see 2.3.4). The number
of cells within or outside of vessels were counted manually. Serial sections had to be
analyzed to carefully determine if a CTrO-labeled T lymphoblast is located within
a spinal cord microvessel or has already migrated into the brain parenchyma.
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2.3 Morphological methods
2.3.1 Reagents
2.3.1.1 Monoclonal antibodies
Tissue culture supernatants of the following rat-anti-mouse hybridoma cells were
either used directly or as purified monoclonal antibodies for flow cytometry, im-
munohistochemistry or immunofluorescence (see 2.1.10, 2.3.3, 2.3.4).
antibody antigen isotype source reference
10E9.6 E-selectin IgG2a BDBiosciences, Heidelberg, Germany Bosse and Vestweber (1994)
11D4 VE-Cadherin IgG2a D. Vestweber, Mu¨nster, Germany Gotsch et al. (1997)
25ZC7 ICAM-1 IgG2a D. Vestweber, Mu¨nster, Germany Steffen et al. (1996)
3C4 ICAM-2 IgG2a BDBiosciences, Heidelberg, Germany Xu et al. (1996)
4RA10 PSGL-1 IgG1 D. Vestweber, Mu¨nster, Germany Pendl et al. (2002)
9B5 human CD44 IgG2a E. C. Butcher, Stanford, CA, USA Jalkanen et al. (1986)
9DB3 VCAM-1 IgG2a D. Vestweber, Mu¨nster, Germany Hahne et al. (1994)
BV11 JAM-A IgG2b E. Dejana, Milano, Italy Del Maschio et al. (1999)
GK1.5 CD4 IgG2b ATCC, Rockville, MD, USA Wilde et al. (1983)
Lyt-2 CD8 IgG2a ATCC, Rockville, MD, USA ATCC, Rockville, MD, USA
M1/70 αM -integrin IgG2b ATCC, Rockville, MD, USA ATCC, Rockville, MD, USA
M1/9 CD45 IgG2a ATCC, Rockville, MD, USA Springer et al. (1978)
Mec13.3 PECAM-1 IgG2a ATCC, Rockville, MD, USA Vecchi et al. (1994)
MECA32 MECA32 antigen IgG2a E. C. Butcher, Stanford, CA, USA Hallmann et al. (1995)
MECA367 MAdCAM-1 IgG2a ATCC, Rockville, MD, USA Briskin et al. (1993)
MECA79 PNAd IgM E. C. Butcher, Stanford, CA, USA Streeter et al. (1988)
Mel-14 L-selectin IgG2a E. C. Butcher, Stanford, CA, USA Gallatin et al. (1983)
M1/70 αMβ2-integrin IgG2b ATCC, Rockville, MD, USA Springer et al. (1978)
MJ7/18 Endoglin IgG2a E. C. Butcher, Stanford, CA, USA Ge and Butcher (1994)
RA3-6B2 CD45R / B220 IgG2a BDBiosciences, Heidelberg, Germany Coffman (1982)
RB40 P-selectin IgG1 D. Vestweber, Mu¨nster, Germany Bosse and Vestweber (1994)
RB6-8C5 Gr-1 IgG2b BDBiosciences, Heidelberg, Germany Fleming et al. (1993)
UZ4 E-selectin IgM R. Hallmann, Erlangen, Germany Hammel et al. (2001)
V3C10 ICAM-2 IgG2a D. Vestweber, Mu¨nster, Germany unpublished
7-188 VAP-1 IgG2b S. Jalkanen, Turku, Finland unpublished
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2.3.1.2 Polyclonal antisera
serum antigen species source dilution
AF880 mouse CCL19 goat R&D, Wiesbaden, Ger-
many
10–20 µg/ml
AF457 mouse CCL21 goat R&D, Wiesbaden, Ger-
many
10–20 µg/ml
P114 mouse CCL21 rabbit Peprotech, London, UK 10 µg/ml
A-19 mouse CCR7 goat Santa Cruz, Heidelberg,
Germany
20 µg/ml
Y-16 mouse CXCR3 goat Santa Cruz, Heidelberg,
Germany
20 µg/ml
C-16 mouse Gβ2 rabbit Santa Cruz, Heidelberg,
Germany
10 µg/ml
C-20 human RACK1 goat Santa Cruz, Heidelberg,
Germany
10 µg/ml
F-16 human hnRNP A2/B1 goat Santa Cruz, Heidelberg,
Germany
10 µg/ml
2.3.1.3 Secondary antisera
Polyclonal secondary antisera used in this present work are listed with their respec-
tive antigen specificity, conjugates, used dilution and the source they were obtained
from.
species antigen conjugate dilution source
goat rabbit IgG biotin 1 drop / 10 ml PBS
(2 % GNS; 2 %
MNS)
Vector; Linaris, Wertheim,
Germany
donkey goat IgG biotin 1:1000 in PBS Jackson Laboratories; Di-
anova, Hamburg, Germany
goat rat IgG biotin 1 drop / 10 ml PBS
(2 % GNS; 2 %
MNS)
Vector; Linaris, Wertheim,
Germany
goat F(ab’)2 rat IgG FITC 1:200 / in PBS (2 %
MNS)
Jackson Laboratories; Di-
anova, Hamburg, Germany
goat F(ab’)2 rat IgG PE 1:200 / in PBS (2 %
MNS)
Biosource; Camarillo, CA,
USA
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2.3.1.4 Lectins
Lectins are listed with their preferred binding specificity and their concentrations
(conc.) used in this present work.
lectin preferred binding specificity conc.
Maackia amurensis lectin II (α-2,3)-sialylgalactose residues 10 µg/ml
Sambucus nigra lectin (α-2,6)-sialylgalactose residues 10 µg/ml
Griffonia simplicifolia lectin I α-galactose residues 10 µg/ml
2.3.1.5 Normal mouse serum preparation
Normal mouse serum was prepared from healthy mice. Therefore, mice were anes-
thetized and blood was taken intracardially. Blood samples were collected at room
temperature, incubated at 37◦C for 15 minutes, put on ice for 5 minutes and cen-
trifuged (3200 g, 10 min, 4◦C). Serum was stored at -20◦C.
2.3.1.6 Preparation of Mowiol solution
Mowiol solution was used as a mounting medium to prevent bleaching of fluorescent
dyes and was prepared as follows. 6 g glycerol and 2.4 g Mowiol type 4-88 were
stirred in a 50 ml tube. 6 ml ddH2O were added and mixed on a rotary shaker for
2 hours. 12 ml 200 mM Tris-HCl pH 8.5 were added and incubated for 10 minutes
at 50◦C. After cooling down to room temperature, it was centrifuged (5000 rpm, 15
min). Pellet was discarded and supernatant stored at -20◦C.
2.3.1.7 Preparation of silanized slides
Slides (Marienfeld; VWR, Darmstadt, Germany) were silanized to prevent detach-
ment of tissue sections. Therefore, they were degreased for 5 minutes in acetone and
coated for 5 minutes with 2 % 3-aminopropyltriethoxysilane (TESPA) in acetone.
Then, they were washed three times for 5 minutes in acetone and air-dried for at
least 1 hour.
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2.3.2 Tissue preparation and sectioning
Mice were anesthetized with isoflurane (CuraMED, Karlsruhe, Germany) and intra-
cardially perfused with either ice-cold sterile PBS or ice-cold filtered 1 % PFA in
PBS. Then, tissues were taken out and embedded in Tissue-Tek (Sakura Finetek;
Vogel, Gießen, Germany) in cryo-molds (Miles Inc; Vogel, Gießen, Germany) and
slowly frozen in isopentane, which had been cooled down with dry-ice. Tissues
were stored at -80◦C. Before sectioning, tissue blocks were warmed-up to -20◦C for
30 minutes and frozen onto the blockholder with Tissue-Tek. Block temperature was
-16◦C. 6 µm sections were prepared and collected on silanized slides (see 2.3.1.7).
Sections were dried for 14 – 16 hours at room temperature and fixed in acetone
(10 min, -20◦C). After drying for 30 minutes at room temperature, they were either
directly used or stored in presence of silicagel at -20◦C.
2.3.3 Immunohistochemistry
For immunohistochemical staining, slides were either used directly after fixation with
acetone, or thawed on silicagel (30 min, RT), fixed in acetone (10 min, -20◦C) and
air-dried (30 min, RT). Sections were delimited using a PAP pen (DakoCytomation,
Hamburg, Germany) to reduce the amount solution needed to completely cover the
section. Volume ranged from 50 – 100 µl per section. Slides were hydrated with
PBS for 5 minutes in a humid chamber and unspecific binding sites were blocked
by 15 min treatment with normal serum, whose originating species depended on the
primary antibody used (Table 2.3.2). Serum was removed and primary antibody
(see 2.3.1.1 and 2.3.1.2) was added (30 min, RT). Sections were washed for 1 min
with PBS and for 5 min PBST (PBS/0.1 % Tween 20). Meanwhile, the secondary
antibody was preincubated with normal mouse serum for 30 minutes (Table 2.3.2)
and then applied to the sections for 30 minutes. Sections were washed as before
and incubated with SA/HRP (VectorStain Kit; Vector; Linaris, Wertheim, Ger-
many) for 30 minutes. After additional washing, 3-amino-ethyl-carbazol (AEC Kit;
Vector; Linaris, Wertheim, Germany) was added and incubated for 5 – 10 minutes
until staining became detectable by light microscopy. Sections were washed, coun-
terstained with hematoxyline, Gill I (Sigma, Deisenhofen, Germany) for 30 seconds
and mounted with Aquatex (Merck, Darmstadt, Germany). Sections were analyzed
39
by bright field microscopy.
primary antibody species blocking reagent secondary antibody
rabbit NGS goat-anti-rabbit
goat NRbS donkey-anti-goat
rat 90 % NGS / 10 % NRbS goat-anti-rat
Table 2.3.2: For immunohistochemical stainings, blocking reagent and secondary antibody were
chosen depending on the origin of the primary antibody.
2.3.4 Immunofluorescence
For immunofluorescent staining of histological sections, sections were treated as de-
scribed until primary antibody was applied and sections were washed (see 2.3.3). A
secondary antibody directly conjugated to a chromophore (see 2.3.1.3) was preincu-
bated with 2 % NMS and 2 % NGS in PBS to block unspecific binding. Sections
were incubated light-protected with this antibody (30 min, RT) and washed with
PBS (1 min, RT) and PBST (5 min, RT). Then, slides were mounted with Mowiol
solution (see 2.3.1.6) and analyzed by fluorescent light microscopy.
Alternatively, biotinylated lectins (see 2.3.1.4) were used instead of the primary
antibodies and detected with Cy3-conjugated strepatividin instead of the secondary
antibody. As a control, sections were pretreated with Clostridium perfringens-
derived sialidase (acylneuraminyl hydrolase EC 3.2.1.18) in 50 mM sodiumacetate
pH 4.5 / 100 µg/ml BSA for 2 hours, to remove (α-2,3)-sialylgalactose residues.
2.3.5 In situ hybridization
While performing this method, strict usage of gloves and careful cleaning of work
spaces with 70 % ethanol was substantial. Glass ware was either baked or treated
with 0.1 % sodium hydroxide solution to prevent RNAse contaminations.
2.3.5.1 Buffers and solutions
2.3.5.1.1 Transcription buffer
In vitro transcription was performed in transcription buffer containing 40 mM
Tris-HCl pH 8.0, 8 mM MgCl2, 50 mM NaCl and 2 mM spermidin.
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2.3.5.1.2 Pronase self-digestion
Pronase (Roche, Mannheim, Germany) was carefully solved in pronase buffer
(50 mM Tris-HCl pH 7.5, 5 mM EDTA) and inactivated by self-digestion for 4 hours
at 37◦C. Aliquots were stored at -20◦C.
2.3.5.1.3 Hybridization buffer
Hybridization buffer was prepared and stored in aliquots at -80◦C.
10 % dextrane sulfate
50 % formamide
10 mM Tris-HCl pH 7.5
10 mM sodiumphosphate pH 6.8
5 mM EDTA
2 × SSC (3 M NaCl, 0.3 M sodiumcitrate pH 7.0)
150 µg/ml yeast tRNA
100 mM UTP
Hybridization buffer was stored at -80◦C. Before use, 1 % (v/v) each of 100 mM
ADPβS, 1 mM ATPγS, 1 M DTT and 1 M β-mercaptoethanol were added.
2.3.5.2 Pretreatment of slides
Slides (Marienfeld; VWR, Darmstadt, Germany) were cleaned with 70 % ethanol
and baked at 180◦C for 6 hours. Afterwards, they were coated with TESPA as de-
scribed to prevent detachment of tissue sections (see 2.3.1.7). Slides were protected
from dust and stored at room temperature until use.
2.3.5.3 Tissue section preparation
Tissues were prepared from mice, which had been perfused with 1 % PFA/PBS (see
2.3.2) and 10 µm sections were prepared. These sections were air-dried on a heating
plate (5 min, 50◦C), fixed in 4 % PFA / PBS (20 min, RT), washed in PBS (5 min,
RT) and dehydrated in ethanol (30 %, 60 %, 80 %, 95 %, 100 %) for 2 minutes each.
Slides were air-dried dust-covered for 1 hour and stored in presence of silicagel at
-80◦C.
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2.3.5.4 RNA probe preparation
2.3.5.4.1 DNA-linearizing
cDNA inserts had to be located in plasmids containing promoters for two dif-
ferent RNA polymerases. Plasmids were linearized using either of two different
restriction enzymes in such a way, that transcription stopped after transcribing the
insert cDNA. Therefore, 5 µg DNA were digested with 20 U restriction endonuclease
in a total volume of 50 µl for 2 hours. Complete linearization was tested by agarose
gel electrophoresis of 2 µl (see 2.4.2.6) and subsequently, DNA was purified using
the Qiagen MinElute PCR purification kit (Qiagen, Hilden, Germany). Therefore,
samples were mixed with 5 volumes buffer PB (recipe not provided by the manu-
facturer) and applied to MinElute columns, so that DNA could bind to the columns.
Columns were centrifuged (13000 rpm, 1 min, RT) and flowthrough was discarded.
Columns were washed with 750 µl PE (recipe not provided by the manufacturer) and
centrifuged twice (13000 rpm, 1 min, RT) to thoroughly wash and dry the columns.
They were put into new microcentrifuge tubes, 10 µl prewarmed ddH2O were added,
incubated for 1 min and centrifuged (13000 rpm, 1 min, RT). 0.5 µl solution were
analyzed on the same agarose gel like used before, comparing it with the previously
tested probe to check DNA loss. Linearized DNA samples were stored at -20◦C until
use.
2.3.5.4.2 In vitro transcription
35S labeled RNA samples were prepared by in vitro transcription using the fol-
lowing reaction mix.
2.0 µl 10× transcription buffer (Stratagene, Amsterdam, The Netherlands)
1.0 µl template DNA (500 ng/µl)
1.0 µl 100 mM DTT
0.5 µl RNAguard (37.3 U/µl; Amersham Biosciences, Freiburg, Germany)
0.5 µl 10 mM ATP, CTP, GTP (Amersham Biosciences, Freiburg, Germany)
4.5 µl 35S-UTPαS (10 µCi/µl; Amersham Biosciences, Freiburg, Germany)
0.7 µl RNA polymerase (10 U/µl; Stratagene, Amsterdam, The Netherlands)
Reaction mixes were incubated for 90 minutes at 37◦C. Subsequently, template
DNA was digested with RNAse-free DNAse I (Roche, Mannheim, Germany) in
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10 mM MgCl2 (10 min, 37
◦C). RNA was purified by affinity chromatography using
a PCR purification kit (Qiagen, Hilden, Germany). Therefore, 5 volumes buffer
PB were added and mixed. Probes were applied to PCR purification columns and
centrifuged (13000 rpm, 1 min, RT). Columns were washed with 750 µl PE and
centrifuged twice (13000 rpm, 1 min, RT). 50 µl ddH2O were added, incubated for
1 minute and RNA was eluted by centrifugation (13000 rpm, 1 min, RT).
2.3.5.4.3 Alkaline hydrolyzis
RNA probes which exceeded 500 bp in size had to be hydrolyzed to guarantee
specific binding. Duration of hydrolyzis was dependent on the size of the RNA probe,
meaning 1 min hydrolysis being necessary per 200 bp RNA probe length, i. e. 5 min
hydrolysis for a 1000 bp probe. Probes were diluted in a total volume of 100 µl
ddH2O. Alkaline hydrolysis was performed on ice by addition of a tenth volume 2 M
sodiumhydroxide solution and stopped by neutralization with a tenth volume of 2 M
acetic acid. RNA was precipitated by addition of 4 µl tRNA (50 mg/ml; Roche,
Mannheim, Germany), 50 µl 6 M ammonium acetate and 500 µl 100 % ethanol
at -20◦C for at least 60 minutes. Then, samples were centrifuged (13000 rpm,
30 min, RT) and supernatant was carefully removed. Precipitates were air-dried
and solubilized in 50 µl ddH2O.
2.3.5.4.4 Detection of RNA probe activity
50 µl RNA probe solution was supplemented with 50 µl formamide and 1 µl
1 M DTT. 1 µl of this solution was diluted in 2 ml scintillation liquid (Lumasafe;
Lumac LSC, Groningen, The Netherlands) and radioactivity was measured by β-
scintillation counting (LS-6500; Beckman-Coulter, Unterschleißheim, Germany).
Probes were either used directly or stored at -20◦C for up to 1 week.
2.3.5.5 Hybridization
Slides were transferred to room temperature in presence of silicagel for at least 1 hour
to thaw from -80◦C. Then, sections were pretreated for RNA probe hybridization at
room temperature unless otherwise stated. Therefore, they were hydrated in ddH2O
(1 min), incubated in 2× SSC (3 M NaCl, 0.3 M sodiumcitrate pH 7.0; 30 min, 70◦C)
and washed in ddH2O (1 min). Subsequently, they were digested with pronase
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(40 µg/ml; see 2.3.5.1.2) in pronasebuffer (50 mM Tris-HCl pH 7.5, 5 mM EDTA)
for 10 min, digestion was stopped in 0.2 % glycine (30 s) and washed in PBS (30 s).
Sections were fixed with freshly prepared 4 % PFA/PBS (20 min, RT), washed
in PBS (3 min), treated with 0.25 % acetic anhydride in 0.1 M triethanolamine
and washed with PBS again (2 min). Sections were dehydrated with ascending
concentration of ethanol (30 %, 60 %, 80 %, 95 %, 100 %; 2 min each) and air-
dried for 1 hour. Slides were prewarmed in a hybridization oven at 60◦C in 50 %
formamide humid chambers, while radioactively labeled RNA probes were diluted in
hybridization buffer to 25000 cpm/µl. Probes were denaturated (2 min, 95◦C) and
immediately applied to the sections. Sections were covered with parafilm (American
National Can; VWR, Darmstadt, Germany). Once all probes were applied, slides
were incubated for 10 minutes at 60◦C. Then the hybridization oven was set to 48◦C,
so that temperature would slowly decrease over night. Hybridization was performed
for 14 – 16 hours.
2.3.5.6 Washing
Sections were washed in washing buffer (50 % formamide, 2× SSC, 10 mM β-
mercaptoethanol) while steadily shaking (3 – 4 h, 37◦C) until parafilms floated
off. Then, they were washed in RNAse buffer (500 mM NaCl, 10 mM Tris-HCl
pH 7.5, 1 mM EDTA) for 20 minutes at 37◦C, single strand RNA was digested in
RNAse buffer supplemented with 20 µg/ml RNAse (Roche, Mannheim, Germany;
20 min, 37◦C) and sections were washed again in RNAse buffer (20 min, 37◦C).
Subsequently, they were washed in washing buffer, supplemented with 5 mM DTT
for 16 – 18 hours. Then sections were dehydrated in ascending concentrations of
ethanol (30 %, 60 %, 80 %, 95 %, 100 %; 2 min each) and air-dried.
2.3.5.7 Exposition
Slides were exposed on a high resolution phosphoimager screen (Fujifilm; Raytest,
Straubenhardt, Germany). Screen was analyzed after 24 hours to evaluate signal in-
tensity and thereby estimate the subsequent exposure time. Exposure times usually
ranged from 2 – 6 weeks. In a darkroom, photoemulsion NTB-2 (Kodak, Stuttgart,
Germany) was emulsified in an equal amount of water, warmed to 42◦C and 190 µl
emulsion were applied per slide. Slides were air-dried for 3 – 4 hours and then stored
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lightprotected in presence of silicagel at 4◦C.
2.3.5.8 Development and counterstain
After 2 – 6 weeks, slides were warmed to room temperature for 1 hour. In darkroom,
they were developed in Kodak D19 developer solution for 3 minutes. Developing
reaction was stopped 1 % acetic acid for 30 secs and fixed in 30 % sodium thiosulfate
for 3 minutes. Slides were washed for 15 minutes with tap water, counterstained
with 0.2 % toluidine blue in 0.2 M sodiumacetate pH 4.2 for 3 minutes, washed in
tap water, destained in PBS, desalted with ddH2O, air-dried for 1 hour and mounted
with entellan (Merck, Darmstadt, Germany).
2.3.5.9 Analysis
Sections were analyzed by dark and bright field microscopy.
2.4 Molecular Biology
2.4.1 Buffers and Solutions
2.4.1.1 Restriction endonuclease buffers
Restriction endonuclease buffers were purchased from New England Biolabs (Schwal-
bach, Germany).
2.4.1.1.1 NEBuffer 1 (yellow)
NEBuffer 1 contained 10 mM Bis Tris Propane-HCl, 10 mM MgCl2 and 1 mM
dithiothreitol (pH 7.0 at 25◦C).
2.4.1.1.2 NEBuffer 2 (blue)
NEBuffer 2 contained 250 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2 and 1 mM
dithiothreitol (pH 7.9 at 25◦C).
2.4.1.1.3 NEBuffer 3 (red)
NEBuffer 3 contained 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2 and 1 mM
dithiothreitol (pH 7.9 at 25◦C).
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2.4.1.1.4 NEBuffer 4 (green)
NEBuffer 4 contained 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM
magnesium acetate and 1 mM dithiothreitol (pH 7.9 at 25◦C).
2.4.1.2 Luria-Bertani (LB) medium
20 g LB-broth (corresponding 10 g bacto-trypon, 5 g bacto-yeast extract, 10 g NaCl,
pH 7.0; Invitrogen, Karlsruhe, Germany) were solved in 1 l ddH2O and autoclaved.
2.4.1.3 LB-agar
1 l LB medium was supplemented with 15 g bacto-agar (BDBiosciences Difco, Hei-
delberg, Germany) and autoclaved.
2.4.1.4 DNA preparation buffers
DNA preparation buffers were purchased from Qiagen (Hilden, Germany).
2.4.1.4.1 Resuspensionbuffer P1
Resuspensionbuffer P1 contained 50 mM Tris-HCl pH 8.0, 10 mM EDTA and
100 µg/ml RNAse A.
2.4.1.4.2 Lysisbuffer P2
Lysisbuffer P2 contained 200 mM NaOH and 1 % (w/v) SDS.
2.4.1.4.3 Neutralizationbuffer P3
Neutralizationbuffer P3 contained 3 M potassiumacetate pH 5,5.
2.4.1.4.4 Equilibrationbuffer QBT
Equilibrationbuffer QBT contained 750 mM NaCl, 50 mM MOPS pH 7.0, 15 %
isopropanol and 0,15 % triton X-100.
2.4.1.4.5 Washbuffer QC
Washbuffer QC contained 1 M NaCl, 50 mM MOPS pH 7.0 and 15 % isopropanol.
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2.4.1.4.6 Elutionbuffer QF
Elutionbuffer QF contained 1.25 mM NaCl, 50 mM Tris-HCl pH 8.5 and 15 %
isopropanol.
2.4.1.5 Sequencing and PCR primers
DNA oligonucleotides used as primers for sequencing and PCR are listed with their
sequences and annealing temperatures (TAN).
Primer sequence TAN
D1 5’-GCTAGATGTCCTGACTGTCC-3’ 58◦C
D2 5’-CCAGTAGCCCAGGTTGCATA-3’ 58◦C
Dneo 5’-TATGGCGCGCCATCGATCTC-3’ 58◦C
M13rev 5’-TTCACACAGGAAACAGCTATGACC-3’ 55◦C
ME18Sfw 5’-CTTCTGCTCTAAAAGCTGCG-3’ 55◦C
ME18Srev 5’-CGACCTGCAGCTCGAGCA-3’ 60◦C
SP6 5’-ATTTAGGTGACACTATAGAATA-3’ 50◦C
T3 5’-AATTAACCCTCACTAAAGGG-3’ 55◦C
T7 5’-GTAATACGACTCACTATAGGGC-3’ 55◦C
Tie1fw 5’-CGAAGGGATGGGAGAGAGAGC-3’ 58◦C
Tie1rev 5’-TGACGCTATGACGACGACGAT-3’ 58◦C
2.4.1.6 Vectors
The following vectors were used in this present work:
pBS-SK . . . . . . . . . . . Stratagene, Amsterdam, The Netherlands
pBSII-KS+ . . . . . . . . Stratagene, Amsterdam, The Netherlands
pBSII-SK+ . . . . . . . . Stratagene, Amsterdam, The Netherlands
pT7T3D-Pac . . . . . . Amersham Biosciences, Freiburg. Germany
pGEM3. . . . . . . . . . . . Promega, Mannheim, Germany
pME18S-FL3 . . . . . . S. Sugano
pλtriplex2 . . . . . . . . . BDBiosciences Clontech, Heidelberg, Germany
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pSPORT1 . . . . . . . . . Invitrogen, Karlsruhe, Germany
pCMV-SPORT6 . . . Invitrogen, Karlsruhe, Germany
2.4.1.7 Plasmids
Plasmids which were used in this present study are shown in Table 2.4.1, listing
their inserts and vector, as well as the source they were obtained from.
2.4.1.8 Bacterial strains
For molecular cloning techniques, the following bacterial E. coli strain XL1-Blue
(Stratagene, Amsterdam, The Netherlands) was used.
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’proAB
lacIqZDM15 Tn10 (Tetr)]
2.4.2 Molecular DNA cloning techniques
2.4.2.1 Preparation of chemically competent XL1-Blue bacteria
Bacteria of the E. coli strain XL1-Blue (Stratagene, Amsterdam, The Netherlands;
2.4.1.8) were prepared to be competent for chemical transformation (see 2.4.2.2).
Therefore, 5 ml LB medium containing 12.5 µg/ml tetracycline were inoculated
with a single bacterial clone of XL1-Blue and incubated in a shaker over night (250
rpm, 12 – 16 h, 37◦C). 400 ml LB medium (12.5 µg/ml tetracycline) were inoculated
with 4 ml of this over night culture and grown in a shaker (250 rpm, 37◦C) for about
3 hours until optical density at 600 nm wavelength OD600nm was between 0.5 – 0.6.
Bacteria were centrifuged (2500 g, 15 min, 4◦C) and carefully resuspended in 30 ml
TSB (5 % (v/v) DMSO, 10 mM MgCl2, 10 mM MgSO4, 10 % PEG 6000 in LB
medium) and incubated for 1 hour on ice. 200 µl aliquots were shock-frozen in
liquid nitrogen and stored at -80◦C until use.
2.4.2.2 Chemical transformation of competent bacteria
100 µl chemically competent E. coli, strain XL1-blue, were thawed on ice. An ice-
cold mixture of 20 µl 5× KCM (500 mM KCl, 150 mM CaCl2, 250 mMMgCl2), 79 µl
ddH2O and 1 µl DNA solution was added and gently resuspended. The mixture was
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plasmid insert vector source reference
mMIG-pME18S CXCL9 pME18S IMAGE:2135986 a b c
mMIG-pBSII CXCL9 pBSII-KS+ mMIG-pME18S c
mIP10-pBSII#12 CXCL10 pBSII-KS+ mIP10-pTOPO-108-32 d e c
mSDF1a-pBSII#21 CXCL12 pBSII-KS+ mSDF1a-pTOPO-82-11d e c
mMCP1-pBSII#52 CCL2 pBSII-KS+ mMCP1-pTOPO-101-92d e c
mMIP1a-pBS-SK#16 CCL3 pBS-SK IMAGE:533862a e c
mMIP1b-pT7T3D#19 CCL4 pT7T3D-Pac IMAGE:621095a b e
mMIP1b-pBSII CCL4 pBSII mMIP1b-pT7T3D#19 c
mRANTES-pT7T3D#22 CCL5 pT7T3D-Pac IMAGE:832342a b e c
mRANTES-pBSII CCL5 pBSII mRANTES-pT7T3D#22 c
mC10-pT7T3D CCL6 pT7T3D-Pac IMAGE:1195057a b c
mC10-pBSII CCL6 pBSII mC10-pT7T3D c
mCCL11-pT7T3D CCL11 pT7T3D IMAGE:1054858a b
mCCL11-pBSII CCL11 pBSII mCCL11-pT7T3D
mELC-pT7T3D CCL19 pT7T3D-Pac IMAGE:832043a b c
mELC-pBSII CCL19 pBSII-KS+ mELC-pT7T3D c
m6CKine-pT7T3D#1 CCL21 pT7T3D-Pac IMAGE:389013a b e c
m6CKine-pBSII CCL21 pBSII-KS+ m6CKine-pT7T3D#1 c
mABCD1-pT7T3D#5 CCL22 pT7T3D-Pac IMAGE:619257a b e c
mABCD1-pBSII CCL22 pBSII mABCD1-pT7T3D#5 c
mLT-pT7T3D XCL1 pT7T3D-Pac IMAGE:576815a b c
mLT-pBSII XCL1 pBSII-KS+ pLT-pT7T3D c
mFKN-pT7T3D CX3CL1 pT7T3D-Pac IMAGE:1230315a b
mFKN-pBSII CX3CL1 pBSII mFKN-pT7T3D
mCXCR3-pT7T3D CXCR3 pT7T3D-Pac IMAGE:3820689a b
mCXCR3-pBSII CXCR3 pBSII-KS+ mCXCR3-pT7T3D
mCCR7-pT7T3D CCR7 pT7T3D-Pac IMAGE:53342a b c
mCCR7-pBSII CCR7 pBSII-KS+ mCCR7-pT7T3D c
mCCR11-pT7T3D CCR11 pT7T3D-Pac IMAGE:51130a b
mCCR11-pBSII CCR11 pBSII-KS+ mCCR11-pT7T3D
mDuffy-pT7T3D DARC pT7T3D-Pac IMAGE:718084a b
mDuffy-pBSIID DARC pBSII-KS+ mDuffy-pT7T3D
mD6-pT7T3D#9 D6 pT7T3D-Pac IMAGE:3385312a b
mD6-pBSII#7 D6 pBSII-KS+ mD6-pT7T3D-Pac#9
mflk1ecII VEGFR2 pGEM3 f c g
acDNA EST clones were obtained from the rzpd (Deutsches Ressourcenzentrum fu¨r Genom-
forschung GmbH, Berlin, Germany, http://www.rzpd.de).
bLennon et al. (1996)
cAlt et al. (2002)
dKindly provided by Hellmut Augustin, Freiburg, Germany.
eAlt (1999)
fKindly provided by Georg Breier, Bad Nauheim, Germany.
gMillauer et al. (1993)
Table 2.4.1: Plasmids are listed with their inserts, vector backbones, their sources and references.
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incubated (20 min, 0◦C) and heat-shocked (10 min, RT). 1 ml prewarmed (37◦C) LB
medium was added and bacteria were shaked for 1 hour at 37◦C to allow development
of antibiotic resistance. 20 µl and 200 µl bacteria suspension were equally distributed
on LB-agar plates containing 100 µg/ml ampicillin (Roche, Mannheim, Germany)
and incubated (14 – 16 h, 37◦C). Single colonies were picked and grown in 5 ml
LB medium containing 50 µg/ml ampicillin (14 – 16 h, 37◦C). These cultures were
analyzed by DNA mini preparation (see 2.4.2.3) and used for DNA midi preparations
(see 2.4.2.4).
2.4.2.3 DNA mini preparation
5 ml LB medium containing 50 µg/ml ampicillin were inoculated with a single
bacterial clone and grown overnight for 12 – 16 hours. 1.5 ml of this suspension
were centrifuged (13000 rpm, 5 min, RT) and pellets were resuspended in 300 µl
resuspensionbuffer P1 (Qiagen, Hilden, Germany) by vortexing. Bacteria were lysed
by addition of 300 µl lysis buffer P2, mixed gently and incubated (3 min, RT).
Lysis was stopped by addition of 300 µl neutralization buffer P3, mixed gently and
incubated (15 min, 0◦C). Subsequently, cell debris and genomic DNA was removed
by centrifugation (13000 rpm, 30 min, 4◦C). 800 µl supernatant were mixed with
560 µl isopropanol and centrifuged again (13000 rpm, 30 min, 4◦C). DNA pellet was
washed twice in 70 % ethanol, air-dried and resuspended in 100 µl ddH2O. DNA
concentration was measured by photometry (see 2.4.2.9) and purity was checked by
agarose gel electrophoresis (see 2.4.2.6).
2.4.2.4 DNA midi preparation
Plasmid DNA was prepared using the Qiagen plasmid midi kit modified from the
suppliers protocol. Therefore, 50 ml LB medium containing 50 µg/ml ampicillin
were inoculated with with a single bacterial clone and grown over night for 12 –
16 hours. Bacterial suspension was centrifuged (4400 g, 15 min, RT). The bacterial
pellet was thoroughly resuspended in 4 ml resuspensionbuffer P1. 4 ml lysisbuffer P2
were added, gently mixed by inversion and incubated (5 min, RT). 4 ml neutraliza-
tionbuffer P3 were added and mixed gently to stop the lysis and then incubated on
ice (15 min, 0◦C). The mixture was centrifuged to pellet cell trash and genomic DNA
(4400 g, 30 min, 4◦C). Meanwhile, a fluted filter was mounted on top of an affinity-
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chromatography column (Qiagen-tip 100) and 4 ml equilibrationbuffer QBT1 were
applied to wet the filter and equilibrate the column. Centrifugation supernatant was
applied to the filter and allowed to flow through the column by gravity. Column
was washed twice with 10 ml washingbuffer QC. DNA was eluted with 5 ml elution-
buffer QF. Eluate was supplemented with 3.5 ml isopropanol at room temperature
to precipitate DNA and centrifuged (4400 g, 30 min, RT). Pellet was resuspended
in 1 ml 70 % ethanol, transferred to a 1.5 ml microcentrifuge column, washed twice
(13000 rpm, 5 min, 4◦C) and air-dried. Dried DNA was redissolved in either ddH2O
or 10 mM Tris HCl pH 8.5. DNA concentration and purity was measured photomet-
rically (see 2.4.2.9). Additionally, purity was checked by agarose gel electrophoresis
(see 2.4.2.6).
2.4.2.5 DNA digestion by restriction endonucleases
2.4.2.5.1 Qualititative digestion
DNA fragments were identified by digestion with restriction endonucleases (New
England Biolabs, Schwalbach, Germany; MBI Fermentas, St. Leon-Rot, Germany).
Therefore, 500 ng DNA were incubated with 3 – 5 units enzyme in 10 µl buffer (see
2.4.1.1) for 2 hours at 37◦C according to the manufacturer’s protocol. Then, DNA
was analyzed by agarose gel electrophoresis (see 2.4.2.6).
2.4.2.5.2 Quantitative digestion
Preparation of DNA fragments for subcloning was done by digestion of 5 mg
DNA with 20 units enzyme in 50 µl buffer for 2 hours at 37◦C according to the
manufacturer’s protocol. DNA fragments were immediately separated by agarose
gel electrophoresis (see 2.4.2.6) and extracted (see 2.4.2.7).
2.4.2.6 Agarose gel electrophoresis
DNA fragments were separated by horizontal agarose gel electrophoresis. 1 %
agarose (Cambrex; Biozym, Hamburg, Germany) was solved in 0.5 % TBE buffer
(45 mM Tris, 45 mM boric acid, 1 mM EDTA) by boiling. Solution was cooled
down to 55◦C and 0.5 µg/ml ethidium bromide were added. Gel was casted in a
tray, combs were immediately added to prepare slots for application of DNA sam-
ples and removed after the gel was solidified. The gel was placed in a gel chamber
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containing 0.5 % TBE buffer. Probes were supplemented with 5× loading buffer
(30 % (v/v) glycerol, 25 % (w/v) bromphenol blue, 0,25 % (w/v) xylenxyanol) and
applied to the slots. As a size marker, a DNA mixture was used (1-kb-ladder; In-
vitrogen, Karlsruhe, Germany). Gels were run at 10 V per centimeter gel length for
30 – 60 minutes. Then, DNA was visualized by ethidium bromide excitation with
UV light (λ=312 nm) and a picture was taken using a videocamera and printed on
thermal paper. Preparative gels were run at lower voltages and higher durations.
2.4.2.7 DNA agarose gel extraction
DNA was extracted from agarose gels using the QIAquick gel extraction kit (Qiagen,
Hilden, Germany). Therefore, DNA fragments were excised from agarose gel using a
clean, sharp scalpel. Subsequently, they were weighed, 3 volumes buffer QX1 (recipe
not provided by the manufacturer) were added and incubated for 10 min at 50◦C
while mixing regularly. One volume isopropanol was added, probes were applied
to QIAquick spin columns and centrifuged (13000 rpm, 1 min, RT). Columns were
washed with 750 µl washing buffer PE (recipe not provided by the manufacturer)
and centrifuged twice (13000 rpm, 1 min, RT). Afterwards, columns were incubated
with 30 µl ddH2O for 1 min and DNA was eluted by centrifugation (13000 rpm,
1 min, RT).
2.4.2.8 DNA fragment ligation
Ligation of compatible DNA fragments was done using the λ-phage T4 DNA ligase
(Roche, Mannheim, Germany). 100 ng vector DNA fragment were incubated with
a 5- to 10-fold molar excess of the integrating fragment in 10 µl 1× T4 ligase buffer
(660 mM Tris-HCl, 50 mM MgCl2, 10 mM dithiothreitol (DTT), 10 mM ATP,
pH 7.5). Incubation was done on thawing ice over night, so that probes slowly
warmed up to room temperature. The next day, bacteria were transformed with
this DNA (see 2.4.2.2).
2.4.2.9 Photometric nucleic acid concentration measurement
Nucleic acids absorb UV light at λ = 260nm, while proteins have their absorption
maximum at λ = 280nm. Therefore, DNA and RNA concentrations cDNA / cRNA
can be determined photometricly by UV light absorbance (A260) at λ = 260 nm if
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diluted by factor DF in TE buffer (10 mM Tris pH 8.0, 1 mM EDTA) according to
the following formulas:
cDNA = 50
ng
µl
×DF× A
cRNA = 47
ng
µl
×DF× A
Absorbance ratio λ260/λ280 indicates purity of the preparation and should range
between 1.8 and 2.0.
2.4.2.10 DNA sequence analysis
Sequencing of plasmid DNA was performed modified as described (Sanger et al.,
1977). Therefore, 200 – 400 ng plasmid DNA were incubated with 2 µl BigDye
Terminator v3.0 Cycle Sequencing Ready Reaction Kit Premix (Applied Biosys-
tems, Darmstadt, Germany) and 1 µl of a respective sequencing primer (10 µM; see
2.4.1.5). Sequencing reaction was done in a Gene Amp PCR System 9700 (Applied
Biosystems, Darmstadt, Germany) as follows:
96◦C 5min
96◦C 10sec
TAN 4min
 25 cycles
4◦C ∞
After reaction, 10 µl ddH2O were added and dye terminators were removed
using the QIAgen DyeEx Kit according to the manufacturer’s instructions. In brief,
Qiagen gel filtration columns were gently vortexed, opened and centrifuged (750 g,
3 min, RT). Sequencing reaction mixes were carefully applied to the middle of the
gel bed and centrifuged (750 g, 3 min, RT). Eluates were collected and measured
by an in-house service facility using a 96-capillary sequencer ABI Prism 3700 DNA
Analyzer (Applied Biosystems, Darmstadt, Germany).
2.4.3 Subtractive suppression hybridization
Brain microvessel preparation of mice afflicted with EAE and healthy littermates
as well as cell samples of encephalitogenic and non-encephalitogenic T cells were
created in this present work. From these materials, Bioserve Biotechnologies Ltd.
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(Laurel, MD, USA) created cDNA libraries cloning libraries, expression libraries and
subtractive suppression hybridization libraries.
2.4.4 High-throughput DNA mini preparation and sequenc-
ing
Screening of cDNA libraries was essentially done by DNA mini preparations
(see 2.4.2.3) and sequencing (see 2.4.2.10) as described. However, preparations
were performed in a 96-well plate format using the silicagel-membrane based QI-
Aprep 96 turbo Miniprep Kit (Qiagen, Hilden, Germany) in a high-throughput
approach according to the manufacturer’s instructions.
In detail, LB-agar was boiled in a microwave oven, cooled down to 55◦C in a
water bath and supplemented with 10 µg/ml ampicillin. Furthermore, 1 mM IPTG
and 50 µg/ml X-gal were added for blue-white selection. 150 mm plates were casted
under sterile conditions, dried for 2 hours and stored protected from light at 4◦C.
A small amount of frozen bacterial suspension was scratched out of the storage
tube without thawing. The storage tube was immediately stored at -80◦C again.
The small amount of bacterial suspension was thawed on ice and its volume was
checked, diluted and plated on dried LB-agar plates in different concentrations.
Plates were incubated (12 – 16 h, 37◦C). White clones were picked and 1.3 ml LB
medium containing 50 µg/ml ampicillin were inoculated in a 96-well masterblock
(Greiner, Nu¨rtingen, Germany). The block was sealed using a porous membrane
(Qiagen, Hilden, Germany) and incubated for 20 – 24 hours. Blocks were covered
with adhesive tape and bacteria were harvested by centrifugation (1500 g, 5 min,
RT). Adhesive tape was carefully stripped off and supernatant was removed by
quickly inverting the block and then firmly drying it on a paper towel. 250 µl buffer
P1 were added per well, the block was sealed with adhesive tape and vortexed
to resuspend bacteria. Tape was removed and 250 µl buffer P2 were added per
well. Block was sealed again, gently inverted 5 times and incubated (5 min, RT).
Tape was removed and lysis was stopped by addition of 350 µl N3 buffer, sealing
and gently inverting 5 times. Tape was removed and lysates were applied to a
TurboFilter plate being placed on top of a QIAprep plate in a QIAvac96 vacuum
holder. 200 mbar vacuum were applied using a vacuum regulator. Thereby, lysates
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were filtered through the TurboFilter to remove cell debris and DNA was bound on
the QIAprep plate. The vacuum holder was slowly ventilated and the TurboFilter
discarded. The QIAprep plate was washed twice with 900 µl PE and bottom outlets
were carefully dried on a towel paper. Plate was dried for 10 minutes at 600 –
750 mbar. 100 µl ddH2O were applied per well, incubated for 1 minute, DNA was
eluted into 96-well plates and stored at -20◦C.
For sequencing, 5 µl DNA solution were supplemented with 1 µl M13rev primer
and 2 µl BigDye premix exactly as described (see 2.4.2.10). After sequencing re-
action was done, 10 µl ddH2O were added. Unincorporated dye terminators were
removed by gel filtration using the DyeEx 96 kit (Qiagen, Hilden, Germany). There-
fore, DyeEx 96 plate were unsealed and dehydrated by centrifugation in a Sigma
Centrifuge 4K15C using a Qiagen rotor (2500 rpm, 3 min, RT). The DyeEx plate
was placed on an elution plate and the sequencing reactions were carefully applied
to the middle of the gel-bed surfaces. DNA was eluted by centrifugation (2500 rpm,
3 min, RT) and stored on ice. Sequencing was performed by an in-house service
facility using an ABI Prism 3700 DNA Analyzer (Applied Biosystems, Darmstadt,
Germany).
2.4.5 Genotyping by polymerase chain reaction
DNA was prepared from tail-biopsies of DARC knockout mice and analyzed by
polymerase chain reaction (PCR) to identify the genotype of these mice as follows.
2.4.5.1 DNA extraction from mouse tissue
Tails of at least 14 day old mice were cut with hot sterile scissors by the animal
caretakers. Tail biopsies were then lysed for 4 – 12 hours at 55◦C in 300 µl ready-
to-use lysis buffer (50 mM KCl, 1.5 mM MgCl2, 10 mM Tris-HCl pH 8.3, 0.45 %
NP-40, 0.45 % Tween 20) supplemented with 4 µl proteinase K (20 mg/ml; Merck,
Darmstadt, Germany). After complete lysis, proteinase K was heat-inactivated
(20 min, 95◦C). DNA solution was either stored at -20◦C or used directly for PCR
analysis.
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2.4.5.2 Analytic polymerase chain reaction
DNA was analyzed by two separate PCR reactions. One of them used primer D1
specific for the wildtype DARC allele exon 1 and primer D2 complementary to wild-
type DARC allele exon 2, thereby creating a 400-bp PCR product in DARC wildtype
mice. In DARC knockout mice, exon 1 had been been deleted and replaced by a
DNA sequence containing a neomycin resistance gene. Therefore, usage of primer
Dneo and D2 creates a 300 bp PCR product in DARC knockout mice. Additionally,
tie-1 specific primers were added as a control (see 2.4.1.5).
Identification of DNA segments was done in 20 µl analytical PCR reactions.
Therefore, 19 µl PCR reaction mix (2 µl 10× PCR buffer, 1.2 µl 25 mM MgCl2,
0.4 µl 10 mM dNTPs, 0.13 µl 100 µM primer 1, 0.13 µl 100 µM primer 2, 0.13 µl
100 µM primer 3, 0.13 µl 100 µM primer 4, 0.2 µl Taq-polymerase (5 U/µl; Promega,
Madison, WI, USA), 14.68 µl ddH2O) were supplemented with 1 µl DNA probe
(approximately 500 ng genomic mouse DNA or 1 pg plasmid DNA) and PCR was
performed in a Gene Amp PCR System 9700 (Applied Biosystems, Darmstadt,
Germany) under the following conditions:
Initial denaturing 94◦C 4 min
Denaturing 94◦C 30 sec
Hybridization 45 sec 35 cycles
Elongation 72◦C 60 sec

Final elongation 72◦C 5 min
4◦C ∞
Reaction products were analyzed by agarose gel electrophoresis (see 2.4.2.6).
2.4.6 Molecular RNA preparation and analysis
2.4.6.1 Silicagel membrane RNA preparation
Tissue samples were prepared as described (see 2.1.4.1) and washed three times in
ice-cold PBS. RNA was prepared using the RNeasy kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. Samples were resuspended in 600 µl buffer
RLT (recipe not provided by the manufacturer) supplemented with 1 % β-ME.
Tissue was homogenized by passing the lysate 20 times through a 0.6 mm needle
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fitted to a syringe and stored at -80◦C until further processing.
Probes were thawed and centrifuged (13000 rpm, 3 min, RT). Supernatant was
transferred to a new vial and 600 µl 70 % ethanol were added and mixed well by
pipetting. Sample was applied to an RNeasy mini spin column in successive 700 µl
aliquots and centrifuged (13000 rpm, 15 s, RT). Column was washed by addition
of 700 µl buffer RW1 (recipe not provided by the manufacturer) and centrifugation
(13000 rpm, 15 s, RT) as well as addition of 500 µl RPE (recipe not provided by the
manufacturer) and centrifugation (13000 rpm, 15 s, RT). Then column was washed
again with 500 µl RPE and centrifuged thoroughly to dry the RNeasy membrane
(13000 rpm, 2 min, RT). RNeasy column was transferred to a new collection tube
and eluated twice with 30 µl ddH2O. RNA concentration was measured (see 2.4.2.9)
and RNA analyzed by agarose gel electrophoresis (see 2.4.6.3).
2.4.6.2 Poly-A RNA preparation
Tissue samples were prepared as described (see 2.1.4.1) and washed three times
with ice-cold PBS. They were transferred to 50 ml centrifugation tubes, shock-
frozen in liquid nitrogen and stored at -80◦C. 4 ml solution D (4 M guanidine thio-
cyanate, 25 mM sodiumcitrate, 100 mM β-mercaptoethanol, 0.5 % lauroylsarcosine,
0.1 % antifoam A) were directly applied and the frozen material was dispersed using
an Ultra-Turrax T25 (IKA Labortechnik, Staufen, Germany), with speed setting
blue/red (about 80 %) for 30 seconds. Subsequently, 0.4 ml 2 M sodiumacetate
pH 4.0, 4 ml phenol and 0.8 ml chloroform were added. Mixture was vortexed for
20 seconds and incubated on ice (15 min, 0◦C). Suspensions were transferred to a
30 ml Corex-tube and centrifuged (8000 rpm, 15 min, 4◦C). Supernatant was sup-
plemented with 7 ml isopropanol and 1 µl tRNA (50 µg/µl) for 12 – 16 hours at
-20◦C. RNA was spun down (5000 rpm, 15 min, 4◦C) and air-dried. Optionally,
total RNA was dissolved in 100 µl ddH2O.
Alternatively, poly-A RNA could be prepared as follows. Total RNA pellet
was dissolved in 5 ml ice-cold STE (0.1 M NaCl, 20 mM Tris pH 7.4, 10 mM EDTA
pH 8.0) and 450 µl 5 M NaCl were added. Meanwhile, 1 g oligo dT cellulose (Roche,
Mannheim, Germany) was resuspended in loading buffer (0.4 M NaCl, 20 mM Tris
pH 7.4, 10 mM EDTA pH 8.0, 0.2 % SDS) and shaked gently (30 min, RT). 3 ml
oligo dT cellulose suspension were added to the total RNA solution and shaked
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gently (3 h – O/N, RT). Suspension was centrifuged (2000 rpm, 5 min, RT), washed
with 10 ml loading buffer (3 × 3 min, RT) and centrifuged (2000 rpm, 5 min, RT).
Oligo dT cellulose was washed with oligo dT washing buffer (0.1 M NaCl, 10 mM Tris
pH 7.4, 20 mM EDTA pH 8.0, 0.2 % SDS) (2 × 3 min) and centrifuged (2000 rpm,
5 min, RT). Oligo dT cellulose was resuspended in 6 ml oligo dT washing buffer and
applied to a column. Poly-A-RNA was eluted with 5 × 1 ml elution buffer (1 mM
Tris pH 7.4, 1 mM EDTA pH 8.0, 0.2 % SDS) into a Corex-tube. 200 µl were
stored for concentration measurement (see 2.4.2.9). Poly-A-RNA was precipitated
by addition of 1 µl tRNA (50 µg/µl) and 880 µl 2 M sodiumacetate pH 4.5. After
shaking, 12 ml 100 % ethanol were added, shaked again and stored at -20◦C over
night. RNA was pelleted by centrifugation (8000 rpm, 45 min, 4◦C), resuspended
in depc-H2O (1 l ddH2O thoroughly mixed with 200 µl depc, incubated for at least
1 hour and autoclaved) to a final concentration of 0.5 µg/µl and stored at -80◦C.
For reuse, oligo dT cellulose was incubated with 0.1 N sodiumhydroxide (30 min,
RT) and washed three times with loading buffer. pH was checked and if it was no
longer basic, oligo dT cellulose was stored at 4◦C for reuse up to 3 times.
2.4.6.3 RNA formaldehyde gel electrophoresis
Denaturing formaldehyde gels were used to analyze RNA preparations. Therefore,
0.4 g agarose were solved in 40 ml ddH2O by boiling and then cooled down to 60
◦C
in a water bath. 1 ml 50×MOPS buffer (1 M MOPS, 0.25 M sodiumacetate, 0.05 M
EDTA pH 7.0; stored light-protected at 4◦C) and 8.5 ml freshly prepared formalde-
hyde (37 %) were added and gel was casted using combs to prepare probe slots.
After gel was solidified, combs were removed, gel was put into the gel chamber and
running buffer (5 ml 50× MOPS, 41.25 ml formaldehyde (37 %), 250 ml ddH2O)
was added. Each RNA sample was supplemented with 30 µl RNA loading buffer
(20 µl formamid, 7 µl formaldehyde, 1 µl 50× MOPS, 2 µl saturated bromphenol
blue solution) to a maximum volume of 50 µl, mixed well, heated (5 min, 70◦C),
chilled on ice and loaded onto the gel. Gel was run with constant voltage (10 V/cm
gellength), stained with SYBR gold (Molecular Probes; MoBiTec, Go¨ttingen, Ger-
many) nucleic acid stain solution (diluted 10000-fold in 10 mM Tris, 1 mM EDTA
pH 8.0) for 20 minutes and photographed using a SYBR Gold gel stain photographic
filter (Molecular Probes; MoBiTec, Go¨ttingen, Germany).
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2.4.7 Gene array analysis
Tissue samples were prepared and shock-frozen in this present work (see 2.1.4.1) and
then were sent to Mrs. Kristina Duvefelt at Astra-Zeneca (So¨derta¨lje, Sweden), who
prepared RNA, applied it to a gene array and identified regulated genes as described
below. Resulting data were subsequently analyzed in this present work.
2.4.7.1 RNA preparation
mRNA was prepared at Astra-Zeneca from approximately 10 mg microvessels (wet
weight) with a Dynabeads mRNA direct kit (Dynal, Oslo, Norway) according to the
manufacturer’s protocol.
2.4.7.2 Gene array
Subsequently, RNA was processed at Astra-Zeneca to be applied to an Affymetrix
Mu6500 GeneChip array set (Affymetrix, Santa Clara, CA, USA) according to
manufacturer’s instructions as follows. Briefly, 75 % of the mRNA obtained were
used for cDNA synthesis with a SUPERSCRIPT choice system (Invitrogen, Carls-
bad, CA, USA) using a T7-dT24 primer for first strand synthesis. From this cDNA,
cRNA was synthesized using a MEGAscript kit (Ambion, Huntingdon, UK) and
biotinylated CTP and UTP nucleotides (Enzo, New York, NY, USA). 15 µg cRNA
were fragmented in fragmentation buffer (40 mM Tris/acetate pH 8.1, 100 mM
potassiumacetate, and 30 mM magnesiumacetate) by heating (35 min, 94◦C) prior
to hybridization. 12 µg of fragmented cRNA, control cRNA and grid alignment
oligonucleotide were hybridized to each array of the Mu6500 GeneChip Array Set
in a GeneChip hybridization oven (60 rpm, 16 h, 45◦C). Optionally, arrays were
washed and stained with streptavidin-phycoerythrin conjugate (Molecular Probes,
Eugene, OR, USA) in an Affymetrix fluidics station 400. Fluorescent signals were
detected by a gene array scanner (Hewlett Packard, Palo Alto, CA, USA). Signal
intensity of each gene present on the chips was calculated by Genechip Software
(Affymetrix, Santa Clara, CA, USA) and thereby quantitative gene expression lev-
els were obtained. Signal intensity was scaled to a single value, 150, for all probes
on a chip to allow comparison of samples.
Fold changes were calculated comparing the data of a main sample and a control
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sample. Changes smaller than 2-fold over baseline had to be considered as back-
ground variability according to the manufacturer. Presence of each individual gene
was scored by Affymetrix data analysis software. Regarding this score, an increase
in expression of an individual gene was only considered significant if this individual
gene was scored positive in the analyzed sample. Accordingly, a decrease in gene ex-
pression was only considered significant if this individual gene was scored present in
the control sample. All probe sets with the suffixes g, f and s for which duplicate
probe sets exist, were omitted.
2.4.7.3 Data analysis
In this present work, regulated genes were analyzed and sorted into functional groups
using NetAffx Analysis Center (Liu et al., 2003) applying respective Mu11K gene
chip probe set identifiers to the respective Mu6500 chip probes according to the
manufacturer. This analysis was supplemented by homology comparisons as well as
literature searches.
2.5 Biochemistry
2.5.1 Preparation of protein samples from animal tissue
Protein samples were prepared from different animal tissues. Therefore, animals
were sacrificed, tissues were prepared, washed in ice-cold PBS and 10 times ho-
mogenized on ice in a Dounce homogenizer (Kontes Glass, Vineland, NJ, USA)
containing either RIPA buffer (120 mM NaCl, 50 mM Tris pH 8.0, 1 % NP40, 0.5 %
sodium deoxycholate, 0.1 % SDS) or RIPAU buffer (6 M urea in RIPA buffer).
Buffers had been supplemented with protease inhibitors just before use (1 µg/ml
aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 mM PMSF). Lysates were cen-
trifuged (13000 rpm, 1 h, 4◦C) and pellets were discarded. Protein concentrations
of lysates were measured (see 2.5.2) and lysates analyzed.
2.5.2 Bicinchoninic acid (BCA) protein assay
This assay modified from Smith et al. (1985) was used to quantify protein concen-
trations utilizing alkaline reduction of cupric ions to cuprous ions by proteins and
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subsequent chelation and color development. Most detergents do not interfere with
this assay. In detail, a dilution series of a BSA calibration standard solutions (1000,
500, 250, 125, 62.5 and 31.25 µg/ml) was prepared. 10 µl of diluted calibration stan-
dard, tenfold and fiftyfold diluted protein-containing sample as well as 10 µl ddH2O
as a blank value were added in duplicates to a 96-well plate. Protein determination
reagent was freshly prepared by mixing 50 volumes bicinchoninic acid (BCA) solu-
tion (Sigma, Deisenhofen, Germany) with 1 volume 4 % coppersulfate-pentahydrate.
200 µl protein determination reagent were applied per well, plates were covered with
a lid, incubated (30 min, 37◦C), cooled down to room temperature and absorbance
A560 at λ = 560nm was measured. Blank values were subtracted, a calibration plot
prepared and protein sample concentration determined by interpolation.
2.5.3 Polyacrylamide gel electrophoresis (PAGE)
Separation of small proteins ranging from 5 – 20 kDa by electrophoresis was achieved
using a Tris-Tricine Buffer system modified as described (Schagger and von Jagow,
1987). A 10 % separating gel was cast and covered with butanol until it was poly-
merized. Butanol was removed and a stacking gel overlaid, using a comb to prepare
slots for probe application. The following solutions were used per two 6 × 8 cm gels:
separating gel stacking gel
48 % acrylamide / 1.5 % bisacrylamide 2440 µl 480 µl
3 M Tris-HCl / 0.3 %SDS pH 8.45 4000 µl 1488 µl
ddH2O 5960 µl 3032 µl
10 % APS 60 µl 30 µl
TEMED 12 µl 6 µl
After polymerization, combs were removed and slots were rinsed with ddH2O
once. Gels were set up in an electrophoresis apparatus (Peqlab, Erlangen, Germany).
The upper chamber was filled with cathode buffer (0.1 M Tris, 0.1 M Tricine, 0.1 %
SDS, pH 8.25; no correction of pH necessary, should be 8.25) and slots were carefully
washed again with cathode buffer using a syringe. Then, the lower chamber was
filled with anode buffer (0.2 M Tris-HCl pH 8.9). Protein samples were prepared as
follows. 75 µg tissue lysate or 25 ng recombinant protein were supplemented with
4× sample buffer (4 % SDS, 12 % glycerol, 50 mM Tris, 2 % β-mercaptoethanol,
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0.01 % Serva Blue G, pH 6.8) in a total volume of 50 µl. Samples were heated
(2 min, 95◦C) and applied to the slots. Gels were run with 30 V until the samples
left the stacking gel, then they were run with 100 V for 4 – 5 hours. Gels were either
stained with Coomassie Blue (see 2.5.4) or proteins were blotted on a membrane
(see 2.5.5) for further analysis (see 2.5.6).
2.5.4 Coomassie staining of SDS-gels
To visualize proteins on polyacrylamide gels, they were washed once with destaining
solution (45 % (v/v) methanol, 10 % (v/v) acetic acid, 45 % (v/v) ddH2O) and
stained in staining solution (0.05 % Coomassie Brilliant Blue in destaining solution)
for 12 – 16 hours. Then, gels were destained in destaining solution until specific
proteins bands became visible. Gels were dried for two hours at 80◦C using a Gel
Dryer Model 583 (Bio-Rad, Munich, Germany).
2.5.5 Semi-dry electroblot
After protein separation on polyacrylamide gel, proteins were electroblotted onto
nitrocellulose (0.2 µm; Schleicher & Schuell, Einbeck, Germany) or polyvinylidene
difluoride membranes (PVDF; 0.45 µm; Millipore, Schwalbach, Germany) using a
semi-dry transfer system. Therefore, 8 sheets of filter paper (Schleicher & Schuell,
Einbeck, Germany) as well as a blotting membrane were cut slightly larger than the
gel containing proteins. PVDF membranes were wet with methanol for 3 seconds
and then washed with ddH2O for about 1 – 2 minutes until the membrane no longer
floated on the water surface. Filter papers and the membrane were thoroughly
soaked with semi-dry blotting buffer (48 mM Tris, 39 mM glycine, 1.3 mM SDS,
20 % methanol). Four filter papers with the transfer membrane being placed on
top of it were put onto the anode unit of a semi-dry transfer cell (Trans-Blot SD;
Bio-Rad, Munich, Germany). The gel was taken out of the electrophoresis unit,
washed in semi-dry blotting buffer, put onto the transfer membrane and covered by
four filter papers. Care had to be taken to avoid air bubbles in between gel, transfer
membrane or filter papers. The cathode unit was put on top of the transfer stack
and proteins were transferred at constant current (1 mA / cm2, 1 hour).
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2.5.6 Immunoblotting (western blotting)
After electrophoretic transfer of proteins on a retentive membrane, unspecific protein
binding sites on the membrane were blocked with 5 % (w/v) low-fat milk powder
in TBST (20 mM Tris-HCl pH 7.6, 50 mM NaCl, 1 % (v/v) Tween 20) for 12 –
16 hours. Subsequently, first antibody (10 µg/ml in 5 % low-fat milk powder in
TBST) was applied (2 h, RT). Blots were washed in TBST (3 × 7 min, RT) and
a biotinylated secondary antibody was applied (see 2.3.1.3; 2 h, RT). In the mean-
while, a streptavidin-biotin-horseradish peroxidase (SA/biotin/HRP) complex was
prepared (StreptABComplex/HRP kit; DakoCytomation, Hamburg, Germany) by
mixing 1 µl streptavidin solution, 1 µl biotinylated-HRP solution and 10 ml Tris-HCl
pH 8.0. Blots were washed (3 × 7 min), the SA/biotin/HRP solution was applied
(1 hour, RT) and blots were washed again (3 × 7 min). Antigens were visualized
by chemoluminescence applying the SuperSignal Reagent Kit (Pierce; Bonn, Ger-
many) for 10 minutes followed by exposure to a photosensitive film (Hyperfilm ECL;
Amersham Biosciences, Freiburg, Germany) and its development and fixation (M35
X-OMAT Developer; Kodak, Stuttgart, Germany).
2.5.7 Proteomics
Proteomic analysis was done in cooperation with Dr. Bosse Franze´n at Astra-Zeneca
(So¨derta¨lje, Sweden). Tissue samples were prepared and shock-frozen in this present
work. Subsequently, they were sent to Astra-Zeneca and by them separated by 2-
dimensional gel electrophoresis. Spots of interest were identified by mass spectrom-
etry.
2.5.7.1 2-dimensional (2D) gel electrophoresis and image analysis
Unless otherwise stated, electrophoresis-grade chemicals were used (Genomic Solu-
tions, Chelmsford, MA, USA).
Frozen microvessels were lysed by addition of 20 µl lysis buffer (8 M urea, 0.5 %
(v/v) NP-40, 2 % (w/v) CHAPS, 0.3 % (w/v) DTT, 0.5 % (v/v) IPG buffer 3-10 NL
and 0.02 % BPB) per mg (wet weight) lysate. Lysates were mixed vigorously for
2 hours and remaining insoluble material was removed by centrifugation (15000 rpm,
15 min). Protein concentration was determined with a modified Bradford method
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(Bio-Rad, Hercules, CA, USA; Bradford (1976)) and 150 µg protein per sample were
applied to isoelectric focusing (IEF).
First-dimension IEF: Samples were diluted to a final volume of 350 µl lysis buffer
and applied to IPG-Phor sample trays (Amersham Biosciences, Uppsala, Sweden).
Immobiline DryStrips (18 cm pH 3 – 10 NL) were processed under a layer of Drystrip
cover fluid at 20◦C according to the manufacturer’s instructions. Focusing was
performed in 5 steps: 30 V for 12 h (rehydration step), 500 V for 1 h, gradient
up to 2000V during 2 h, gradient up to 8000V during 1 h and finally 8000 V for
5 h to reach a total of 48.6 kVh (all steps at 50 mA/strip). After IEF, cover fluid
was poured off and DryStrips were equilibrated while shaking gently (2 × 10 min).
First equilibration was performed in 30 % (w/v) glycerol, 6 M urea, 2 % SDS,
50 mM Tris-HCl pH 8.8, 65 mM DTT and a trace of BPB as tracking dye. Second
equilibration was done in the same solution, besides DTT being replaced by 260 mM
iodoacetamide (St. Louis, MO, USA; Gorg et al. (1995)).
Second-dimension SDS-PAGE: Equilibrated strips were sealed at the top of the
second-dimension polyacrylamidegel (12 % T, 2.1 % C) with 0.6 % agarose (FMC
BioProducts, Rockland, ME, USA) in SDS running buffer. Electrophoresis was
performed in the IsoDalt tank (Hoefer, San Francisco, CA, USA) until the tracking
dye reached the anodic end of the gels (100 V, approximately 18 h). Ten gels were
run in parallel.
Staining of gels: SYPRO Ruby staining was performed according to the manu-
facturer (Molecular Probes, Eugene, OR, USA) with minor modifications. Au-
tostainers (Amersham Biotechnologies, Uppsala, Sweden) were used in order to ob-
tain maximal reproducibility of staining intensities.
Image analysis: A cooled CCD camera-based instrument, Fluor-S MultiImager
(Bio-Rad, Hercules, CA, USA) was used to image SYPRO Ruby-stained gels. Raw
scans were processed using the 2D software PDQuest (v6.1.0; Bio-Rad, Hercules,
CA, USA). Spots were detected according to the manufacturer’s instructions. Spot
patterns of different gels were matched so that each spot was given a unique identi-
fication number (SSP). Resolved proteins were individually quantified and normal-
ized to the total intensity of detected spots in each gel. The average intensities
of resolved spots were compared by statistical and quantitative analysis using the
PDQuest software (Mann-Whitney non-parametric test, p<0.05; t-test, p<0.05) to
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find spots that differed quantitatively between controls and main groups.
2.5.7.2 Identification of proteins by mass spectrometry
2.5.7.2.1 In-gel digestion and peptide extraction
Protein spots of interest were cut out of stained wet gels using a scalpel. Gel pieces
were placed in 0.5 ml microreaction tubes which had been washed with ethanol
and in-gel digested according to the procedure described by the mass spectrometry
facility of the UCSF (University of San Fransisco, San Francisco, CA, USA) with
some modifications:
Step 1: Gel pieces were washed with water, incubated for 30 minutes and all
liquid was removed. Step 2: 25 mM bicarbonate (NH4HCO3) pH 8.0 was added and
incubated for 10 minutes. An equal volume of CH3CN was added and incubated
for another 10 minutes. Then step 2 was repeated. Step 3: Just enough CH3CN
was added to cover the gel pieces. After shrinking of the gel pieces, liquid was
removed. Step 4: Gel pieces were dried in a SpeedVac vacuum evaporator for
30 min. Step 5: Approximately 10 µl freshly prepared and chilled digestion solution
containing 10 ng/µl trypsin (Promega, Madison, WI, USA) in 25 mM NH4HCO3,
enough to cover the gel pieces, were added and incubated (30 min, RT). Step 6:
15 µl of 25 mM NH4HCO3 pH 8.0 buffer were added and incubated overnight at
37◦C. Step 7: Finally, peptides were extracted by addition of 25 µl 1 % formic acid
and incubation for 1 hour.
2.5.7.2.2 Matrix assisted laser desorption/ionization time-of-flight mass
spectrometry
1 – 2 µl peptide extracts were mixed with the same volume of α-cyano-4-
hydroxycinnamic acid solution (10 mg/ml; Hewlett-Packard, Bo¨blingen, Germany)
and mixtures were spotted onto a MALDI target (Micromass, Manchester, UK).
Internal mass calibration was achieved by use of trypsin autodigestion products
(842.51 Da and 2211.11 Da). External calibrants were added in a 1 : 2 mix-
ture of Hewlett-Packard α-cyano-4-hydroxycinnamic acid solution (10 mg/ml) and
1 % formic acid containing 50 – 100 fmol/µl each of human bradykinin ([M+H]+
1060.5691), angiotensin I ([M+H]+ 1296.685), renin ([M+H]+ 1759.9395), human
ACTH clip 18–39 ([M+H]+2465.199) and β-amyloid 1–28 ([M+H]+ 3263.511).
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MALDI-TOF-MS analysis was performed using a Micromass TofSpec 2E (Manch-
ester, UK) in reflectron mode.
2.5.7.2.3 Nano-electrospray ionization tandem mass spectrometry
Trypsin digest peptides were extracted and desalted with a small bed of Poros R20
(Applied Biosystems, Foster City, CA, USA) which had been prepared in a gel load
tip. Bed was prewashed with 50 % acetonitrile containing 1 % formic acid, followed
by 1 % formic acid before sample loading. 10 µl of peptide mixture were applied
on the Poros R20 bed, washed with 10 µl of 0.1 % formic acid and peptides were
eluted with 5 µl of 50 % acetonitrile containing 1 % formic acid into a borosilicate
nanospray capillary needle (Protana, Denmark) for subsequent MS/MS analysis.
The mass spectrometer used therefore was a hybrid instrument Q-ToF 2 (Micromass,
Manchester, UK) and was calibrated with fragment ions of [Glu1]-fibrinopeptide.
2.5.7.2.4 Database searching
SWISS-PROT / TrEMBL database searches using the Mascot peptide mass fin-
gerprinting search programs (Matrix Science, London, UK) identified the proteins.
Peptide mass fingerprinting criteria for positive identification were as follows; (i) hit
should score relevant by the Mascot algorithm; (ii) a minimum of four matching
peptides should be found; (iii) no less than 50 % of the measured masses should
match the theoretical fragments. If the isotopic pattern of the measured peptide
masses was clearly atypical, or could be attributed to known artifacts or to ad-
jacent, identified proteins, measured peptide masses could be excluded. Two or
more MS/MS sequences were required for identification by MS/MS, unless support-
ing peptide mass fingerprinting data were accessible. Theoretical Mr/pI values of
matching candidates were compared with calculated values obtained from the 2D
electrophoresis gels.
Chapter 3
Results
3.1 Expression and functional involvement of
chemokines in lymphocyte recruitment across
the endothelial BBB
Involvement of chemokines in recruiting lymphocytes across the endothelial blood-
brain barrier during EAE requires their presence at the luminal surface of the en-
dothelial blood-brain barrier. Therefore, they need to be either expressed by en-
dothelial cells themselves or would have to be actively transported from the CNS
parenchyma across the endothelial BBB to the luminal surface of the endothelial
cells by a yet unknown mechanism. Chemokine expression can only be investigated
by in situ hybridization.
3.1.1 Preparation of chemokine cDNA clones
Some cDNA clones which were required to detect murine chemokine and receptor
mRNA expression by in situ hybridization had been obtained and subcloned in an
earlier study (Table 2.4.1). Additional cDNA clones of murine chemokines and re-
ceptors were obtained as follows. Sequences were obtained by ENTREZ database
search (http://www.ncbi.nlm.nih.gov/entrez) and checked against the complete pri-
mary mouse cDNA database using the Basic Local Alignment Search Tool (BLAST)
algorithm (http://www.ncbi.nlm.nih.gov/BLAST/) to obtain the longest published
cDNA sequence of a given gene. Mouse expressed sequence tag (EST) database
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was searched for these sequences by BLAST to identify publicly available cDNA
clones. The longest cDNA containing the full proteincoding sequence was chosen
and ordered from rzpd (Deutsches Ressourcenzentrum fu¨r Genomforschung GmbH,
Berlin, Germany, http://www.rzpd.de). Thereby, cDNA clones for the chemokines
CXCL9, CCL6, CCL11, CCL19, XCL1; the chemokine receptors CXCR3, CCR7,
CCR11, CX3CL1 and the receptor D6 were obtained in this present study (Ta-
ble 2.4.1).
These potential clones were ordered, streaked on LB agar plates containing
100 µg/ml ampicillin, incubated (12 – 16 hours, 37◦C) and 3 – 6 single colonies
were investigated by DNA mini preparation and restriction analysis (Figure 3.1.1
and Figure 3.1.2) to exclude possible contaminations. Subsequently, clones were se-
quenced and analyzed by DNAstar (DNAstar Inc. Madison, WI, USA) to identify
correct cDNA inserts.
Probes for in situ hybridization have to be created by in vitro transcription using
T3, T7 or SP6 RNA polymerases. To create RNA probes from either direction,
plasmids containing cDNA clones for in situ hybridization need to have a promoter
site for two different RNA polymerases. It turned out in this present study, that
there are significant differences in promoter activity between different plasmids.
Especially the pT7T3D-Pac plasmid, which was used to create EST cDNA libraries,
has a very low efficiency T7 promoter site, while the promoter sites in pBSII-KS+
have a very good efficiency. Therefore, in situ hybridization probe inserts were
subcloned into pBSII-KS+ (Figure 3.1.1 and Figure 3.1.2).
3.1.2 Functional expression of the lymphoid chemokines
CCL19 and CCL21 at the blood-brain barrier
For chemokines to be involved in recruitment of T cells or monocytes across the
endothelial BBB, they need to be present at the luminal surface of the endothelial
cells. Thus, they need to be either expressed by the endothelial cells themselves
or would have to be actively transported from the CNS parenchyma across the en-
dothelial blood-brain barrier to the luminal surface of the endothelial cells. Searching
for chemokines being expressed at the endothelial BBB, in situ hybridizations for a
large panel of chemokines were performed on brain and spinal cord sections of SJL/N
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antisense T7ff
EcoRI BamHI
5’ CCL2-pBSII 3’
-31 447450-
T3 sense
antisense T3ff
EcoRI XhoI
5’ CCL3-pBS 3’
-76 1 279 710-
T7 sense
antisense T7ff
EcoRI Not-I
5’ CCL4-pBSII 3’
-62 1 279 599-
T3 sense
antisense T7ff
EcoRI Not-I
5’ CCL5-pBSII 3’
-57 1 275 504-
T3 sense
antisense T7ff
EcoRI Not-I
5’ CCL6-pBSII 3’
-49 1 351 808-
T3 sense
antisense T7ff
EcoRI Not-I
5’ CCL11-pBSII 3’
-42 1 294 958-
T3 sense
antisense T7ff
EcoRI Not-I
5’ CCL19-pBSII 3’
-275 1 327 563-
T3 sense
antisense T7ff
EcoRI Not-I
5’ CCL21-pT7T3D 3’
-43 1 402 991-
T3 sense
antisense T7ff
EcoRI Pst-I
5’ CCL21-pBSII 3’
-43 1 305 402-
T3 sense
antisense T7ff
EcoRI Not-I
5’ CCL22-pT7T3D 3’
-14 1 279 1910-
T3 sense
1000bp
Figure 3.1.1: cDNA inserts of plasmids encoding CC chemokines are shown. Coding sequences
are marked with bold numbers. Lengths of inserts are approximated by sequencing results up to
the named restriction sites, possibly including adapter sequences used for cloning. Additionally,
restriction sites and RNA polymerases used for creation of antisense and sense probes for in situ
hybridization are listed.
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antisense T7ff
Bsp120I/Xho-I Xho-I/EcoRI
5’ CXCL9-pBSII 3’
-75 1 381 1300-
T3 sense
500bp
antisense T7ff
EcoRI Xba-I
5’ CXCL10-pBSII 3’
-31 297300-
T3 sense
antisense T7ff
EcoRI Xba-I
5’ CXCL12-pBSII 3’
-31 270274-
T3 sense
antisense T7ff
EcoRI Not-I
5’ XCL1-pBSII 3’
-21 1 345 507-
T3 sense
antisense T7ff
EcoRV/EcoRI EcoRI/Pst-I
5’ CX3CL1-pBSII-I 3’
1 60 1022 1188-
T3 sense
antisense T7ff
EcoRI Not-I
5’ CXCR3-pBSII-3 3’
-60 1 1104 1565-
T3 sense
250bp
antisense T7ff
EcoRI Not-I
5’ CCR7-pBSII 3’
1 783 1137 1924-
T3 sense
500bp
antisense T7ff
EcoRI Not-I
5’ CCR11-pBSII 3’
1 754 1053 1631-
T3 sense
250bp
antisense T7ff
EcoRI Not-I
5’ DARC-pBSII 3’
1 651 1005 1083-
T3 sense
antisense T7ff
EcoRI Not-I
5’ D6-pBSII-7 3’
-124 1 1137 1376-
T3 sense
Figure 3.1.2: cDNA inserts of plasmids encoding CXC chemokines and chemokine receptors are
shown. Coding sequences are marked with bold numbers. Lengths of inserts are approximated by
sequencing results up to the named restriction sites, possibly including adapter sequences used for
cloning. Additionally, restriction sites and RNA polymerases used for creation of antisense and
sense probes for in situ hybridization are listed.
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brain spinal cord
inflamm. cells endoth. cells inflamm. cells endoth. cells
CXCL9 (MIG) ++ - ++ -
CXCL10 (IP-10) ++ - ++ -
CXCL12 (SDF-1)a + - + -
CCL2 (MCP-1) + - ++ -
CCL3 (MIP-1α) + - ++ -
CCL4 (MIP-1γ) + - ++ -
CCL5 (RANTES) + - ++ -
CCL6 (C10) ++ - ++ -
CCL19 (ELC) - ++ - ++
CCL21 (SLC) - ++ - ++
CCL22 (MDC) + - + -
XCL1(Lymphotactin) - - - -
aExpression was detected in choroid plexus and in brain parenchymal cells not spatially corre-
lated to inflammatory cuffs.
Table 3.1.1: Semiquantitative analysis of the expression of chemokine mRNA during EAE.
Semiquantitative analysis was performed by counting the total number of inflammatory cuffs per
section in relation to the number of inflammatory cuffs with specific in situ hybridization signals.
Results were divided into three groups: ++, >50 % of the infiltrates show positive cells; +, <
50 % of the infiltrates show positive signals; -, no detectable hybridization signal. (Reproduced
with permission from Alt et al., 2002).
mice, afflicted with EAE and of healthy SJL/N mice as a control (Figure 3.1.1 and
Figure 3.1.2). These results were taken together with the results from an earlier
study (Alt, 1999) and semiquantitatively analyzed (Table 3.1.1).
Besides CCL19 and CXCL12, expression of chemokine mRNA was not detectable
in brain and spinal cord sections of healthy SJL/N mice by in situ hybridization.
While CXCL12 was detected within the choroid plexus, in astrocytes or microglial
cells scattered throughout the CNS parenchyma and in some rare perivascular cells
(Figure 3.1.3), expression of CCL19 was localized to cerebral venules as shown by
a hybridization signal exactly resembling expression of the endothelial cell-specific
VEGF receptor 2 / flk-1 (Figure 3.1.4).
During EAE, expression of the lymphoid chemokine CCL19 was tremendously
upregulated and thereby detected in almost all venules which were surrounded by
inflammatory cuffs (Table 3.1.1 and Figure 3.1.5). Moreover, expression of another
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Figure 3.1.3: In situ hybridization analysis of CXCL12 mRNA expression in the healthy brain
of an SJL/N mouse is shown. A specific hybridization signal for CXCL12 can be localized to CNS
parenchymal cells of healthy SJL/N mice with the CXCL21 antisense probe, Additionally, CXCL12
expression can be detected in the choroid plexus. Sections are counterstained with toluidine blue.
Bright and dark field illumination are shown. Bar =100 µm.
lymphoid chemokine CCL21/SLC was observed to be induced in almost all venules
surrounded by perivascular infiltrates in brain and spinal cord sections of mice af-
flicted with active EAE. Expression of the common receptor for both chemokines,
CCR7, could be detected in a subpopulation of cells present within inflammatory
cuffs (Figure 3.1.5).
As expression of CCL19 and CCL21 has been described in lymph nodes be-
fore (Cyster, 1999; Luther et al., 2000), in situ hybridization was performed for
both chemokines on frozen sections of lymph nodes as a control for CNS expres-
sion of CCL19 and CCL21. Thereby, CCL19 expression was detected in stromal
cells located in the T cell zones of peripheral lymph nodes which had been derived
from healthy SJL/N mice (Figure 3.1.5). Additionally, expression of CCL21 mRNA
could be specifically detected in lymph node high endothelial venules (HEV) at lev-
els which were comparable to those found in inflamed venules in the CNS of mice
afflicted with EAE (Figure 3.1.5). In addition, CCR7 expression was observed in a
number of lymph node parenchymal cells (Figure 3.1.5).
Induction of no other chemokine investigated in this present study could be
detected in BBB endothelial cells during EAE (Table 3.1.1). Rather, expression
of these additionally expressed cells was observed within the brain or spinal cord
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Figure 3.1.4: In situ hybridization analysis of CCL19 mRNA expression in the healthy brain
of an SJL/N mouse is shown. A hybridization signal for CCL19 can be localized to venules of
the CNS of healthy SJL/N mice with the CCL19 antisense probe, whereas no hybridization signal
is seen with the CCL19 sense control probe. The endothelial cell specific hybridization signal for
VEGF-receptor-2 mRNA is shown for comparison. Sections are counterstained with toluidine blue.
Bar = 20 µm. (Reproduced with permission from Alt et al., 2002).
parenchyma, either in cells localized within inflammatory cuffs or alternatively in
astrocytes or microglial cells in no spatial relation to the distribution of cellular
infiltrates (Table 3.1.1). The expression pattern of CXCL12/SDF-1 in the CNS
during EAE was not distinguishable from its expression pattern in the healthy CNS.
Finally, expression of XCL1/lymphotactin could not be detected in brain or spinal
cords of mice afflicted with EAE.
Therefore, in contrast to the expression of the inflammatory chemokines like
CXCL9, CXCL10, CCL2, CCL3, CCL4, CCL5, CCL6 and CCL22, which were
only observed in cells within the CNS parenchyma, constitutive expression of the
lymphoid chemokine CCL19 and inducible expression of the lymphoid chemokine
CCL21 could be detected in CNS venules. Additionally, expression of their common
receptor, CCR7 in infiltrating cells during EAE implies a possible involvement of
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Figure 3.1.5: CCL19 and CCL21 are expressed at the inflamed BBB. In situ hybridization
analysis for CCL19, CCL21 and their common receptor CCR7 in the brain of an SJL/N mouse
afflicted with EAE (day 14, clinical score 2/3) and in a peripheral lymph node derived from a
healthy SJL/N mouse is shown. A specific hybridization signal for CCL19 and CCL21 mRNA can
be localized to inflamed vessels surrounded by inflammatory cells, whereas a hybridization signal
for CCR7 mRNA can be localized to individual cells present within the inflammatory cuff. Control
in situ hybridization for both lymphoid chemokines and their receptor on peripheral lymph nodes
demonstrates their known expression within the lymph node parenchyma (CCL19, CCR7) and in
high endothelial venules (CCL21). Sections are counterstained with toluidine blue. Bar = 20 µm.
(Reproduced with permission from Alt et al., 2002).
these chemokine/receptor pairs in recruitment of inflammatory cells across the BBB
into the CNS parenchyma.
3.1.3 CCL19 and CCL21 are present in inflammatory cuffs
in the CNS of mice afflicted with EAE
After having detected expression of CCL19 and CCL21 in blood-brain barrier en-
dothelial cells, the question arose if these two proteins are really present at the
endothelial blood-brain barrier. Therefore, immunohistochemistry was performed
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Figure 3.1.6: Detection of CCL19 and CCL21 on the protein level in healthy and EAE brain. In
healthy brain, immunostaining for CCL19 but not CCL21 can be demonstrated on a subpopulation
of venules throughout the brain. In EAE, immunostaining for both chemokines can be detected
within inflammatory cuffs. Identical staining with several control sera showed no background
staining (data not shown). Immunoperoxidase staining with hematoxyline counterstain. Bar =
20 µm. (Reproduced with permission from Alt et al., 2002).
on brain sections of mice afflicted with EAE and healthy littermates to localize
CCL19 and CCL21 proteins in the CNS of SJL/N mice. Consistent with the mRNA
expression pattern detected in the CNS of healthy SJL/N mice, a specific immuno-
staining for CCL19 could be observed on a small subpopulation of venules, while
CCL21 could not be detected in the healthy CNS (Figure 3.1.6). However, during
EAE, immunostaining was observed within perivascular infiltrates for both lymphoid
chemokines, CCL19 and CCL21 (Figure 3.1.6). This staining was mostly diffuse but
strictly limited to inflammatory cuffs. This suggests that both lymphoid chemokines
CCL19 and CCL21 might either be released into the perivascular space by the BBB
endothelial cells or might be additionally detected on inflammatory cells bound to
their specific receptors.
3.1.4 Quantification of CCL19 and CCL21 in whole brain
lysate of mice afflicted with EAE
Next we asked if CCL19 and CCL21 protein expression changes can be quantified
in the brain of mice afflicted with EAE in comparison to healthy untreated control
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Figure 3.1.7: A: Immunoblot of whole brain lysates with CCL19 and CCL21 antisera (AF880
and AF457) on PVDF membranes. Recombinant CCL19 and CCL21 could be detected. However,
neither of these two chemokines could be detected in either brain or spleen lysates. B: Immunoblot
without primary antibodies shows unspecific binding of the secondary antibody.
mice. Therefore, lysates were prepared from whole brains of SJL/N mice afflicted
with EAE and of healthy SJL/N mice. Furthermore, lysates were prepared from
spleens or lymph nodes of Balb/C mice, where CCL19 and CCL21 expression has
been described before. As chemokines are known to strongly bind to extracellular
matrix proteins, RIPA buffer containing anionic, cationic and neutral detergents
was used to create tissue lysates. Protein concentrations were determined by bicin-
choninic acid (BCA) assay. About 200 µg protein lysate were loaded per midi gel
lane and separated by Tris-Tricine buffered SDS-PAGE. As a control, 60 ng re-
combinant chemokine (R&D, Wiesbaden, Germany) were loaded. Proteins were
electroblotted on PVDF membranes. By immunoblot using either goat-anti-CCL19
antiserum (AF880; see 2.3.1.2) or goat-anti-CCL21 antiserum (AF457; see 2.3.1.2)
and a biotinylated donkey-anti-goat IgG second stage antibody, which was visual-
ized by chemiluminescence, recombinant CCL19 or CCL21 could be detected (Fig-
ure 3.1.7). However, although the secondary antibody alone did result in unspecific
binding, neither CCL19 nor CCL21 could be detected in any lysate (Figure 3.1.7).
To allow detection of CCL19 or CCL21 in the lysates, several modifications of the
protocol were undertaken. RIPA buffer containing 6 M urea was used for better
denaturation during lysate preparation to make sure that no chemokines remained
bound to extracellular matrix components, however, without success. Recombinant
CCL19 or CCL21, which had been added to the tissue lysates as a control, could be
detected as expected and were neither masked nor bound to other lysate proteins.
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Lysates were blotted alternatively on nitrocellulose or PVDF membranes, to test
if CCL19 or CCL21 preferably bound to either of these two membranes. PVDF
membranes appeared to result in slightly better control protein detection, however,
nothing was detected in any lysate (data not shown). Different primary antibod-
ies recognizing CCL21 (rabbit-anti-CCL21; Peprotech, London, UK; 4B1, kindly
provided by Martin Dorf, Boston, MA, USA) were tested but did not allow detec-
tion of the recombinant protein (data not shown). Alternate secondary antiserum
(rabbit-anti-goat; Vector; Linaris, Wertheim, Germany) did not allow detection of
the protein in lysates and provided even more unspecific signals (data not shown).
Therefore, CCL19 and CCL21 were not detectable by immunoblot in brain or spleen
lysates with the currently available antibodies.
3.1.5 CCR7 and CXCR3 are present on encephalitogenic
T lymphocytes
While CCR7 is the common receptor of CCL19 and CCL21, it has been described
by one research group, that mouse CCL21 does additionally bind and signal via
the CXC chemokine receptor CXCR3 (Soto et al., 1998). Therefore, immunohis-
tochemical stainings of cytospin preparations of encephalitogenic T lymphoblasts
were performed to investigate the presence of CCR7 and CXCR3. By this, specific
staining for both chemokine receptors, CCR7 and CXCR3 could be detected (Fig-
ure 3.1.8). This strongly suggests that CCL19 and CCL21 can bind to their specific
receptors on encephalitogenic T lymphoblasts.
3.1.6 Encephalitogenic T lymphocytes express L-selectin in
vivo
In contrast to other observations, that effector memory T lymphocytes do not ex-
press CCR7 and L-selectin (Sallusto et al., 2000), freshly restimulated encephali-
togenic T lymphoblasts did express CCR7, however, L-selectin surface expression
could not be detected by flow cytometry. Therefore, the questions arose, whether
they represent a new group of T cells and if they may express L-selectin in vivo. To
analyze this, freshly restimulated SJLB.PLP6 T lymphoblasts were labeled with Cell
Tracker Green (CTrG) and injected into SJL/N mice. After 48 and 72 hours, single
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Figure 3.1.8: CCR7 and CXCR3 are present on encephalitogenic T cell blasts. Immunostaining
for CCR7 and CXCR3 on cytospin preparations of SJL.PLP6 are shown. After fixation with
acetone, T cells were stained with purified goat anti CCR7 and purified goat anti-mouse CXCR3.
The apparent intracellular staining for CCR7 is partially explained by the fact that the antibody is
directed against the intracellular C terminus. Staining for CD45 is shown as positive control, and
staining with irrelevant goat IgG as a negative control. Both chemokine receptors can be detected
on encephalitogenic T lymphoblasts. Immunoperoxidase staining with hematoxyline counterstain.
Bar = 20 µm. (Reproduced with permission from Alt et al., 2002).
cell suspensions were prepared from spleens, blood samples, mesenteric and periph-
eral (mixture of axillary, inguinal and popliteal) lymph nodes. These cells were
stained with Mel 14 and phycoerythrin-conjugated secondary antibody to detect
L-selectin surface expression. Cells were analyzed by flow cytometry, scattergating
for lymphocytes and gated for green fluorescent cells (Figure 3.1.9A).
CTrG-labeled T lymphoblasts had been cultured in parallel in vitro for flow cy-
tometer calibration to be able to find the CTrG stained cell in vitro. After 48 hours,
99.6 % of these SJLB.PLP6 cells stained positive for CTrG, however, they did not
express L-selectin (Figure 3.1.9B). 0.3 % of the splenocytes, 0.1 % of the mesenteric
lymphocytes and 0.7 % of the peripheral lymphocytes stained positive for CTrG,
while blood samples did not contain enough cells for analysis. L-selectin expression
of these freshly prepared cells was increased (Figure 3.1.9B).
After 72 hours, 99.9 % of the in vitro cultured SJLB.PLP6 remained positive
for CTrG, while L-selectin surface expression was not detectable (Figure 3.1.9B).
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Figure 3.1.9: L-selectin expression of CTrG labeled encephalitogenic T lymphoblasts in vivo.
SJLB.PLP6 lymphoblasts were labeled with CTrG directly after restimulation and intravenously
injected into SJL/N mice. In parallel, a small subset of labeled cells was cultured in vitro. After 48
and 72 hours, splenocytes, mesenteric lymphocytes and peripheral lymphocytes were prepared and
stained with Mel-14, an antibody directed against murine L-selectin. A: Cells were scattergated
for lymphocytes (G1) and for green fluorescent cells (G2). B: In comparison to in vitro cultured
SJLB.PLP6 T lymphocytes, L-selectin expression is increased in splenocytes, mesenteric lymph
node cells (MLN) and peripheral lymph node cells (PLN) after 2 or 3 days in vivo. 9B5 negative
control stained cells are shown in blue, M1/9 positive control stained cells are shown in green and
Mel-14 stained cells are shown in red. 1 of 2 independent experiments is shown.
However, numbers of CTrG positive cells of freshly prepared lymph node cells were
increased (splenocytes 4.4 %, mesenteric lymphocytes 2.6 %, peripheral lympho-
cytes 3.4 %). Additionally, there were distinct L-selectin expressing populations
detectable in spleen and mesenteric lymph nodes and a very prominent population
in the peripheral lymph nodes (Figure 3.1.9B). Therefore we concluded, that en-
cephalitogenic T lymphoblasts can reexpress L-selectin in vivo, while losing it in
vitro.
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3.1.7 Encephalitogenic T lymphocytes specifically chemo-
tax towards CCL19 and CCL21
Next we asked, whether encephalitogenic T cells can specifically chemotax towards
CCL19 and CCL21 in a two-chamber system in vitro (see 2.1.6). Already in the ab-
sence of either chemokine, encephalitogenic T lymphocytes spontaneously migrated
across fibronectin-coated filters into the lower chamber of the two-chamber system
(Figure 3.1.10).
Addition of increasing concentrations of either CCL19 or CCL21 to the lower
chambers did significantly increase the number of migrating T lymphocytes. Migra-
tion was concentration dependent, with CCL19 having its effect at concentrations
of 1 ng/ml and CCL21 at 10 ng/ml. Interestingly, only chemotaxis towards CCL19
but not CCL21 reached a plateau level. Simultaneous presence of both chemo-
kines in the lower chamber did not increase the chemotactic efficacy (Figure 3.1.11).
CCL19 or CCL21 induced chemotaxis of towards CCL19 or CCL21 was comparable
to that observed for lymphocytes which had been freshly isolated from lymph nodes
(Figure 3.1.10). As pretreatment of either chemokine with a respective blocking
antibody reduced the chemotaxis rate of autoaggressive T lymphocytes to back-
ground levels, migration was specifically induced by the investigated chemokines
(Figure 3.1.10). Additionally, increased migration towards both chemokines required
intact Gαi-protein signaling of the T lymphocytes, as pretreatment with PTX but
not with MTX reduced migration to background levels irrespective of chemokine
concentrations (Figure 3.1.10). Therefore, CCL19 and CCL21 specifically induced
G-protein-dependent chemotaxis of encephalitogenic T cells in vitro.
3.1.8 Transmigration of encephalitogenic T cells towards
chemokines
The next question was, whether encephalitogenic T cells transmigrate across brain
endothelioma cell lines towards chemokines in a concentration dependent manner.
To answer this question, bEnd5 cells were seeded onto two-chamber filter inserts
and grown for two days until confluency. Then, chemokines were added to the
lower chamber and encephalitogenic T cells, which were untreated or pretreated
with either PTX or MTX, were added to the upper chamber. Cells were incubated
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Figure 3.1.10: Encephalitogenic T cells specifically chemotax towards CCL19 and CCL21.
(A) Migration of SJL.PLP6 across fibronectin-coated Transwell filters is shown. SJL.PLP6 mi-
grated in a concentration-dependent manner towards CCL19 or CCL21 (triangles). Migration
could be specifically reduced to spontaneous migration levels by pretreatment of the chemokine
with its respective blocking antibody (bars; 50 µg/ml). Pretreatment of SJL.PLP6 with pertussis
toxin (PTX) (stars) but not mutated PTX (MTX; diamonds) abrogated the directed migration
to the level of spontaneous migration. MTX (PTX-9K/129G) had been kindly provided by R.
Rappuoli, Chiron SpA, Siena, Italy (Pizza et al., 1989). (B) Comparison of chemotaxis of en-
cephalitogenic T cells (triangles) and lymphocytes (circles) freshly isolated from lymph nodes is
shown. Encephalitogenic T cells demonstrate increased migration towards CCL19 and CCL21 at
lower concentrations compared to increased migration of lymph node lymphocytes. (Reproduced
with permission from Alt et al., 2002).
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Figure 3.1.11: Combination of CCL19, CCL21 and CXCL12 does not increase specific chemotac-
tic efficacy of encephalitogenic T cells as shown by comparison of chemotactic response to either
single chemokines (open symbols) or combinations of two chemokines (filled symbols). One repre-
sentative experiments shows specific chemotaxis of encephalitogenic T cells towards CCL19 (open
triangles) and CCL21 (open diamonds), while combination of these two chemokines (filled trian-
gles) does not increase chemotaxis but rather resembles the chemotactic response towards CCL19
(n=2). Additionally, preliminary data of one experiment show that neither combined application
of CCL19/CXCL12 (filled circles) nor CCL21/CXCL12 (filled quadrangles) result in increased
chemotaxis as compared to CXCL12 alone (empty circles).
Figure 3.1.12: Transmigration of encephalitogenic T cells across bEnd5 cells towards CCL21.
Four independent experiments showing numbers of SJLB.PLP6 lymphocytes at day 2 after res-
timulation transmigrating across TNFα–stimulated bEnd5 endothelioma cell monolayers towards
increasing concentrations of CCL21 (circles, solid lines). As a comparison, T lymphocytes had
been pretreated with either PTX (triangles, dotted lines) to block chemokine receptor signaling as
well as MTX (diamonds, dashed lines) as a control.
for four hours and migrated cells were counted using a CASY TT Cell Counter
(Figure 3.1.12). Untreated cells showed a dose-dependent migration towards the
chemokine, which could be inhibited by blocking chemokine receptor signaling with
PTX treatment. However, although PTX treatment blocked the dose dependent
migration towards each chemokine, it surprisingly resulted in increased baseline
migration of the encephalitogenic T cells, suggesting a haptotactic effect of PTX.
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Even more surprisingly, MTX pretreatment of T cells, which was used as a negative
control and should not have had any effect, did in fact increase the baseline levels of
T cell migration in the majority of the experiments. Furthermore, additional factors
may be important in this experimental setup. I. e., chemokines may be expressed
by bEnd5 endothelioma cells themselves, which was not measured. Taken together,
these experiments have to be considered inconclusive.
3.1.9 Reduced binding of encephalitogenic T lymphocytes
to inflamed brain venules in vitro
In order to get more direct evidence of CCL19 and CCL21 to be functionally in-
volved in adhesion strengthening of encephalitogenic T lymphocytes to CNS venules,
modified Stamper-Woodruff-binding assays were performed on unfixed frozen sec-
tions of EAE brains (Stamper and Woodruff, 1976; Steffen et al., 1994). Thereby,
selective binding of encephalitogenic T lymphocytes to inflamed venules exposed in
frozen sections of EAE brains was observed (Figure 3.1.13A). General inhibition of
chemokine receptor signaling by pretreatment of T lymphocytes with PTX or spe-
cific functional deletion of CCR7 and CXCR3 by desensitization with high doses of
CCL19 and CCL21 significantly reduced the number of firmly adhering T lympho-
cytes on inflamed venules in EAE brains (Figure 3.1.13). Alternatively, the number
of T lymphocytes firmly adhering to cerebral vessels of EAE brains was reduced
by pretreatment of frozen sections with blocking antisera directed against CCL19
and CCL21. Therefore, functional binding of the lymphoid chemokines CCL19 and
CCL21 to their respective receptor(s) participates in adhesion strengthening induc-
tion of encephalitogenic T lymphocytes to inflamed venules located in EAE brains
in vitro.
3.1.10 Functional involvement of CCL19 and CCL21 in lym-
phocyte recruitment across the endothelial BBB in
vivo
Next we asked, if we can prove functional involvement of CCL19 and CCL21 in
lymphocyte recruitment across the endothelial BBB in vivo. Therefore, encephali-
togenic T lymphoblasts SJLB.PLP7 were stained with Cell Tracker Orange (CTrO)
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Figure 3.1.13: A: CCL19 and CCL21 are involved in adhesion strengthening of encephalitogenic
T cells to inflamed vessels in EAE brain. Adhesion of the encephalitogenic T cells to inflamed
venules exposed in serial frozen sections of EAE brains is shown for each condition. Pretreat-
ment of T lymphocytes with PTX significantly reduced the number of firmly adhering T cells
(a: control, 26 bound T cells; b: PTX-pretreated T cells, 3 bound T cells) as did desensitization
of T lymphocytes with CCL19 and CCL21 (c: control, 15 bound T cells; d: desensitized T cells, 8
bound T cells). Also blocking CCL19 and CCL21 interfered with adhesion strengthening of T cells
(e: control, 23 bound T cells; f: in presence of blocking antibodies, 8 bound T cells). Toluidine
blue counterstain. Bar = 50 µm. (Reproduced with permission from Alt et al., 2002). B: A
representative experiment shows adhesion of PTX pretreated (a) and untreated (b) encephalito-
genic T cells to inflamed venules exposed in serial frozen sections of EAE brains. Pretreatment of
T lymphocytes with PTX significantly reduced the number of firmly adhering T cells which was
counted for serial sections. Inflamed venules which could not be analyzed due to tissue quality are
marked with an X, while numbers of T cells which aggregated with each other were marked with
an asterix. In both cases, these results were excluded. Toluidine blue counterstain.
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Figure 3.1.14: Firm adhesion of encephalitogenic T lymphoblasts after CCL19 desensitization
as analyzed by intravital fluorescence videomicroscopy in SJL/N mice (n = 2). Desensitization
with CCL19 reduces firmly adhering SJLB.PLP7 T lymphoblasts as compared to mock-treated
T lymphoblasts in vivo.
and optionally pretreated with a high concentration of CCL19 to desensitize CCR7
by receptor internalization. Dr. Peter Vajkoczy (Klinikum Mannheim, University
of Heidelberg) prepared a catheter in the right common carotid artery of SJL/N
mice and opened the spine and dura mater to be able to watch the spinal cord.
He injected FITC-dextrane into the right carotid artery to visualize the vascular
system. Subsequently, CTrO labeled encephalitogenic T cells were injected and in-
teraction with spinal cord microvasculature was followed. The following analysis
was performed in this present work. Lymphoblasts adhering to spinal cord venules
were counted 10 min, 1 hour and 2 hours after injection. Comparison of CCL19-
and mock-pretreated T lymphoblasts revealed a slightly reduced firm adhesion of en-
cephalitogenic T lymphoblasts to spinal cord microvessels (Figure 3.1.14). Although
this preliminary experiment proposes functional involvement of CCL19 in lympho-
cyte recruitment across the endothelial BBB in vivo, the results has to be considered
not significant. Additional studies are required to obtain final proof.
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3.2 Gene and protein expression profiling of cere-
bral microvessels in EAE
3.2.1 Gene chip analysis of cerebral microvessels
In order to identify new genes being involved in lymphocyte recruitment from the
bloodstream across the endothelial BBB into the brain parenchyma, in this present
work cerebral microvessels were isolated from two different mouse strains afflicted
with EAE as well as age and strain-matched healthy mice (see 2.1.4.1.2).
These microvessel preparations were shock-frozen and sent to Mrs. Kristina Du-
vefelt (Astra-Zeneca, So¨derta¨lje, Sweden), who performed the following experiments:
0.25 mg mRNA was obtained from 10 mg cerebral microvessels (wet weight) isolated
from 12 C57Bl/6 mice afflicted with EAE (day 12 post immunization, mean disease
score 0.5 ± 0.1) and 0.60 mg mRNA were isolated from 10 mg cerebral microvessels
(wet weight) of 9 SJL mice afflicted with EAE (day 14 p.I., mean clinical disease score
2.8 ± 1.2). In both cases, control preparations were done from respective numbers
of age and strain-matched healthy mice. Oligonucleotide microarrays representing
6500 murine genes and ESTs were used to investigate gene expression profiles of
cerebral microvessels isolated from two different mouse strains afflicted with EAE
and compared to gene expression profiles obtained for cerebral microvessels isolated
from age and strain-matched healthy mice.
In this present thesis, 2-fold expression changes were considered to be significant,
according to the manufacturer. 238 regulated genes were found in tissue samples
derived from C57Bl/6 mice, 139 genes were upregulated and 99 genes were down-
regulated. In cerebral microvessels derived from SJL mice 177 regulated genes were
found, 134 of which were upregulated and 43 downregulated. These regulated genes
were evaluated and sorted into functional clusters. When comparing both gene ar-
ray profiles 128 of the genes regulated in each model were found to be regulated in
cerebral microvessel preparations derived from both EAE models, while 288 genes
were found in preparations from either EAE model (Figure 3.2.1). Thus, common
but also uniquely regulated gene expression was defined in the present approach.
Genes coding for proteins involved in different cellular and molecular processes were
found and great care was taken to functionally group them into 26 different sub-
86 CHAPTER 3. RESULTS
Figure 3.2.1: Cluster Analysis of Microarrays. 288 genes were found to be regulated in ei-
ther C57Bl/6 or SJL mice during EAE and sorted into different functional groups. Groups which
were mainly upregulated are shown in white, genes which were mainly downregulated are shown
in black and groups of genes with similar numbers of upregulated and downregulated genes are
shown in gray. About one quarter of the regulated genes was involved in immune responses: im-
mune receptors (IR), antigen presentation (AP), adhesion molecules and their modification (AM),
cytokines, chemokines and receptors (CK) and innate immunity (II). Another quarter of molecules
was involved in general metabolism and transport mechanisms: enzymes and metabolism (ENZ),
lipid metabolism (LM), channels and transporters (CT), vesicular transport, secretory pathways
and membrane traffic (VT), junctional and cell-cell contact molecules (J). A third quarter of genes
was involved in regulatory processes: signal transduction (ST), phosphatases (P), transcription
factors and nuclear proteins (TF) and protein synthesis (PS). The last quarter consisted of genes
involved in different functions like cytoskeletal molecules (CM), extracellular matrix (ECM), type
I interferon regulated molecules (IFN), glycosylation enzymes (GLY), hormones, mediators and
receptors (H), cell cycle, cell growth, cell survival and apoptosis (CC), growth factors, receptors
and related molecules (GF), CNS-related molecules (CNS), coagulation (CA), lysosomal proteins
(LY) and miscellaneous (M).
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groups (Table 3.2.1). Besides these previously described genes, 11 genes of unknown
function had been found, which require further investigation (Table 3.2.1: U).
Table 3.2.1: Genes which were up- or downregulated at least 2-fold according to the non-antibody-
enhanced gene array in cerebral microvessels of EAE afflicted C57Bl/6 (MOG-induced EAE) and
SJL/N (PLP-induced EAE) mice are listed. Genes are grouped by function of their geneproducts
and listed alphabetically. Within each group genes regulated in both EAE models are listed first.
Respective gene accession numbers and fold change values in either mouse strain are shown. Data
for gene regulation detected only by antibody-enhanced gene array are not included except a given
gene was found to be regulated in both EAE models including these values. Values obtained only
by antibody-enhanced gene array are marked with an asterix.
acc. no. name MOG PLP
adhesion molecules and their modification (AM)
X14951 β2-integrin 7.1 7.9
M68903 β7-integrin 2.6 3.9
L32812 CD157 antigen 4.1 6.7*
X17501 CD48 antigen 4.3 3.2
Z16078 CD53 antigen 2.9 3.2
X97227 CD53 antigen 3.2 3.0
X14943 contactin 1 -3.8 -3.2
M31585 intercellular adhesion molecule-1 2.0 2.7
M25324 L-selectin 7.7* 2.4
X68273 macrosialin 5.2 7.0*
M87861 P-selectin 3.0 3.1*
X91144 P-selectin glycoprotein ligand 1 4.4 5.0
W08454 transmembrane 4 superfamily member 8, pending -2.3 -2.1*
M87862 E-selectin 7.0
D26483 transmembrane 4 superfamily member 2 -5.0
Y00023 CD2 antigen 5.3
AA028405 intercellular adhesion molecule-2 -4.3
AA124859 intercellular adhesion molecule-2 -4.0
L15429 transmembrane 4 superfamily member 1 -2.2
antigen presentation (AP)
V01527 class II antigen, I-A-beta 3.8 5.5
K01923 histocompatibility 2, class II antigen A, alpha 12.8* 7.3
U35323 histocompatibility 2, class II, locus Mb1 2.5* 2.7
M57890 histocompatibility 2, complement component factor B 21.6 7.1
X00496 Ia-associated invariant chain 3.6 3.5
M55637 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 3.1
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Table 3.2.1: Regulated genes during EAE in cerebral microvessels of C57Bl/6 and SJL/N mice
acc. no. name MOG PLP
X00702 histocompatibility 2, class II antigen E beta 4.2
X62743 histocompatibility 2, class II, locus Mb1 5.9
X62742 histocompatibility 2, class II, locus Mb1 7.2
cell cycle, cell growth, cell survival and apoptosis(CC)
L16462 B-cell leukemia/lymphoma 2 related protein A1a 2.6 13.5
U09507 cyclin-dependent kinase inhibitor 1A (P21) 2.3 3.2
X59846 growth arrest specific gene 6 -2.0 -4.1
X82786 Ki-67 antigen 5.4* 3.5
X70398 P311 -2.8 -6.8
AA059662 protease, serine, 11 (Igf binding) -2.9 -3.9
M90397 B-cell leukemia/lymphoma 3 11.1
M64292 B-cell translocation gene 2 2.1
U22399 cyclin-dependent kinase inhibitor 1C (P57) -2.1
X67644 immediate early response 3 6.5
M93310 metallothionein-III -2.8
X83570 neuronatin -2.2
D49429 RAD21 homolog (S. pombe) -2.3
X92665 ubiquitin-conjugating enzyme E2E 1 -2.7
M64279 B lymphoma Mo-MLV insertion region 1 -2.6
L49433 baculoviral IAP repeat-containing 3 2.3
M83749 cyclin D2 -2.4
X54149 growth arrest and DNA-damage-inducible 45 β 4.1
channels and transporters (CT)
M92378 gamma-aminobutyric acid (GABA-A) transporter 1 -5.0 -2.3*
L02914 aquaporin 1 -3.3
X61433 ATPase, Na+/K+ transporting, beta 1 polypeptide -2.4
M14757 ATP-binding cassette, sub-family B (MDR/TAP), member 1B 3.2
AA145535 FXYD domain-containing ion transport regulator 1 -2.1
J04036 solute carrier family 4 (anion exchanger), member 2 -5.5
U20372 voltage-dependent calcium channel β3 subunit -3.3
AA109109 transient receptor potential cation channel, subfamily C, mem-
ber 2
-2.2
U69135 uncoupling protein 2, mitochondrial 2.7
CNS-related molecules (CNS)
X72230 5-hydroxytryptamine (serotonin) receptor 2C -3.0
X59520 cholecystokinin -4.8
U51908 neurotensin receptor 2 -6.2
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Table 3.2.1: Regulated genes during EAE in cerebral microvessels of C57Bl/6 and SJL/N mice
acc. no. name MOG PLP
M37335 proteolipid protein -5.2
U57324 presenilin 2 2.8
coagulation (CA)
M16238 fibrinogen-like protein 2 2.6 3.4
W70579 coagulation factor X 2.7
J03520 tissue plasminogen activator 2.9
cytokines, chemokines and receptors (CK)
D17292 adrenomedullin receptor 5.5 2.1
X80992 bone morphogenetic protein 6 -2.8 -2.7*
M19681 CCL2 2.7 4.8
U02298 CCL5 5.8 11.3
M58004 CCL6 11.5 6.4
X70058 CCL7 6.4 4.3
U15209 CCL9 7.4 20.1
J04596 CXCL1 5.8 4.1*
M86829 CXCL10 2.2 2.8
M34815 CXCL9 5.6 8.2
M58288 G-CSF receptor 12.5 6.0
M64404 interleukin-1 receptor antagonist 2.0* 3.6
M15131 interleukin-1β 12.0 9.8
M83649 tumor necrosis factor receptor superfamily member 6 2.6 2.8
U77630 adrenomedullin 8.4
U56819 CCR2 7.8
M20658 CD121a antigen 2.2
M27960 CD124 antigen 2.6
U21795 CD132 antigen 2.0
X57796 tumor necrosis factor receptor superfamily member 1a 2.4
M59378 tumor necrosis factor receptor superfamily member 1b 2.2
X57413 transforming growth factor β 2 -2.7
U06950 tumor necrosis factor 4.1
cytoskeletal molecules (CM)
AA106190 calmodulin-like 4 -18.5 -3.0*
X54511 capping protein (actin filament), gelsolin-like 2.9 2.0
M90316 lymphocyte specific 1 3.3 4.1
D00208 S100 calcium binding protein A4 2.8 3.3
X66449 S100 calcium binding protein A6 (calcyclin) 2.2 3.1
X87966 S100 calcium binding protein A8 (calgranulin A) 29.8 17.5
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Table 3.2.1: Regulated genes during EAE in cerebral microvessels of C57Bl/6 and SJL/N mice
acc. no. name MOG PLP
M83219 S100 calcium binding protein A9 (calgranulin B) 25.1 13.8
AA097087 kinesin family member 5B -2.4
D37837 lymphocyte cytosolic protein 1 3.3
L22144 S100 beta -4.8
X60671 villin 2 -2.8
AA153569 centrin 2 -2.3
enzymes and metabolism (ENZ)
M22679 alcohol dehydrogenase 1 -3.5 -2.6
K00811 carbonic anhydrase 2 -6.3 -2.2
U37091 carbonic anhydrase 4 -3.4 -3.2
U49350 cytidine 5’-triphosphate synthase 3.8 2.5*
AA028501 cytochrome c oxidase, subunit VIIIh -13.3 -3.5
AA028501 cytochrome c oxidase, subunit VIIIh -4.4 -3.5
AA028501 cytochrome c oxidase, subunit VIIIh -4.3 -3.1
U44389 hydroxyprostaglandin dehydrogenase 15 (NAD) -5.3 -11.9*
U51805 liver arginase 1 11.8 5.7
D44464 uridine phosphorylase 5.4 2.6*
X75129 Xanthine dehydrogenase 4.0 2.7
U12791 3-hydroxy-3-methylglutaryl-coenzyme A synthase 2 -2.8
W09791 aldolase 3, C isoform -4.2
W53351 aldolase 3, C isoform -9.6
U49430 ceruloplasmin 2.8
M74149 creatine kinase, brain -3.6
W16151 diazepam binding inhibitor -2.4
M61215 ferrochelatase -2.2
Z11911 glucose-6-phosphate dehydrogenase X-linked 6.3
U24428 glutathione S-transferase, mu 5 -2.8
X51905 lactate dehydrogenase 2, B chain -4.6
U27195 leukotriene C4 synthase -2.8
M36084 malate dehydrogenase, soluble -2.3
J02652 malic enzyme, supernatant -3.6
U35646 puromycin-sensitive aminopeptidase -3.0
W81960 sulfotransferase family 1A, phenol-preferring, member 1 2.2
D26123 carbonyl reductase 2 -3.7
L25069 catalase 1 -2.3
U36993 cytochrome P450, 7b1 4.6
U09816 GM2 ganglioside activator protein 2.3
91
Table 3.2.1: Regulated genes during EAE in cerebral microvessels of C57Bl/6 and SJL/N mice
acc. no. name MOG PLP
U29947 mannosidase 2, alpha B1 5.1
Z14986 S-adenosylmethionine decarboxylase 1 -2.2
L10244 spermidine/spermine N1-acetyl transferase 2.4
extracellular matrix (ECM)
X66976 collagen 8 alpha 1 chain -3.0 -2.8*
M28312 tissue inhibitor of metalloproteinase 1 4.0* 6.1
L19932 transforming growth factor, beta induced, 68 kDa 6.2 7.4
X94322 cartilage derived retinoic acid sensitive protein -3.4
L33416 extracellular matrix protein 1 2.0
L02918 procollagen, type V, alpha 2 -3.2
glycosylation enzymes (GLY)
X73523 sialyltransferase 4A (beta-galactosidase alpha-2,3-
sialyltransferase)
2.6
W36875 sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-
sialyltransferase)
-3.5
growth factors, receptors and related molecules (GF)
L05439 insulin-like growth factor binding protein 2 -3.0
X81582 insulin-like growth factor binding protein 4 14.7
X81584 insulin-like growth factor binding protein 6 3.3
L40459 latent transforming growth factor beta binding protein 3 -2.6
U59230 nel-like 2 homolog (chicken) 192.1
X96793 placental growth factor 2.6
W29430 serine protease inhibitor, Kunitz type 2 -3.3
M70641 connective tissue growth factor 3.7
W16389 latent transforming growth factor beta binding protein4 -3.9
AA106674 latent transforming growth factor beta binding protein4 -3.6
hormones, mediators and receptors (H)
AA002750 arachidonate 5-lipoxygenase activating protein 2.1 3.7
W83564 arachidonate 5-lipoxygenase activating protein 18.8 8.7
L13593 prolactin receptor -5.0 -5.7
X07751 c-erbA alpha2 (thyroid hormone receptor) -2.5
M88242 cyclooxygenase 2 3.2
W20990 thyroid hormone receptor alpha (Thra) -2.5
X04418 prolactin 6.6
immune receptors (IR)
M34510 CD14 antigen 23.2 18.2
X02339 CD3δ antigen 6.8 8.6
92 CHAPTER 3. RESULTS
Table 3.2.1: Regulated genes during EAE in cerebral microvessels of C57Bl/6 and SJL/N mice
acc. no. name MOG PLP
M14343 CD45 antigen 3.1 4.3
M31314 Fc gamma receptor I 5.2 4.5
M63284 Fc gamma receptor IIb 16.8 15.4
W41745 Fc receptor, IgE, high affinity I, gamma polypeptide 2.9 3.7
U05265 gp49B 11.3 8.3
W75007 antigen identified by monoclonal antibody MRC OX-2 2.9
V00802 immunoglobulin kappa chain variable 28 (V28) 3.3
J00475 Ig germline alpha-chain gene C-switch region 20.2
M80423 IgK chain gene, C-region 17.0
V00802 immunoglobulin kappa chain variable 28 (V28) 5.0
M26053 T-cell receptor germline beta-chain gene constant region (CT) 2.5
M12379 Thy-1.2 glycoprotein 3.8
innate immunity (II)
X94353 cathelin-like protein 2.5 6.2
X58861 complement component 1, q subcomponent, alpha polypeptide 2.9 5.5
M22531 complement component 1, q subcomponent, beta polypeptide 3.5 4.3
X66295 complement component 1, q subcomponent, c polypeptide 2.2 4.4
J00369 complement component 3 11.0 22.8
M96827 haptoglobin 7.0 3.6
J03298 lactotransferrin 5.5 3.9
X16834 lectin, galactose binding, soluble 3 2.5 4.0
M21050 lysozyme M 3.4 5.7
L20315 macrophage expressed gene 1 5.0 13.9
W13166 neutrophil gelatinase-associated lipocalin 28.7 2.2
L37297 neutrophilic granule protein 5.4 8.3
X86374 peptidoglycan recognition protein 3.5 3.4
U73004 secretory leukocyte protease inhibitor 9.3 6.7
X03505 serum amyloid A 3 16.5 20.6
M17790 serum amyloid A 4 14.0* 13.3
M17440 complement component 4, a subcomponent 2.3
X04072 granzyme B 5.8
X99347 lipopolysaccharide binding protein -3.1
M64085 serine (or cysteine) proteinase inhibitor, clade A, member 3G 3.0
junctional and cell-cell contact molecules (J)
Z70023 Connexin-30 -3.7* -2.7
W97077 cadherin 13 5.5
U19582 claudin-11 -5.8
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Table 3.2.1: Regulated genes during EAE in cerebral microvessels of C57Bl/6 and SJL/N mice
acc. no. name MOG PLP
U49185 occludin -2.1
M90364 beta-catenin -2.9
lipid metabolism (LM)
W55620 apolipoprotein D 2.9 3.0*
U04827 brain fatty acid-binding protein -8.0 -2.2*
Z22216 apolipoprotein C-II 6.2
AA036067 apolipoprotein E -5.2
X14961 fatty acid binding protein 3, muscle and heart -5.4
M21285 stearoyl-Coenzyme A desaturase 1 -3.7
M26270 stearoyl-Coenzyme A desaturase 2 -2.3
U06670 very low density lipoprotein receptor -6.5
AA016431 fatty acid binding protein 5 2.7
M60847 lipoprotein lipase 5.7
U34277 phospholipase A2 group VII (platelet-activating factor acetylhy-
drolase, plasma)
7.1
U37226 phospholipid transfer protein -2.4
lysosomal proteins (LY)
AA146437 cathepsin S 3.6 10.8
AA089333 cathepsin S 5.2 10.2
AA106931 interferon gamma inducible protein 30 2.3 3.4
U29539 retinoic acid-inducible E3 protein 2.5 4.3
phosphatases (P)
M99054 acid phosphatase type 5 43.2* 4.4
J02980 alkaline phosphatase 2, liver -2.5* -12.0
X61940 dual specificity phosphatase 1 2.2 3.4
AA016397 ectonucleotide pyrophosphatase/phosphodiesterase 2 -7.8 -2.7
AA059550 ectonucleotide pyrophosphatase/phosphodiesterase 2 -5.7 -2.7
AA116737 protein phosphatase 1, regulatory (inhibitor) subunit 1A -4.0 -2.5*
M68902 SHP-1 3.3 5.5
L43371 hydrogen peroxide inducible protein 53 -2.7
U24700 protein tyrosine phosphatase, non-receptor type 1 2.4
M90388 protein tyrosine phosphatase, non-receptor type 8 3.0
X58289 protein tyrosine phosphatase, receptor type, B -2.1
signal transduction (ST)
U70622 endothelial differentiation, lysophosphatidic acid G-protein-
coupled receptor, 2
-3.0 -2.4
X84797 hematopoietic cell specific Lyn substrate 1 3.1 3.6*
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Table 3.2.1: Regulated genes during EAE in cerebral microvessels of C57Bl/6 and SJL/N mice
acc. no. name MOG PLP
J03023 hematopoietic cell kinase 5.5 8.0
U20159 lymphocyte cytosolic protein 2 3.2 4.1
U15635 SAM domain and HD domain, 1 2.7 2.4
M64086 serine (or cysteine) proteinase inhibitor, clade A, member 3N 4.2 2.8
M12056 tyrosine protein kinase p56-tck 4.4 4.1
L04538 amyloid beta (A4) precursor-like protein 1 -3.2
M69260 annexin A1 2.4
D87117 discs, large homolog 3 (Drosophila) -2.3
U28728 embryonal Fyn-associated substrate -6.3
AA028742 guanine nucleotide binding protein (G protein), gamma trans-
ducin activity polypeptide 2
2.6
AA153021 guanylate nucleotide binding protein 2 2.7
X15373 inositol 1,4,5-triphosphate receptor 1 -2.7
AA166439 kinase interacting protein 2 -2.8
M57696 lynB 2.6
D86176 phosphatidylinositol-4-phosphate 5-kinase, type 1 alpha -2.6
M94632 PKCζ -2.6
X17320 Purkinje cell protein 4 -10.1
AA104043 raf-related oncogene -3.4
X53247 RAS-related C3 botulinum substrate 2 2.3
U06924 signal transducer and activator of transcription 1 4.0
U08378 signal transducer and activator of transcription 3 2.0
W15802 similar to Serine/threonine-protein kinase pim-3 2.4
Z46299 sperm autoantigenic protein 17 -2.4
U15636 T-cell specific GTPase 2.2
AA106492 cyclic AMP-dependent protein kinase A regulatory subunit 1A 41.3
U36220 FK506 binding protein 5 (51 kDa) 2.8
AA163272 FK506 binding protein 9 -3.1
X61399 MARCKS-like protein 3.0
Z49877 spleen tyrosine kinase 3.9
W46019 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activa-
tion protein, theta polypeptide
-2.2
transcription factors and nuclear proteins (TF)
U29762 albumin gene D-Box binding protein gene 2.5 -10.9
X62600 CCAAT/enhancer binding protein (C/EBP), beta 5.9 6.3
X61800 CCAAT/enhancer binding protein (C/EBP), delta 7.4 3.4
V00727 c-fos 5.1 4.6
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acc. no. name MOG PLP
X01023 c-myc 2.9 2.7*
X07414 excision repair cross-complementing rodent repair deficiency, com-
plementation group 1
2.2* 3.1
AA050733 glucocorticoid-induced leucine zipper 3.1 2.1*
AA097366 glucocorticoid-induced leucine zipper 3.7 3.0
Z46757 high mobility group box 2 2.5 2.7
J03236 junB 12.9 9.0
U19118 activating transcription factor 3 5.1
AA051446 cerebellar degeneration-related 2 -5.8
J03482 H1 histone family, member 2 -2.5
X75018 inhibitor of DNA binding 4 -3.2
X62648 small nuclear ribonucleoprotein N -15.1
U31967 SRY-box containing gene 2 -7.9
W82793 topoisomerase (DNA) III beta -2.9
AA016424 X-box binding protein 1 2.7
U63133 c-fos 8.0
J04179 high mobility group AT-hook 1 3.7
U70662 Kruppel-like factor 4 (gut) 2.0
protein synthesis (PS)
M55561 ribosomal protein L7 4.3 5.7
AA153342 carbon catabolite repression 4 homolog (S. cerevisiae) -2.3
M22432 eukaryotic translation elongation factor 1 alpha 1 2.3
U50631 heat-responsive protein 12 -3.4
U48363 nascent polypeptide-associated complex alpha polypeptide -2.1
D78135 cold inducible RNA binding protein 2.2
type 1 interferon regulated molecules (IFN)
U19119 interferon inducible protein 1 2.8
AA145371 interferon stimulated gene 12 2.1
X56602 interferon-stimulated protein (15 kDa) -2.2
vesicular transport, secretory pathways and membrane traffic (VT)
W13196 caveolin, caveolae protein, 22 kDa -2.2* -2.1
M64782 folate receptor 1 (adult) -8.7 -2.1*
AA138226 clathrin, light polypeptide (Lcb) 3.2
D38613 complexin II -2.3
U02982 secretogranin III -14.8
U58887 SH3 domain protein 2 C2 -2.8
D83206 vesicular membrane protein p24 -4.9
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Table 3.2.1: Regulated genes during EAE in cerebral microvessels of C57Bl/6 and SJL/N mice
acc. no. name MOG PLP
L38971 integral membrane protein 2A -2.6
D13003 reticulocalbin -2.8
miscellaneous (M)
X15592 cytotoxic T lymphocyte-associated protein 2 beta 3.3 3.6
U69488 G7e protein (G7e-pending) 7.8 6.9
AA031158 brain abundant, membrane attached signal protein 1 -2.2
M29325 L1Md-9 repetitive sequence (EXTRACTED 3’UTR) -2.5
U17259 neuron specific gene family member 2 -3.3
X52622 IN gene for the integrase of an endogenous retrovirus 3.9
unknown (U)
AA153032 hypothetical protein 4930422C14 2.9 3.9*
W29508 interferon induced transmembrane protein 2 like 24.4 3.8
W77701 similar to human acylphosphatase 1, erythrocyte (common) type
(ACYP1)
-2.1* -2.9
AA013976 from neonate thymus, retrovirus related endonuclease 2.3
AA138866 hypothetical protein MGC47046 / similar to human polymerase
(RNA) II (DNA directed) polypeptide B, 140kDa
2.4
AA062342 similar to human/rat RAB28, member RAS oncogene family -4.2
AA124453 similar to rat interferon-inducible protein 16 7.0
W50088 “predicted” sequence -2.1
W13739 similar to human dimerization cofactor of hepatocyte nuclear fac-
tor 1 (HNF1) from muscle (DCOHM)
-2.4
W10459 similar to rat ATP synthase, H+ transporting, mitochondrial F1
complex, epsilon subunit (Atp5e)
-2.2
AA120109 similar to rat-IFI271 / rat-ERG2 -3.0
Supporting the current concept of EAE as a model for chronic inflammatory de-
myelinating diseases of the CNS with an autoimmune pathogenesis, gene array anal-
ysis resulted in the upregulation of genes coding for molecules involved in adaptive
immune functions such as immune cell activation or antigen presentation (“immune
receptors”, “antigen presentation”; Table 3.2.1) or leukocyte recruitment (“adhe-
sion molecules and their modification” and “cytokines, chemokines and receptors”).
Increased expression of the intercellular adhesion molecule-1 (ICAM-1) was val-
idated by in situ hybridization and immunohistochemistry with both approaches,
demonstrating increased expression of ICAM-1 mRNA and protein in inflamed cere-
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Figure 3.2.2: A: In situ hybridization analysis of ICAM-1, CCL2, CCL5, CCL6, CXCL9 and
CXCL10 mRNA expression in brain of a healthy SJL mouse (a) and SJL mice afflicted with
acute EAE (b) – (g) is shown. ICAM-1 mRNA was detected (a) and (b), as well as mRNA of
inflammatory chemokines CXCL9 (c), CXCL10 (d), CCL2 (e), CCL5 (f) and CCL6 (g). Vessels
(a) or vessels surrounded by inflammatory cuffs are shown (b) – (g). Toluidine blue counterstain.
Bar = 20 µm. B: Presence of ICAM-1 (a) – (d) and ICAM-2 (e) – (f) in vessels of healthy brain,
(a), (b), (e) and (f), or vessels surrounded by inflammatory cuffs in diseased brain (c), (d), (g) and
(h) are shown. This was done in either C57Bl/6 (a), (c), (e) and (g), or SJL/N mice (b), (d), (f)
and (h). Immunoperoxidase staining with hematoxyline counterstain. Bar = 20 µm.
bral venules in brains of mice afflicted with EAE when compared to healthy con-
trols (Table 3.2.1: AM; Figure 3.2.2). Also, increased expression of inflammatory
chemokines CCL2, CCL5, CCL6, CXCL9 and CXCL10 observed in the oligonu-
cleotide microarray analysis could be confirmed by means of in situ hybridization
(Table 3.2.1: CK, Figure 3.2.2), with undetectable expression in brains of healthy
mice (data not shown), but a strong induction of their expression in close vicin-
ity to inflamed cerebral venules surrounded by inflammatory cuffs in EAE brains
(Figure 3.2.2). Additionally, we found T cell specific genes encoding CD3δ or the
T cell receptor (TCR) β chain as well as macrophage specific genes i. e. coding for
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CD14 (Table 3.2.1: IR), or genes coding for leukocyte adhesion receptors such as
β2-integrin or L-selectin (Table 3.2.1: AM) in our screen.
Regulation of endothelial cell specific genes was detected, which was demon-
strated by the finding that gene expression for caveolin was found to be downreg-
ulated in both EAE models (Ikezu et al., 1998). Furthermore, in the SJL mouse
EAE model but not in the C57Bl/6 model, downregulation of intercellular adhesion
molecule-2 (ICAM-2) mRNA was detected by gene array analysis (Table 3.2.1: AM)
although ICAM-2 is also present on T lymphocytes. Immunohistochemistry demon-
strated endothelial cell specific staining for ICAM-2, however, failed to distinguish
between different protein expression levels of ICAM-2 at cerebral microvessels in
healthy or EAE brains (Figure 3.2.2). E-selectin expression was not found to be
induced in the microarray screen in the SJL mouse, while P-selectin induction could
only be observed after antibody amplification of the signals. In contrast upregu-
lation of E- and P-selectin was observed in the MOG-induced EAE model in the
C57Bl/6 mouse. CD53 was found to be upregulated during EAE in this present
study (Table 3.2.1: AM). Upregulation of 16 genes coding for molecules involved in
innate immunity in both EAE models was detected, i. e. complement component
C3 was found to be upregulated by 11- or even 22-fold in MOG-induced versus
PLP-induced EAE respectively.
The largest groups of genes regulated at the level of cerebral microvessels based
on the gene array analysis were found to code for enzymes involved in general cell
metabolism (“enzymes and metabolism”) and in lipid metabolism with expression of
most genes in both groups being downregulated during EAE. This was accompanied
by a reduced gene expression for ion channels as well as genes coding for proteins
involved in vesicular transport, secretory pathways, membrane traffic mechanisms
and cell-cell-contact proteins (Table 3.2.1).
Furthermore altered expression levels of genes coding for “signaling molecules”,
“phosphatases”, “transcription factors and nuclear proteins”, “protein synthesis”
were found in both models with a tendency to upregulation of gene expression
within these groups (Table 3.2.1). One of the most prominently regulated genes
was found to be the gene coding for the transcription factor JunB with 12-fold and
9-fold upregulation in the C57Bl/6- and SJL-model respectively (Table 3.2.1: TF).
Changes of gene expression as detected with the oligonucleotide microarrays
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Figure 3.2.3: Inflammation of Gr-1 expressing cells can be observed during EAE in C57Bl/6
mice (day 17 after induction of disease, clinical disease score 1) but hardly in SJL/N mice (day 14
after induction of disease, clinical disease score 2). Immunoperoxidase staining with hematoxyline
counterstain. Bar = 20 µm.
were extended to genes coding for cytoskeletal or extracellular matrix proteins (Ta-
ble 3.2.1), underlining changes in tissue architecture at the BBB during EAE be-
yond the protein level. Additionally arachidonate 5 lipoxygenase activating pro-
tein (ALOX5AP) and cyclooxygenase-2 (Cox-2) were upregulated (Table 3.2.1: H).
Also, altered gene expression of extracellular matrix proteins was found in both
EAE models as for example tissue inhibitors of matrix metalloproteases (TIMP-1;
Table 3.2.1: ECM) was found to be upregulated in both EAE models.
Furthermore, genes coding for type 1 interferon regulated proteins, namely in-
terferon inducible protein 1 (IFI1), interferon stimulated gene 12 (ISG12) and
interferon-stimulated protein 15 kDa (ISG15) were found to be upregulated in
both EAE models (Table 3.2.1: IFN). Altered gene expression of beta-galactosidase
alpha-2,3-sialyltransferase 4A (SiaT4A) and CMP-NeuAc:lactosylceramide alpha-
2,3-sialyltransferase (SiaT9), also known as ganglioside GM3 synthase, was detected
in mRNA in cerebral microvessels in the MOG EAE model but not in the PLP
EAE model (Table 3.2.1: GLY). Additionally, difference in granulocyte recruitment
during EAE in C57Bl/6 and SJL/N mice can be observed (Figure 3.2.3). The ques-
tion arose, whether regulation of SiaT4A does result in altered glycosylation during
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Figure 3.2.4: MALII binding on choroid plexus and vessels of EAE afflicted C57Bl/6 mouse brain
(a). Binding is largely prevented by pretreating sections for 2 hours with sialidase (b). Shown is
1 preliminary experiment.
EAE pathogenesis. Maackia amurensis lectin II (MALII) has been described to bind
preferably to the glycosylation product of SiaT4A, (α-2,3)-sialylgalactose residues
and additionally bind to (α-2,6)-sialylgalactose residues. Therefore, MALII bind-
ing to brain sections of C57Bl/6 mice afflicted with EAE (day 20 after induction
of disease, clinical disease score 3) was investigated. Preliminary results showed
binding of MALII to brain vessels and choroid plexus of C57Bl/6 mice afflicted
with EAE (Figure 3.2.4). Binding could be partially prevented by pretreating the
sections with Clostridium perfringens-derived sialidase, which preferably digests (α-
2,3)-sialylgalactose residues, according to the manufacturer (Figure 3.2.4). However,
this pretreatment could not totally abolish lectin binding. Furthermore, sialidase
pretreatment seemed to unmask additional binding sites (data not shown). There-
fore, care has to be taken considering these preliminary results. In an alternate
approach, (α-2,3)-sialylgalactose residues were detected by flow cytometry on brain-
derived in vitro cultured bEnd5 endothelioma cells (Figure 3.2.5). Preliminary re-
sults show MALII binding, suggesting bEnd5 endothelioma cells to possess (α-2,3)-
sialylgalactose residues, weak Sambucus nigra lectin binding, suggesting (α-2,6)-
sialylgalactose residues as well as Griffonia simplicifolia lectin I binding, suggesting
bEnd5 endothelioma cells to express α-galactose residues (see Figure 3.2.5).
3.2.2 Subtractive suppression hybridization analysis of cere-
bral microvessels
While gene array analysis allows to detect regulation of known genes, unknown genes
which are not present on the array are missed. Alternatively, subtractive suppression
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Figure 3.2.5: Lectin binding to bEnd5 endothelioma cell lines. Binding of Maackia amurensis
lectin II (MALII), Sambucus nigra lectin and Griffonia simplicifolia lectin (GSL) on bEnd5 en-
dothelioma cell lines as detected by flow cytometry. (A) Endothelial cells were scattergated. (B)
Overlays for MALII, SNL and GSL show surface staining on bEnd5 endothelioma line cells (thick
line) in comparison to no lectin (thin line).
hybridization (SSH) with subsequent high-throughput sequencing allows identifica-
tion of so far unknown genes possibly being involved in lymphocyte recruitment
across the endothelial blood-brain barrier during EAE.
First we asked, whether separation of cerebral microvessel by mechanic ho-
mogenization with a Dounce homogenizer (see 2.1.4.1.2) or by enzymatic diges-
tion (see 2.1.4.1.1) resulted in higher quality of RNA. For the first preparation,
10 age-matched B6C3F1 mice were sacrificed, brains taken out, cerebellums and
meninges were removed. Cerebrums were homogenized with two scalpels and di-
gested with collagenase type II for 30 minutes at 37◦C. Digestion mix was diluted
in ice-cold buffer A, centrifuged and the pellet was applied to BSA gradient cen-
trifugation, thereby separating microvessels from myelin components. Microvessels
were carefully resuspended, shock-frozen in liquid nitrogen and stored at -80◦C . For
the second preparation, 10 age-matched B6C3F1 mice were sacrificed, brains were
taken out, cerebellums and meninges removed. Brains were homogenized using a
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Figure 3.2.6: Comparison of RNA yield resulting from enzymatic (1) and mechanic (2) microves-
sel preparations showed a high quality and quantity of total RNA in the enzymatic preparation,
while the mechanic preparation hardly resulted in any RNA. A control RNA preparation was added
(3), which had been kindly provided by Dr. Ru¨diger Arnold and Dr. Friedemann Kiefer.
Dounce homogenizer with a large clearance pestle and filtered over a 180 µm nylon
mesh. Flow through was homogenized using a small clearance pestle and microves-
sels which got stuck on a 63µm nylon mesh were collected, shock-frozen in liquid
nitrogen and stored at -80◦C. Total RNA was prepared from frozen microvessel
preparations without thawing the samples as described (see 2.4.6.2). Equal volumes
of both samples were compared by RNA agarose gel electrophoresis (see 2.4.6.3).
The first preparation by enzymatic digestion resulted in a high RNA yield, while
the second preparation by mechanic separation resulted in a much lower RNA yield
(Figure 3.2.6). Therefore, the enzymatic digestion was the method of choice to
prepare cerebral microvessels for subsequent RNA preparation.
For the microvessel preparation, SJL/N mice were immunized on two subsequent
days subcutaneously, and 3× 109 heat inactivated organisms of Bordetella pertussis
were injected on day 1 and day 3 after immunization intravenously with the help
of Irene Ku¨chenmeister. 125 mice which had a clear onset of disease resulting in a
disease score of 1 – 3 were sacrificed from day 11 – 16 after immunization. In paral-
lel, 120 untreated age-matched control mice were sacrificed. Cerebral microvessels
were prepared as described by enzymatic digestion of about 20 brains per batch,
shock-frozen in liquid nitrogen and stored at -80◦C. Meninges were removed with
the help of Irene Ku¨chenmeister, Katharine Ling, Monika Rieschel and Veronika
Schmidt. Once all preparations and control preparations were performed, samples
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library vector number created
standard brain microvessels, EAE #13 pSPORT1 1.3× 107 01/10/2001
standard brain microvessels, EAE #14 pCMV-SPORT6 3.8× 107 01/10/2001
standard brain microvessels, control, #2 pλtriplex2 3.5× 106 12/11/2001
standard brain microvessels, control, #3 pλtriplex2 3.6× 106 12/11/2001
subtraction brain microvessels, EAE – control, #1 pBSII-SK+ 3.2× 106 a 11/01/2001
subtraction brain microvessels, EAE – control, #5.1 pBSII-SK+ 1.6× 104 a 01/10/2001
subtraction brain microvessels, EAE – control, #5.2 pBSII-SK+ 6.0× 104 a 01/25/2001
subtraction brain microvessels, control – EAE, #2 pBSII-SK+ 3.2× 106 a 11/01/2001
SMART subtraction brain microvessels, EAE – control, #7.1 pBSII-SK+ 4.8× 104 a 01/10/2001
SMART subtraction brain microvessels, EAE – control, #7.2 pBSII-SK+ 8.0× 104 a 01/25/2001
aNumbers refer to clones which scored negative after blue-white selection and therefore have
lost their β-galactosidase activity due to cDNA fragment integration.
Table 3.2.2: cDNA libraries of cerebral microvessels were created from 125 mice afflicted with
EAE (day 11 – 14 after immunization, clinical score 1 – 3) as well as 120 healthy age-matched
control mice in cloning and expression vectors. Additionally, subtractive and SMART subtracted
libraries were created.
were sent to Bioserve Biotechnologies Ltd. (Laurel, MD, USA), where the libraries
were created by Robert Skurla. The following libraries were obtained and analyzed
by us (Table 3.2.2).
To identify genes, which were regulated during EAE in cerebral microvessels,
the library “subtraction brain microvessels, EAE – control, #1” was analyzed in
this present thesis by high-throughput sequencing. Therefore, 10 µl frozen glycerol
stock were scratched off and diluted in 1000 µl LB medium. Immediately, 100 µl
diluted bacterial suspension, containing about 540 clones, were plated per 150 mm
LB agar plate containing ampicillin as well as X-Gal and IPTG for selection and
grown over night. 375 unstained clones, which had no β-galactosidase activity, were
used to inoculate LB medium (40 µg/ml ampicillin), grown over night and DNA
was prepared using the QIAprep 96 turbo miniprep kit. DNA preparations were
sequenced unidirectional using the M13rev primer, dye terminators were removed
and sequencing reactions were measured by an in-house service facility.
Sequence data files were analyzed using the GCG software package v10.2 (Ge-
netics Computer Group (GCG), Madison, WI, USA), which was located on a server
at the Gesellschaft fu¨r Wissenschaftliche Datenverarbeitung, Go¨ttingen (gwdg;
Go¨ttingen, Germany). Sequence data files were transferred to this server and sub-
sequently compared with the non-redundant gene bank database by use of the fol-
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lowing shellscript, which had been written in this present thesis:
\#!/usr/local/bin/bash
\# automated blast-searches for several files
for query in ‘ls | grep .seq‘
do
echo "Starting to process \$query ..."
reformat -default -monitor \$query
echo "\$query reformatted!"
blast2 -IN2=gb\_nt -DBN -EXP=10 -LIS=10 -OUT=\${\rmfamily \\
\{ }query\%.seq{\rmfamily \} }.blastn -BEG=141 -END=380 \$query
echo "\$query done!"
done
This script automatically reformats each sequence file to be readable by the GCG
software, and then does a BLAST comparison of the nucleotides 141 – 380 with the
non-redundant gene bank database gb-nt, thereby omitting sequenced vector back-
bone DNA. In case of short insert cDNA, this approach did result in preferably
recognizing the vector DNA. In these cases, this vector DNA had to be excluded
by additional manual BLAST comparisons. Of the 375 clones analyzed, 188 could
be identified (see 3.2.3), while 7 clones contained repetitive elements, 15 contained
only vector sequences and maybe very short inserts. 165 clones could not be identi-
fied by sequencing. Adhesion molecules, immune receptors, innate immunity related
molecules and MHCII molecules were detected, which allude to leukocyte contami-
nations in the microvessel preparation, as experienced in the gene array analysis as
well. However, cytoskeletal proteins may refer to alterations of endothelial cells, as
well as possible modifications to the extracellular matrix and cell-cell contacts. Inter-
estingly, Duffy antigen / receptor for chemokines (DARC) and three more serpentine
receptors were found to be upregulated. As chemokine receptors are serpentine re-
ceptors, these molecules are of particular interest as possible chemokine receptors.
Additionally, 28 sequences referred to unknown genes, either being as EST clones
or genomic sequences in the gene bank database.
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Table 3.2.3: Genes enriched in cerebral microvessel preparations during EAE as detected by SSH
are listed in different functional groups. Internal clone numbers, gene bank accession numbers and
gene names are listed together with the first and last nucleotide of the respective clone as compared
to the listed gene bank entry.
acc. no. name start – stop clone no.
adhesion molecules and their modification
19852057 clone cDSL-Z6 Down syndrome cell adhesion
molecule-like protein
242 – 71 185
9910157 C-type (calcium dependent, carbohydrate recogni-
tion domain) lectin, superfamily member 10
10 – 233 25
antigen presentation
13540710 histocompatibility 2, class II antigen A, alpha 36 – 122 216
3169659 histocompatibility 2, class II antigen A, alpha 364 – 594 102
6996918 histocompatibility 2, complement component fac-
tor B
276 – 37 35
ditto 281 – 446 316
ditto 282 – 57 124
ditto 323 – 481 83
ditto 1656 – 1889 9
ditto 1656 – 1889 290
ditto 1656 – 1889 21
ditto 1656 – 1682 319
ditto 1656 – 1859 48
ditto 1692 – 1726 72
ditto 2013 – 1774 187
ditto 2278 – 2041 103
ditto 2292 – 2069 100
ditto 2304 – 2065 73
ditto 2306 – 2068 113
20878874 Ia-associated invariant chain (Ii) 165 – 57 174
ditto 251 – 436 81
ditto 436 – 258 5
ditto 436 – 247 112
2555188 Major Histocompatibility Locus class II region 120289 – 120468 14
199449 MHC class II H2-IA-alpha (d haplotype) 1 – 133 136
ditto 1 – 133 159
ditto 14 – 133 170
199465 MHC class II H2-IA-alpha (s haplotype) 40 – 8 196
199489 MHC class II H2-IA-beta (s haplotype) 194 – 1 285
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Table 3.2.3: Enriched genes in cerebral microvessel preparations during EAE as detected by SSH
acc. no. name start – stop clone no.
cell cycle, cell growth, cell survival and apoptosis
12963604 apoptosis-associated speck-like protein containing a
CARD
206 – 403 186
6753597 defender against cell death 1 (Dad1) 79 – 260 115
2522268 EAT/MCL-1 1531 – 1391 50
12659133 melanoma antigen family D1 1193 – 1100 62
3860228 neuronal apoptosis inhibitory protein 2 1576 – 1789 133
ditto 1583 – 1698 157
20894856 ras association (RalGDS/AF-6) domain family 1 224 – 64 184
20885862 retinoblastoma-like 2 4130 – 3902 125
6755567 schlafen 1 1661 – 1456 189
3983149 schlafen 2 190 – 1 168
5932000 similar to: Serf1 protein, survival of motor neuron
protein, neuronal apoptosis inhibitory protein-rs6,
and neuronal apoptosis inhibitory protein-rs3
59026 – 58974 137
6678284 telomerase associated protein-1 5452 – 5527 16
channels and transporters
7657517 ATP-binding cassette, sub-family E (OABP), mem-
ber 1
987 – 1220 106
6678735 lactotransferrin 769 – 538 275
6755565 solute carrier family 9 (sodium/hydrogen ex-
changer), isoform 3 regulator 1
1718 – 1868 122
coagulation
2664219 coagulation factor X 1163 – 925 162
cytokines, chemokines and receptors
20910320 chitinase 3-like 1 775 – 537 130
ditto 776 – 975 182
ditto 803 – 975 40
ditto 1216 – 1146 289
6753415 chitinase 3-like 3 178 – 328 155
ditto 404 – 166 191
ditto 419 – 228 47
ditto 422 – 182 160
ditto 424 – 190 1
ditto 426 – 585 68
ditto 585 – 420 181
6753629 Duffy blood group 6 – 54 243
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Table 3.2.3: Enriched genes in cerebral microvessel preparations during EAE as detected by SSH
acc. no. name start – stop clone no.
6754313 interferon gamma inducing factor binding protein 535 – 393 59
ditto 573 – 393 288
6754329 interleukin 1 receptor, type II 438 – 518 265
ditto 440 – 679 108
ditto 470 – 656 94
7305180 interleukin 2 receptor, gamma chain 710 – 850 188
ditto 850 – 663 90
3153815 oncostatin M specific receptor 2062 – 2237 252
cytoskeletal molecules
6671508 actin, beta, cytoplasmic 1265 – 1166 175
2252815 Axin 1643 – 1755 312
21361132 MAP/microtubule affinity-regulating kinase 3 (homo
sapiens)
615 – 732 127
2443283 motor domain of KIF6 102 – 13 29
6679384 plastin 2, L 178 – 378 70
ditto 1830 – 1676 204
21687243 RAN GTPase activating protein 1 2148 – 2381 117
13161248 sad1-unc84-like protein 661 – 885 31
20899777 tubulin, beta 5 35 – 184 241
ditto 722 – 922 55
enzymes and metabolism
7106254 arginase 1, liver 620 – 514 358
20342361 enolase 1, alpha non-neuron 1 – 170 96
204490 glutathione S-transferase (rat) 134 – 17 63
12642663 glycine N-methyltransferase 3234 – 3384 82
2388721 liver carnitine palmitoyltransferase I 3885 – 4109 144
18426808 Niemann Pick type C2 1 – 31 32
extracellular matrix
20848653 fibronectin 1 2436 – 2288 78
ditto 2955 – 3137 163
20888218 similar to putative dipeptidase (LOC244632) 793 – 907 110
6678320 transforming growth factor, beta induced, 68 kDa 2496 – 2261 13
G protein coupled receptors
7707356 CD97 antigen 2139 – 2371 280
14249165 Homo sapiens seven transmembrane domain protein
(NIFIE14)
394 – 593 277
22095024 vomeronasal 1 receptor, A2 3261 – 3301 295
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Table 3.2.3: Enriched genes in cerebral microvessel preparations during EAE as detected by SSH
acc. no. name start – stop clone no.
glycosylation enzymes
6754683 mannoside acetylglucosaminyltransferase 1 1410 – 1533 30
growth factors and related molecules
2547133 neuropilin-2(a5), alternatively spliced 40 – 5 46
immune receptors
6753331 CD14 antigen 39 – 200 166
ditto 196 – 1 19
ditto 556 – 768 43
ditto 767 – 538 17
14719423 CD52 antigen 22 – 167 154
6941603 gp49A 3973 – 4204 107
195552 Ig nonexpressed rearranged heavy-chain V-region
(V-J), clone 264
61 – 109 264
1806127 IgG2c gene for immunoglobulin constant heavy
chain, allele Igh-1
934 – 1113 92
ditto 1506 – 1700 56
13540502 immunoglobulin superfamily, member 6 1 – 209 180
ditto 13 – 234 132
ditto 240 – 13 183
11096337 lymphocyte antigen 116 739 – 500 169
6754581 lymphocyte antigen 6 complex, locus C 2489 – 2462 193
6754583 lymphocyte antigen 6 complex, locus D 395 – 156 28
ditto 642 – 403 109
6678747 lymphocyte antigen 6 complex, locus E 15 – 167 45
198927 lymphocyte differentiation antigen Ly-6C.2 32 – 265 165
ditto 611 – 372 291
54826 rearranged immunoglobulin gamma 2b heavy chain 1006 – 1197 138
1199649 thymic shared antigen-1 742 – 705 33
innate immunity
6753471 cathelin-like protein 361 – 528 22
ditto 420 – 259 292
ditto 493 – 353 190
ditto 500 – 367 10
192278 complement component C3, alpha and beta subunits 4451 – 4684 121
1209751 gp91phox 1275 – 1174 131
8850218 haptoglobin 14 – 229 88
ditto 15 – 230 116
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Table 3.2.3: Enriched genes in cerebral microvessel preparations during EAE as detected by SSH
acc. no. name start – stop clone no.
ditto 246 – 52 140
ditto 246 – 136 336
ditto 246 – 60 80
20824061 lipocalin 2 1 – 78 229
ditto 191 – 1 150
ditto 192 – 1 172
ditto 249 – 412 148
20983337 properdin factor complement 912 – 992 254
20858952 serine protease inhibitor 2-1 717 – 533 104
20859248 similar to serine protease inhibitor 2-2 (LOC238393) 74 – 1 101
ditto 1015 – 1254 126
lysosomal proteins
21450788 cathepsin D 1 – 150 139
2746722 cathepsin S precursor 652 – 472 64
1439569 cystatin B 611 – 482 171
11345387 lysosomal thiol reductase precursor 675 – 747 215
signal transduction
16418422 guanylate binding protein 4 (H. sapiens) 188 – 149 281
6382003 ionized calcium binding adapter molecule 1 233 – 21 37
458709 signal transducer and activator of transcription 1176 – 1414 53
13992531 suppression of tumorigenicity 5 gene, L27a gene and
Kiaa0298 gene
125308 – 125249 274
20864092 tumor protein D52 833 – 938 147
54813 tyrosine protein kinase p56-tck 1594 – 1372 76
transcription factors and nuclear proteins
9800524 GTF2IRD1 and CYLN2 197331 – 197300 98
19168506 MAIL gene for molecule possessing ankyrin-repeats
induced by lipopolysaccharide, exons 3 to 14
2190 – 2429 276
22137804 modulator recognition factor 2 167 – 406 192
20344706 signal transducer and activator of transcription 2 1261 – 1355 2
18860912 SKI-interacting protein (homo sapiens) 967 – 814 118
7305600 TXK tyrosine kinase 868 – 1094 75
1261918 45S pre rRNA gene 0 – 0 85
protein synthesis
194026 heat-shock protein 84 908 – 1137 158
198642 ribosomal protein L19 1 – 198 156
1938405 ribosomal protein S11 106 – 2 34
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Table 3.2.3: Enriched genes in cerebral microvessel preparations during EAE as detected by SSH
acc. no. name start – stop clone no.
12963510 ribosomal protein S19 156 – 354 27
13592066 ribosomal protein S9 (rattus norvegicus) 613 – 522 97
20866310 similar to 60S ribosomal protein L21 (LOC216390) 513 – 317 179
20825378 similar to RNA binding motif protein 3 (LOC226497) 546 – 665 128
7710041 IQ motif containing GTPase activating protein 1 1137 – 954 153
miscellaneous
20886552 proteasome (prosome, macropain) 26S subunit, non-
ATPase, 7
513 – 748 279
3930524 sex-determination protein homolog Fem1a 3498 – 3615 142
20899569 similar to viral envelope protein G7e 2763 – 2732 79
20820998 ubiquitin A-52 residue ribosomal protein fusion
product 1
6 – 245 3
6941889 ubiquitin-specific processing protease 2918 – 2994 177
12841057 10 day old male pancreas cDNA, RIKEN full-length
enriched library, clone:1810013K23:homolog to E1-
LIKE PROTEIN
10 – 153 87
unknown
12841677 10 day old male pancreas cDNA, RIKEN full-
length enriched library, clone:1810054D07:homolog
to HYPOTHETICAL 65.8 KDA PROTEIN (FRAG-
MENT)
195 – 58 167
26084120 12 days embryo embryonic body between diaphragm
region and neck cDNA, RIKEN full-length enriched
library, clone:9430022I10 product:unknown EST
357 – 891 111
26329388 adult male cecum cDNA, RIKEN full-length
enriched library, clone:9130222K18 prod-
uct:hypothetical eukaryotic thiol (cysteine) proteases
active site containing protein
2286 – 2428 60
12832925 adult male kidney cDNA, RIKEN full-length en-
riched library, clone:0610031L02:unclassifiable tran-
script
190 – 83 99
12857810 adult male medulla oblongata cDNA,
RIKEN full-length enriched library,
clone:6330419P03:unclassifiable transcript
1467 – 1282 7
12857460 adult male thymus cDNA, RIKEN full-length en-
riched library, clone:5830427D03:unclassifiable
951 – 766 129
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acc. no. name start – stop clone no.
12857556 adult male thymus cDNA, RIKEN full-length en-
riched library, clone:5830460E08:unclassifiable tran-
script
166 – 19 249
16303564 BAC clone RP11-510H11 from 2 (homo sapiens) 191008 – 190990 355
19387740 chromosome 15, clone RP11-184D12 (homo sapiens) 152197 – 152220 120
22203334 chromosome 2 clone RP24-394D4 154315 – 154264 321
22138544 chromosome 3 clone RP24-545E4 64174 – 64156 6
3287367 chromosome 6 BAC-284H12 (Research Genetics
mouse BAC library)
122370 – 122556 20
18463962 clone 33L10 alpha globin gene cluster 16749 – 16988 173
20072138 clone IMAGE:1328913 27 – 206 8
18605613 clone MGC:27898 IMAGE:3499319 1707 – 1565 145
19353356 clone MGC:35713 IMAGE:4973059 103 – 1 74
19909475 clone RP23-3D14, complete sequence 18744 – 18894 15
1673296 DNA (homo sapiens) 25 – 58 250
14422212 DNA sequence from clone RP21-544J17 on chromo-
some 5
65593 – 65766 58
18855252 DNA sequence from clone RP23-209G11 on chromo-
some 13
3946 – 3964 11
20798989 DNA sequence from clone RP23-317F9 on chromo-
some 11
214268 – 214247 66
18070910 DNA sequence from clone RP23-319B15 on chromo-
some 11
24599 – 24447 26
16307419 MAP kinase-interacting serine/threonine kinase 2,
clone MGC:5881 IMAGE:3257646
2963 – 2853 151
20161859 Oryza sativa (japonica cultivar-group) genomic
DNA, chromosome 1, BAC clone:B1139B11
90883 – 90904 266
2653780 peptidase homolog (homo sapiens) 27 – 9 247
18043719 RIKEN cDNA 1600014C10 gene, clone MGC:29915
IMAGE:5123719
960 – 874 114
Applying these two different techniques, gene array analysis as well as SSH with
subsequent high-throughput sequencing HTS to microvessel preparations, allowed
identification of genes being regulated during EAE in SJL/N mice by two different
methods. By application of these two techniques, 13 genes were identified in parallel
(Table 3.2.4). All of these 13 genes had been identified by SSH/HTS and by gene
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array analysis to be upregulated. Thus, there were no contradictory results and
both techniques can be considered complementary.
3.2.3 Proteomic analysis of cerebral microvessels
In this present work, cerebral microvessels from EAE afflicted SJL mice were pre-
pared as described (see 2.1.4.1.2) and shock-frozen.
Frozen materials were further investigated by Dr. Bosse Franze´n at Astra-Zeneca
(So¨derta¨lje, Sweden) as follows. 150 µg protein lysate were obtained from 5 mg cere-
bral microvessels (wet weight) isolated from 5 SJL mice afflicted with EAE (day 16
post immunization, mean disease score 1.0 ± 0.6) and 200 µg protein lysate were
isolated from 9 mg cerebral microvessels (wet weight) of 8 SJL mice afflicted with
EAE (day 13 p. i., mean clinical disease score 1.1 ± 1.2). In both cases, control
preparations were done from at least five age and strain-matched healthy mice.
These preparations were applied to 2D gel electrophoresis and protein sample spots
that differed between EAE and healthy controls were identified by mass spectrom-
etry (Figure 3.2.7). The proteomics approach allowed to identify 6 differentially
acc. no. name fold change.clone no.
J00369 complement component 3 22.8 121
M34510 CD14 antigen 18.2 17, 19, 43, 166
AA146437 cathepsin S 10.8 64
AA089333 cathepsin S 10.2 64
L19932 transforming growth factor, beta induced, 68 kDa 7.4 13
K01923 histocompatibility 2, class II antigen A, alpha 7.3 102, 216
M57890 histocompatibility 2, complement component factor B 7.1 35
U69488 G7e protein (G7e-pending) 6.9 79
X94353 cathelin-like protein 6.2 10, 22, 190, 292
U51805 liver arginase 1 5.7 358
M12056 tyrosine protein kinase p56-tck 4.1 76
M96827 haptoglobin 3.6 80, 88, 116, 140, 336
X00496 Ia-associated invariant chain 3.5 5, 81, 112, 174
W70579 coagulation factor X 2.7 162
U06924 signal transducer and activator of transcription 1 4.0a 53
a Expression change during EAE in C57Bl/6 mice.
Table 3.2.4: Differentially regulated genes during EAE as detected by gene array analysis and
SSH. Accession numbers of genes which have been detected to be regulated during EAE in SJL/N
mice by gene array analysis and found in the cDNA library which had been created by SSH.
Respective clone numbers are listed.
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Figure 3.2.7: 2D gel electrophoresis maps showing identified proteins of cerebral microvessels
from EAE afflicted and healthy SJL mice. Comparative SYPRO Ruby-stained gels of cerebral
microvessel preparations of mice afflicted with EAE and healthy controls are shown. Protein
sample spots, expression levels of which were detected by PDQuest software to be reproducibly
altered during EAE, are marked. Protein identifiers as determined by mass spectrometry are
added.
expressed proteins, whereby genes of 5 of these proteins were found to be repre-
sented on the Affymetrix chip (Table 3.2.5). Only one of them, fibroleukin was
found to be significantly upregulated in both, the proteomics and oligonucleotide
microarray screen (Table 3.2.5). While purine nucleosid phosphorylase was detected
to be not transcriptionally regulated, regulation of receptor of activated protein ki-
nase C 1 (RACK-1), tailless complex polypeptide 1B and transducin beta chain 2
correlated with their transcriptional regulation, as corresponding genes and proteins
were either both upregulated or both downregulated. However, according to the
manufacturer, these results could not be considered significant (Table 3.2.5). Thus,
no contradictory results comparing gene and protein expression level changes were
found and both techniques can be considered complementary. Upregulated protein
expression was detected for an acidic and basic variant of heterogeneous nuclear
ribonucleoprotein (hnRNP) A2/B1, which was not represented on the Affymetrix
chip. Confirmation of these results by immunohistochemistry using polyclonal an-
tisera against RACK-1, GBB2 or hnRNP (Santa Cruz, Heidelberg, Germany) did
unfortunately not reveal any conclusive results.
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proteomics gene array
SSP fold
change
MALDI /
Q-TOF
acc. no. name acc. no. fold
change
4621 +3.9 FIBB P14480 rat fibroleukin precursor / fib-
rinogen like protein 2
M16238 +3.4
8309 +2.4 ROA2 O88569 mouse heterogeneous nuclear ri-
bonucleoprotein A2/B1
not on array
8301 +1.6 ROA2 O88569 mouse heterogeneous nuclear ri-
bonucleoprotein A2/B1
not on array
4202 +1.8 PNPH P23492 mouse purine nucleosid phospho-
rylase
X56548 ±1.0
7208 +1.6 GBLP P25388 human guanine nucleotide-
binding protein beta subunit
like protein 12.3 / receptor of
activated protein kinase C 1
W78338
X75313
AA089264
+1.1
+1.2
+1.3
4708 –1.45 TCP P11983 tailless complex polypeptide 1B D90344 –1.1
2306 –1.45 GBB2 P54312 guanine nucleotide-binding pro-
tein G(I)/G(S)/G(T) beta sub-
unit 2 / transducin beta chain 2
W41722 –1.2
Table 3.2.5: Protein expression analysis: Identities of altered protein expression during EAE
in cerebral microvessels of SJL mice. 7 sample spots (SSP) were detected to be either up- or
downregulated and identified by MALDI or Q-TOF. Protein database accession numbers (acc. no.)
and gene names are listed. Additionally, gene accession numbers (acc. no.) of corresponding
genes represented on the Affymetrix Mu6500 gene array are shown together with the detected
transcriptional changes.
3.3 Gene expression profiling of encephalitogenic
T cells
PLP-specific T cell lines established from SJL/N mice are referred to as encephali-
togenic or non-encephalitogenic depending on their ability to transfer clinical EAE
into na¨ıve syngeneic recipients. Independent of this capability, encephalitogenic and
non-encephalitogenic T cells do neither differ in antigen specificity nor does com-
parison of adhesion molecule and cytokine expression patterns of encephalitogenic
T cell lines reveal any difference. Additionally, encephalitogenic T cells lines lose
their encephalitogenicity after several in vitro restimulation steps with their specific
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antigen. Therefore, the question arose, what molecular differences are crucial for
encephalitogenicity of T lymphoblasts.
3.3.1 Gene array analysis of encephalitogenic T cells
Differences in gene expression between encephalitogenic and non-encephalitogenic
T lymphoblasts were assessed by gene array analysis of 8 × 106 encephalitogenic
T lymphoblasts SJLB.PLP7 in comparison to 8× 106 non-encephalitogenic T lym-
phoblasts SJLB.PLP3. Freshly restimulated T lymphoblasts were separated by den-
sity gradient centrifugation, thoroughly washed, frozen and sent to Mrs. Kristina
Duvefelt (Astra-Zeneca, So¨derta¨lje, Sweden).
At Astra-Zeneca, gene array analysis was performed as follows: Two gene arrays
analyzed the expression of encephalitogenic T cells, while two arrays analyzed the
expression of non-encephalitogenic T cells, thereby resulting in four different com-
parisons. Additionally, all arrays were amplified with streptavidin, thereby resulting
in another 4 different comparisons.
In this present thesis, further analysis was performed. Genes were scored to
be regulated, if they were positive in at least all 4 streptavidin-amplified compar-
isons. Thereby, 73 regulated genes were found, of which 36 were up- and 37 were
downregulated each (Table 3.3.1).
Adhesion molecule expression was hardly different. Cytokine and cytokine recep-
tor expression overall appeared to be lower in encephalitogenic T cells as compared
to the non-encephalitogenic T cells. Cytoskeletal molecules as well as extracellu-
lar RNA expression was altered. Furthermore, mRNA levels of 4 so far unknown
genes were partially highly increased in encephalitogenic T cells as compared to the
non-encephalitogenic cells and may result in relevant differences. However, more de-
tailed analysis is required to elucidate the function of these molecules in lymphocyte
recruitment into the CNS.
116 CHAPTER 3. RESULTS
Table 3.3.1: Altered mRNA levels in encephalitogenic vs. non-encephalitogenic T cells which
were at least least 3-fold increased in 4 non-streptavidin-phycoerythrin enhanced gene arrays are
listed. If genes were detected to be altered in 4 streptavidin-phycoerythrin enhanced arrays, but
not in all 4 non-enhanced arrays, fold-changes (f. c.) are marked with an asterix.
acc. no. name f. c.
adhesion molecules and their modification
W98255 CD81 antigen 3.7
cell cycle, cell growth, cell survival and apoptosis
W41072 cell division cycle 34 homolog (S. cerevisiae) 4.1
AA110061 cell division cycle 6 homolog (S. cerevisiae) 10.9
AA021788 death-associated kinase 3 13.3*
X54149 growth arrest and DNA-damage-inducible 45 beta -3.7
L41495 serine/threonine protein kinase pim-2 -3.5*
channels and transporters
AA153484 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 60.0
AA117973 ATPase, Na+/K+ transporting, alpha 1 polypeptide 6.6
AA032860 ATP-binding cassette, sub-family F (GCN20), member 2 6.8
X57349 transferrin receptor 4.5
cytokines, chemokines and receptors
U28404 CCR1 -7.2
D87757 chitinase 3-like 3 -4.7
X53798 CXCL2 -9.9
W62918 Epstein-Barr virus induced gene 3 3.1*
X03019 granulocyte-macrophage colony stimulating factor 4.2
X64534 IL-3 receptor alpha chain -4.4
D13695 interleukin 1 receptor-like 1 -4.7
J03783 interleukin 6 -6.9
X59769 interleukin-1 receptor type 2 -3.2
M37897 interleukin-10 -7.1
U64199 interleukin-12 receptor beta2 3.3
M25892 interleukin-4 -6.6
cytoskeletal molecules
AA015415 kinesin 2 9.9
AA059763 tubulin beta 2 4.7
AA152515 actinin alpha 2 -17.4
AA137524 calcium binding protein P22 53.3
enzymes and metabolism
W41963 acetyl-Coenzyme A synthetase 2 (ADP forming) 8.9
Y08135 acid sphingomyelinase-like phosphodiesterase 3a -4.4*
117
Table 3.3.1: Altered mRNA levels in encephalitogenic vs. non-encephalitogenic T cells
acc. no. name f. c.
W33415 ATP citrate lyase 3.7*
AA073296 ATP CITRATE-LYASE 3.2*
M69109 indoleamine 2,3-dioxygenase 4.0*
M63445 methylenetetrahydrofolate dehydrogenase (NAD+ dependent),
methenyltetrahydrofolate cyclohydrolase
-4.5
extracellular matrix
M16238 fibrinogen-like protein 2 -4.7
X16490 plasminogen activator inhibitor 2 -7.7*
X70296 protease-nexin 1 4.9
L19932 transforming growth factor, beta induced -7.5
growth factors, receptors and related molecules
L41352 schwannoma-derived growth factor -5.8
immune receptors
X05719 cytotoxic T-lymphocyte-associated protein 4 -3.3
innate immunity
U73004 secretory leukocyte protease inhibitor -7.1
X03505 serum amyloid A 3 -4.8
X04072 granzyme B -4.1
peroxisomal proteins
W66916 peroxisomal farnesylated protein 13.1*
phosphatases
W34891 protein phosphatase 1G (formerly 2C), magnesium-dependent,
gamma isoform
4.0*
U35368 protein tyrosine phosphatase, receptor type, E -7.1
protein biosynthesis
AA104940 arginyl-tRNA synthetase 5.3*
W13693 DnaJ (Hsp40) homolog, subfamily A, member 4 18.7
AA109180 eukaryotic translation initiation factor 2B, subunit 5 epsilon 4.3*
W51433 heat shock protein 1 alpha 3.3
U44940 quaking type I -3.6
AA067335 tumor rejection antigen gp96 4.4
signal transduction
W77226 ADP-ribosylation-like 3 5.0*
X12616 c-fes -41.0
D13759 mitogen activated protein kinase kinase kinase 8 -6.0
transcription factors and nuclear proteins
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Table 3.3.1: Altered mRNA levels in encephalitogenic vs. non-encephalitogenic T cells
acc. no. name f. c.
X62600 CCAAT/enhancer binding protein beta -4.0
U63133 c-fos oncogene -57.5
V00727 c-fos oncogene -5.5
X67083 chop-10 mRNA -80.7
AA104319 damage specific DNA binding protein 1 4.0
AA166139 damage specific DNA binding protein 1 4.0
J03482 histone H1c -3.2*
U20532 nuclear, factor, erythroid derived 2, like 2 -3.7
W50655 nucleosome assembly protein 1-like 4 3.8
D14636 runt related transcription factor 2 -3.6
J00424 tetradecanoyl phorbol acetate induced sequence 7 -4.7
W08822 zinc finger protein 289 3.5*
M58691 zinc finger protein 36 -3.7
miscellaneous
AA153021 guanylate nucleotide binding protein 2 5.4
M21050 lysozyme -14.6
U60593 N-myc downstream regulated-like 1 -4.0
unknown
AA170375 hypothetical protein MGC6725 4.1
AA027669 RIKEN cDNA 2410044K02 gene 23.6
AA008547 RIKEN cDNA 9130211I03 gene 3.5
W91360 RIKEN cDNA 9130221H12 gene 12.3
3.3.2 Subtractive-suppression hybridization analysis of en-
cephalitogenic T cells
The next question was, whether additional genes have altered RNA levels in en-
cephalitogenic T lymphoblasts as compared to non-encephalitogenic T lymphoblasts,
especially genes which were not represented on the Affymetrix Mu6500 gene ar-
ray. To identify such genes, 5.0× 107 freshly restimulated encephalitogenic T lym-
phoblasts (line SJLB.PLP6, 5th in vitro restimulation) and 4.2×107 freshly restim-
ulated non-encephalitogenic T lymphoblasts (line SJLB.PLP3, 6th in vitro restim-
ulation) were shock-frozen and sent to Bioserve Biotechnologies Ltd. (Laurel, MD,
USA).
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name vector number creation date
standard T cell, non-enc. pSPORT1 1.2× 107 08/29/2001
standard T cell, non-enc. pCMV-SPORT6 3.9× 107 11/31/2001
standard T cell, non-enc., #15 pCMV-SPORT6 1.4× 106 02/08/2001
standard T cell, enc., #16 pSPORT1 2.6× 106 01/10/2001
standard T cell, enc., #17 pCMV-SPORT6 8.3× 106 01/10/2001
subtraction T cell, enc. – non-enc, #3 pBSII-SK+ 4.9× 106 a 11/01/2001
subtraction T cell, enc. – non-enc, #10.1 pBSII-SK+ 1.6× 104 a 01/10/2001
subtraction T cell, enc. – non-enc, #10.2 pBSII-SK+ 2.3× 105 a 02/08/2001
subtraction T cell, non-enc. – enc, #4 pBSII-SK+ 3.2× 106 a 11/01/2001
subtraction T cell, non-enc. – enc, #11 pBSII-SK+ 4.0× 104 a 01/10/2001
Table 3.3.2: Standard cloning and expression cDNA libraries were created from freshly
restimulated encephalitogenic T lymphoblasts (line SJLB.PLP6, 5th restimulation) and non-
encephalitogenic T lymphoblasts (SJLB.PLP3 6th restimulation). Cloning libraries were used
to create subtractive T cell libraries.
At Bioserve, standard cloning cDNA libraries, expression cDNA libraries as well
as SSH libraries were created (Table 3.3.2).
In this present thesis, preliminary analysis of the library “subtraction T cell,
enc. – non-enc, #10.1” was performed. Therefore, frozen clones of the library “sub-
traction T cell, enc. – non-enc, #10.1” were scratched off the frozen stock solution,
diluted in LB medium containing 50 µg/ml ampicillin, plated on LB agar plates
containing ampicillin and X-Gal/IPTG for selection and grown over night. White
clones were inoculated in LB agar (50 µg/ml ampicillin), grown over night, plasmid
DNA was prepared and 18 clones were sequenced using an M13rev primer. Sequenc-
ing results were compared to the non-redundant gene bank database and results are
shown in Table 3.3.3. Comparing the gene array analysis and SSH/HTS did not
reveal any gene being detected by both techniques.
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acc. no. name start – end clone no.
5295972 chaperonin containing TCP-1 zeta-2 subunit 544 – 1201 9
5295972 chaperonin containing TCP-1 zeta-2 subunit 544 – 1202 16
3057136 epsilon-sarcoglycan 1443 – 953 17
33859481 eukaryotic translation elongation factor 2 15 – 640 7
33859481 eukaryotic translation elongation factor 2 15 – 667 10
33859481 eukaryotic translation elongation factor 2 2603 – 2979 15
33859481 eukaryotic translation elongation factor 2 3070 – 2716 18
21410869 hook homolog 1 (Drosophila) 1765 – 1948 13
21410869 hook homolog 1 (Drosophila) 2603 – 2979 12
1469399 T cell death associated gene 51 5 – 24 6
1469399 T cell death associated gene 51 1765 – 1949 2
1644303 calcitonina 5882 – 5863 5
17467265 lysta 97 – 75 5
aClone no. 5 did not allow identification of a distinct gene, but rather two different genes.
Table 3.3.3: Genes being expressed at higher mRNA levels in encephalitogenic T lymphoblasts
in comparison to non-encephalitogenic T lymphoblasts as detected by SSH and subsequent plasmid
DNA preparation of library “subtraction T cell, enc. – non-enc, #10.1”. Shown are internal clone
numbers as well as the homolog sequences as defined by BLAST algorithm analysis with their
respective starting and ending points.
3.4 Involvement of DARC in leukocyte recruit-
ment across the endothelial blood-brain bar-
rier
3.4.1 Expression of DARC during EAE
As described earlier, DARC mRNA levels were found to be increased during EAE in
brain microvessel preparations, as detected by SSH. This supported earlier findings,
which showed upregulation of DARC in inflamed cerebral vessels during EAE by
in situ hybridization (Alt, 1999). Thus, DARC mRNA expression was induced in
BBB endothelial cells themselves during EAE. So we asked, if DARC is involved
in chemokine transcytosis from the CNS parenchyma across the endothelial BBB
to the luminal surface of the endothelial cells, and if it thereby affects lymphocyte
recruitment into the CNS.
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Figure 3.4.1: Active EAE in C57Bl/6 wildtype and DARC-deficient mice was induced with
MOG35−55. Clinical score and weight change was measured daily. In knockout mice (n = 8; gray
quadrangles), disease onset was delayed as compared to wildtype mice (n = 4; black triangles),
however disease was more severe in DARC-deficient mice. One representative experiment is shown
(n = 3).
3.4.2 Experimental autoimmune encephalomyelitis in
DARC-deficient mice
Focusing on the functional role of DARC mRNA induction during EAE pathogen-
esis, the question arose, if DARC is involved in lymphocyte recruitment across the
endothelial BBB. This question was approached by investigation of DARC-deficient
mice, which had been created by Dawson et al. (Dawson et al., 2000) and were
kindly provided by Antal Rot (Novartis, Vienna, Austria). These knockout animals
were backcrossed into the C57Bl/6 background for 8 generations to obtain mice sus-
ceptible for EAE. After four generations of backcrossing, initial EAE experiments
were performed by immunization with MOG35−55 in CFA (see 2.2.1.2; Figure 3.4.1).
These preliminary experiments revealed a delayed disease onset, but a more se-
vere disease course in DARC-deficient mice, as compared to untreated littermates
(Figure 3.4.1). Next, possible differences in both groups regarding the expression of
endothelial cell specific molecules (Figure 3.4.2B), adhesion and junctional molecules
(Figure 3.4.2C) as well as the composition of inflammatory cells (Figure 3.4.2D) were
investigated by immunohistochemistry. No significant differences could be defined.
To perform transfer EAE experiments, MOG-specific T cell lines had to be
established from C57Bl/6 mice. Therefore, primary T cells were prepared from
lymph nodes and spleens of C57Bl/6 mice (Harlan-Winkelmann, Borchen, Germany)
15 days after immunization with MOG in CFA. Primary culture of splenocytes de-
rived from these mice did specifically proliferate in presence of MOG35−55 as com-
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Figure 3.4.2: Surface molecule expression is compared by immunohistochemistry in mouse brain
at day 23 after DARC-deficient -/- (clinical disease score 2) and C57Bl/6 wildtype +/+ (clinical
disease score 0.25). Control stainings are shown (A). No significant difference in expression of
endothelial cell markers (B), adhesion and junctional molecules (C) or leukocyte surface molecules
(D) could be detected. Immunoperoxidase staining with hematoxyline counterstain. Bar = 20 µm.
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Figure 3.4.3: Proliferation of C57H.MOG T lymphocyte lines C57H.MOG5 (prepared from
popliteal and inguinal lymphocytes) and C57H.MOG6 (prepared from spleens) in response to
different antigens as measured by 3H-dT incorporation. MOG35−55 resulted in a specific response
of C57H.MOG6 splenocytes, but not C57.MOG5 lymphocytes as compared to baseline levels. PPD
resulted in an antigen-specific proliferation in both cell lines. Proliferation was as well be stimulated
by treatment of T cells with ConA.
pared to baseline levels, while primary inguinal and popliteal lymphocytes showed
less specific proliferation (see Figure 3.4.3). Additionally, proliferation in response
to purified protein derivate (PPD) of Mycobacterium tuberculosis was measured. As
to be expected due to the immunization procedure with CFA, which contained in-
activated Mycobacterium tuberculosis, proliferation in response to PPD was high.
However, the time constraints of this dissertation prevented from accomplishing
these transfer EAE experiments.
3.4.3 Endothelioma cell lines lacking DARC
To elucidate a possible function of DARC in vitro, i. e. by adhesion and transmi-
gration experiments, DARC-deficient endothelioma cell lines would be of great help
and were to be established. Therefore, brains and additionally lungs, where a mod-
ified immune response had been described before in DARC-deficient mice (Dawson
et al., 2000; Luo et al., 2000, 2003), were prepared from 2 – 7 day old newborn
DARC-deficient mice, cut into small pieces with two scalpels and digested with col-
lagenase type II. Microvessel fragments were separated by BSA density gradient
centrifugation and plated on collagen-coated tissue culture dishes over night. Cells
were retrovirally transduced with the polyoma middle T oncogene (pymT), which
preferably transforms endothelial cells. Transformed endothelial cells are currently
cultured to obtain pure cell lines (Figure 3.4.4).
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Figure 3.4.4: DARC-deficient endothelioma cell lines are shown by phase contrast microscopy.
Lung-derived luEndD10 form a nice monolayer, while brain-derived bEndD4, bEndD5 and bEndD7
are forming islands in-between fibroblasts and are crowding other cell types out. Bar = 250 µm.
MluI NotI
5’ DARC-pCMV-SPORT6 3’
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Figure 3.4.5: Full-length DARC cDNA sequence
In parallel, a full-length cDNA-DARC EST clone IRAKp961L2217 was obtained
from rzpd (Deutsches Ressourcenzentrum fu¨r Genomforschung GmbH, Berlin, Ger-
many, http://www.rzpd.de) and sequenced (Figure 3.4.5). This cDNA contains the
full length DARC cDNA and will be used to reconstitute DARC expression in the
DARC deficient endothelioma cells. Comparing the interaction of encephalitogenic
T cells and DARC-deficient vs. DARC-reconstituted endothelioma cell lines in vitro
by means of adhesion or transmigration assays will hopefully provide further insight
into the function of DARC in lymphocyte recruitment.
Chapter 4
Discussion
4.1 Functional expression of CCL19 and CCL21
at the endothelial BBB
Chemokines are suggested to be crucially involved in the successful recruitment
of encephalitogenic T cells across the BBB by the requirement for signaling via G-
protein-coupled, PTX-sensitive receptors on encephalitogenic T cells to firmly arrest
on BBB endothelium in vivo and to successfully transfer EAE (Vajkoczy et al.,
2001; Alt et al., 2002). Therefore, we hypothesized that chemokines mediating the
G-protein-dependent arrest of encephalitogenic T cells within CNS microvessels in
vivo should be produced by the BBB endothelium itself.
Searching for chemokines expressed by BBB endothelium, in situ hybridizations
were performed on brain and spinal cord sections of SJL/N mice afflicted with EAE
and of healthy littermates. Out of 12 chemokines investigated, none of the inflam-
matory chemokines was found to be induced at the BBB during EAE. In contrast,
constitutive expression of the lymphoid chemokine CCL19 was detected in CNS
venules of healthy animals and its upregulation in inflamed venules in the CNS of
mice afflicted with EAE was observed. Additionally, expression of the lymphoid
chemokine CCL21, which was not detected to be expressed at the healthy BBB,
was induced in inflamed CNS venules during EAE. CCR7, the common receptor
for CCL19 and CCL21 as well as the alternative CCL21 receptor, CXCR3, were
found on encephalitogenic T lymphoblasts which specifically chemotaxed towards
both chemokines in a concentration-dependent manner comparable to na¨ıve lym-
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phocytes in vitro. Additionally, binding assays on frozen sections of EAE brains
demonstrated a functional involvement of CCL19 and CCL21 in adhesion strength-
ening of encephalitogenic T lymphocytes to inflamed venules in the brain. Thus,
the lymphoid chemokines CCL19 and CCL21 are functionally expressed at the BBB
and might, therefore, be critically involved in the initiation and chronic maintenance
of CNS inflammation during EAE.
Chemokines have been implicated in the pathogenesis of EAE before, as CNS ex-
pression of high levels of a diversity of inflammatory chemokines like CCL2, CCL3,
CCL5 and CXCL10 was observed in tight temporal correlation to disease onset,
as well as in tight spatial correlation to the appearance of inflammatory infiltrates
around CNS venules (reviewed in Karpus and Ransohoff, 1998). In agreement with
the in situ hybridization studies in this present thesis, previous studies demonstrated
that the major producing source for CXCL10 and CCL2 was astrocytes (Ranso-
hoff et al., 1993) and for CCL3, CCL4, CCL5 and CCL6 was both astrocytes and
mononuclear cells within perivascular cuffs (Miyagishi et al., 1997; Asensio et al.,
1999). Additionally, in this study similar expression patterns for CXCL9 and CCL22
were found. It is important to note that the major cellular sources for inflammatory
chemokines detected during EAE were located “behind” the BBB.
Functional evidence for the involvement of CNS chemokines in the pathogenesis
of EAE resulted from in vivo neutralization studies where blocking antibodies di-
rected against CCL2 or CCL3 inhibited onset of EAE or ameliorated chronic EAE,
respectively (Kennedy et al., 1998). Furthermore, antibodies against CXCL10 were
shown to interfere with the development of EAE transferred with encephalitogenic
T cells (Fife et al., 2001). CNS specific expression of CCL6 was shown to induce
leukocyte infiltration into the CNS (Asensio et al., 1999). In contrast, absence of
CCL2 was shown to lead to amelioration of EAE, while absence of its receptor CCR2
inhibits onset of the disease (Fife et al., 2000; Izikson et al., 2000; Huang et al., 2001).
Lack of CCR1, which is a receptor for both CCL5 and CCL7, has been described to
result in less severe EAE (Rottman et al., 2000), while absence of CCR5, which is
an additional receptor for CCL5 was shown to have no influence EAE pathogenesis
(Tran et al., 2000). This suggests that lack of CCR5 can be compensated by CCL5
binding to CCR1, while lack of CCR1 results in lack of CCL5 and CCL7 binding
which cannot be compensated. While mice lacking CXCR2 and CXCR3, which are
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receptors for CXCL1, CXCL9 and CXCL10, have been generated, a potential effect
of the absence of these receptors during EAE has not been reported yet. Mice lack-
ing the receptors for CCL6 and CCL9 do not exist, as these receptors are currently
still unknown.
In contrast to microvessels elsewhere, the highly specialized endothelium of the
BBB forms a physical barrier between the bloodstream and CNS parenchyma, hin-
dering paracellular or transcellular diffusion of chemokines across the BBB by the
complex tight junctions between the BBB endothelial cells and the lack of pinocy-
totic activity of the BBB endothelium, respectively. Consequently, the obvious ques-
tion arose, how chemokines produced within the CNS parenchyma could possibly
attract lymphocytes in the bloodstream from which they are separated by the BBB.
Transport of chemokines from the abluminal to the luminal surface of endothelial
cells in vivo has so far only been observed in dermal microvessels (Middleton et al.,
1997) and in HEV of peripheral lymph nodes (Baekkevold et al., 2001). Although
the inflammatory chemokines CCL2 and CCL3 can bind to the abluminal side of
freshly isolated human brain microvessels in vitro (Andjelkovic et al., 1999; And-
jelkovic and Pachter, 2000), it remains to be demonstrated whether these chemokines
can be transported across the endothelial BBB in vivo and subsequently induce G-
protein-dependent leukocyte arrest on the luminal surface of the BBB endothelium
under shear.
CCL19 and CCL21 are structurally related chemokines referred to as lymphoid
chemokines, because they are constitutively expressed within secondary lymphoid
tissue (summarized in Cyster, 1999; Moser and Loetscher, 2001). There, they reg-
ulate the homing of lymphocytes into the lymph nodes as well as the formation of
secondary lymphoid tissue by acting via their common receptor CCR7, as demon-
strated in a mutant mouse, the plt (paucity of lymph node T cells) mouse, lacking
detectable levels of both CCL19 and CCL21 expression (Nakano et al., 1997; Gunn
et al., 1999) and in CCR7-deficient mice (Forster et al., 1999). This is further
supported by the observation that T lymphocyte homing from blood into lymphoid
tissues by triggering their integrin-mediated arrest on the HEV is regulated by CCR7
and its ligand CCL21 in vivo (Warnock et al., 2000).
Constitutive expression outside of secondary lymphoid tissues, has only been
demonstrated for CCL21, but not for CCL19 in tertiary lymphatic endothelium.
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Inducible expression of CCL19 and CCL21 outside of secondary lymphatic tissue
has been observed during experimental autoimmune diabetes (Hjelmstrom et al.,
2000) and rheumatoid arthritis (Takemura et al., 2001) in spatial and temporal
correlation to the formation of tertiary lymphoid tissue in the respective target
organs. In EAE, development of tertiary lymphatic tissue has not been observed
within the CNS. However, induction of the cytokines TNF-α and lymphotoxin-α,
which have been shown in lymphoid tissue to maintain the constitutive expression
of CCL19 and CCL21 (Ngo et al., 1999), are induced in the CNS during EAE
(Issazadeh et al., 1995; Juedes et al., 2000) and could therefore be responsible for
the expression of both chemokines at the BBB.
EAE can only be transferred by freshly activated, autoantigen-specific CD4+
T lymphoblasts, usually from the TH1 subset, but not by resting T lymphocytes,
which is suggested to be due to their ability to access the CNS (Wekerle et al.,
1986; Hickey et al., 1991). Surface expression of chemokine receptors on T cells has
been reported to be regulated such that, upon activation, T cells lose lymphoid-
organ homing receptors like L-selectin and CCR7 while gaining expression of other
subsets of adhesion molecules or chemokine receptors, enabling efficient immuno-
surveillance of non-lymphoid tissues for injury and infection (Butcher et al., 1999).
In human peripheral blood, activated / memory T cells have been divided into two
subpopulations according to their CCR7 expression. While CCR7-negative T cells
were defined as effector / memory T cells producing large amounts of inflammatory
cytokines, CCR7-positive T cells lacking profound cytokine production showed sur-
face expression of L-selectin and were referred to as central memory T cells, which
could possibly account for those activated / memory T cells able to migrate to lymph
nodes (Sallusto et al., 2000). However, it has been recently described, that this con-
cept does not hold absolutely true in the murine system, suggesting a more complex
network there (Bjorkdahl et al., 2003). Encephalitogenic T cells are maximally ac-
tivated effector / memory T cells at the time point of their injection and produce
high amounts of pro-inflammatory cytokines, however, despite their positive stain-
ing for CCR7, they lack surface expression of L-selectin at that stage (Laschinger
and Engelhardt, 2000). Thus, it seems that these in vitro cultured encephalitogenic
T cells can either not be grouped into any of these previously described phenotypes
or the absence of L-selectin is a result of the in vitro culture, as these cells express
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L-selectin after in vivo culture. The chemokines and chemokine receptors involved
in the homing of effector / memory T lymphocytes into non-lymphoid tissue during
immunosurveillance have not been well characterized. At a first glance it appears
surprising that encephalitogenic T cells should use the lymphoid chemokines CCL19
and CCL21 expressed at the BBB and their common receptor CCR7 to specifically
migrate into the CNS. However, it was demonstrated that T lymphoblasts require
high-affinity α4-integrin to be captured on VCAM-1 expressed by CNS microves-
sels under flow in vivo (Vajkoczy et al., 2001). While α4-integrin-mediated capture
of T cells was independent of G-protein-signaling, subsequent α4-integrin-mediated
adhesion strengthening required G-protein-mediated signals in situ. In this thesis,
binding assays performed on frozen sections of EAE brains provided more proof for
functional involvement of CCL19 and CCL21 in adhesion strengthening of encephal-
itogenic T lymphocytes to inflamed venules in the brain in vitro, which was further
emphasized by preliminary results, which were obtained by intravital microscopy
in vivo, showing a slight reduction of firmly adhering encephalitogenic T cells after
functional inhibition of CCR7. Therefore, it is tempting to speculate that captured
T cells can bind CCL19 or CCL21, which via CCR7 triggers an increase in α4-integrin
avidity. Subsequently, this may lead to the adhesion strengthening of encephalito-
genic T cells on VCAM-1 in CNS venules and their transmigration via LFA-1 as ob-
served previously in vivo (Vajkoczy et al., 2001; Laschinger et al., 2002). In contrast,
na¨ıve T lymphocytes are unlikely to see the lymphoid chemokines present on BBB
endothelium, as they lack high-affinity α4-integrin which is required to stop within
CNS venules. Furthermore, while L-selectin mediated T cell tethering and rolling
is a prerequisite for CCR7 engagement of CCL19 and CCL21 in HEV, there are no
L-selectin ligands described to be expressed on BBB endothelium. However, new
L-selectin ligands have been shown within lymphoid endothelial cells (M’Rini et al.,
2003; van Zante et al., 2003) and their potential expression by BBB endothelial cells
has not been analyzed yet. Vice versa, encephalitogenic T cells lacking L-selectin
would rather home to the immunoprivileged CNS than to peripheral lymph nodes as
they lack luminal expression of VCAM-1 on their HEV. However, one can imagine
that L-selectin ligands might be induced on the inflamed BBB later during chronic
inflammatory disease. This might then allow lymphocytes, which usually home to
secondary lymphoid tissues, to migrate into the CNS, thereby maintaining chronic
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CNS inflammation.
In this present thesis, functional involvement of CCL19 and CCL21 in adhe-
sion strengthening of encephalitogenic T lymphocytes was demonstrated by bind-
ing assays on frozen brain sections of mice afflicted with EAE in vitro. Moderate
inhibitory effects observed after functional inhibition of CCR7 by intravital fluo-
rescence videomicroscopy in spinal cord of healthy mice supported these findings
in vivo, however, they had to be considered as not significant. Therefore, these
preliminary results have to be considered inconclusive at present, however, they
suggest involvement of additional, potentially unknown chemokines to be involved
in lymphocyte recruitment across the endothelial BBB into the immunoprivileged
CNS.
In summary, these findings suggest an additional function for the lymphoid
chemokines CCL19 and CCL21 besides regulating lymphocyte homing to secondary
lymphoid tissue. Due to their functional expression at the BBB, they might be
involved in the migration of activated effector T lymphocytes across the healthy
BBB into the immunoprivileged CNS and in the recruitment of mononuclear cells
across the inflamed BBB during chronic autoimmune disease. However, the moder-
ate effect observed by functional inhibition of these chemokines suggests additional,
potentially new, chemokines, receptors as well as unknown molecules to be involved
in this process. These were to be identified by gene array, SSH and proteomics
approaches in this present thesis.
4.2 Gene and protein profiling of cerebral mi-
crovessels
Oligonucleotide microarrays representing 6500 murine genes and ESTs were used in
collaboration with Astra-Zeneca (So¨derta¨lje, Sweden) to investigate gene expression
profiles of cerebral microvessels isolated from two different mouse strains afflicted
with EAE in comparison to gene expression profiles obtained for cerebral microves-
sels isolated from age and strain-matched healthy mice. Regulated genes were found
in tissue samples derived from either C57Bl/6 or SJL mice to be up- or downregu-
lated. When comparing both gene array profiles, genes were found to be regulated in
cerebral microvessel preparations derived from either both or only one EAE model.
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Thus, we were able to define genes commonly regulated in both EAE models, but
also genes specifically regulated in either model. Genes coding for proteins involved
in different cellular and molecular processes were found and great care was taken to
functionally sort them into different subgroups.
Supporting the current concept of EAE as a model for chronic inflammatory
demyelinating diseases of the CNS with an autoimmune pathogenesis, gene array
analysis detected the upregulation of genes coding for molecules involved in adaptive
immune functions such as immune cell activation or antigen presentation (“immune
receptors”, “antigen presentation”) or leukocyte recruitment (“adhesion molecules
and their modification” and “cytokines, chemokines and receptors”). Increased ex-
pression of the intercellular adhesion molecule-1 (ICAM-1), previously suggested to
be involved in EAE pathogenesis (Archelos et al., 1993) was validated by in situ
hybridization and immunohistochemistry, with both approaches demonstrating in-
creased expression of ICAM-1 mRNA and protein in inflamed cerebral venules in
brains of mice afflicted with EAE, when compared to healthy controls. Also, in-
creased expression of inflammatory chemokines CCL2, CCL5, CCL6, CXCL9 and
CXCL10 were observed in the oligonucleotide microarray analysis and could be con-
firmed by means of in situ hybridization, with undetectable expression in brains of
healthy mice, but a strong induction of their expression in close vicinity to inflamed
cerebral venules surrounded by inflammatory cuffs in EAE brains. Thus, not only
endothelial cell expressed genes, but also genes which were upregulated in inflam-
matory cells located in close proximity to the cerebral microvessels were identified
by gene expression profiling. This was confirmed by our findings that T cell specific
genes encoding CD3δ or the T cell receptor (TCR) β chain as well as macrophage
specific genes, i. e. the gene encoding CD14, or genes coding for leukocyte adhesion
receptors, such as β2-integrin or L-selectin, were found in our screen. Hence, gene
expression comparison of cerebral microvessels from healthy and EAE brains only
allowed to separate the inflamed compartment, but did not allow the complete sep-
aration of cerebral microvessels from inflammatory cells, microglial cells, pericytes
and astrocytic endfeet. Thus, localization of the expression of regulated genes needs
to be confirmed by in situ hybridization or immunohistochemistry.
Despite our finding that increased gene expression of chemokines did not nec-
essarily localize to the inflamed endothelial cells proper, but was rather detected
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in close vicinity to inflamed cerebral microvessels, functional importance for the
chemokines described in this present study in the inflamed microvascular compart-
ment during EAE has been demonstrated before (see 4.1).
This study did detect the regulation of endothelial cell specific genes, which is
demonstrated by the finding that gene expression for caveolin-1 was also found to
be downregulated during both EAE models (Ikezu et al., 1998). Furthermore, in
the SJL mouse EAE model but not in the C57Bl/6 model, downregulation of inter-
cellular adhesion molecule-2 (ICAM-2) mRNA was detected by gene array analysis
although ICAM-2 is also present on T lymphocytes. Immunohistochemistry demon-
strated endothelial cell specific staining for ICAM-2, however, failed to distinguish
between different protein expression levels of ICAM-2 at cerebral microvessels in
healthy or EAE brains. Supporting our previous observations of the lack of ex-
pression and functional involvement of the endothelial E- and P-selectin in EAE
pathogenesis in the SJL mouse (Engelhardt et al., 1997), we did not find any E-
selectin induction in the microarray screen in this model. P-selectin induction could
only be observed after antibody amplification of the signals suggesting that this
might also be derived from low levels of mRNA present in platelets. In contrast
upregulation of E- and P-selectin was observed in the MOG-induced EAE model
in the C57Bl/6 mouse supporting a possible involvement of endothelial selectins in
neutrophil recruitment into the CNS, which are detectable in this but not in the
SJL EAE model.
CD53 was found to be upregulated during EAE in this present study as well as
by others (Ibrahim et al., 2001; Carmody et al., 2002). Interestingly, CD53 has been
described to coimmunoprecipitate with α4β1-integrin (Mannion et al., 1996), which
is involved in EAE pathogenesis (Engelhardt et al., 1998; Vajkoczy et al., 2001).
Upregulation of genes coding for molecules involved in innate immunity in both
EAE models underlines the involvement of the innate immune system in the au-
toimmune pathogenesis especially at the level of the BBB. In our present study,
complement component C3 was found to be upregulated by 11 or even 22-fold in
MOG- induced versus PLP-induced EAE respectively, whereas a previous study
comparing gene expression in entire spinal cord tissue during EAE found upregula-
tion of C3 to be only 3- to 4-fold (Ibrahim et al., 2001). It should be noted that
C3 was found to be amongst the susceptibility genes for EAE in linkage studies
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and mice lacking complement are resistant to EAE (Davoust et al., 1999; Ibrahim
et al., 2001). Thus complement activation at the level of cerebral vessels is of major
importance in EAE pathogenesis.
The largest groups of genes regulated at the level of cerebral microvessels based
on the gene array analysis were found to code for enzymes involved in general cell
metabolism (“enzymes and metabolism”) and in lipid metabolism with expression of
most genes in both groups being downregulated during EAE. This was accompanied
by a reduced gene expression for ion channels as well as genes coding for proteins
involved in vesicular transport, secretory pathways, membrane traffic mechanisms
and cell-cell-contact proteins, suggesting that breakdown of the BBB during EAE is
accompanied by a reduced gene expression for those molecules otherwise responsible
for the maintenance of a functional BBB.
Furthermore altered expression levels of genes coding for “signaling molecules”,
“phosphatases”, “transcription factors and nuclear proteins”, “protein synthesis”
were found in both models with a tendency to upregulation of gene expression within
these groups. One of the most prominently regulated genes was found to be the gene
coding for the transcription factor JunB with 12-fold and 9-fold upregulation in the
C57Bl/6- and SJL- model respectively. Whereas loss of JunB in vivo was shown to
have severe consequences already during placentation (Schorpp-Kistner et al., 1999)
overexpression of JunB in vivo did not lead to an apparent phenotype with exception
to the CD4+ T cell population where JunB expression was shown to be essential
(Schorpp-Kistner et al., 1999). A recent study demonstrated that JunB expression
has to be tightly adjusted in CD4+ T cells to ensure proper cell function (Hartenstein
et al., 2002). Thus, as speculated, before a dysbalance of TH1 versus TH2 response
might be critically involved in EAE pathogenesis. Interestingly, upregulation of
JunB was not reported by Ibrahim et al. (Ibrahim et al., 2001), who performed a
similar microarray study from spinal cord preparations derived from C57Bl/6 mice
afflicted with EAE. In contrast, a 6.02-fold upregulation of JunB was observed during
acute EAE in spinal cord preparations of Lewis rats and subsequently downregulated
to 0.41-fold after recovery of the mice for at least 5 days (Carmody et al., 2002).
Changes of gene expression as detected with the oligonucleotide microarrays
were extended to genes coding for cytoskeletal or extracellular matrix proteins, un-
derlining changes in tissue architecture at the BBB during EAE beyond the protein
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level. This extends previous findings that cytoskeletal changes are required within
cerebral endothelial cells in order to allow inflammatory cell recruitment across the
BBB (Etienne-Manneville et al., 2000). Additionally, upregulation of arachidonate
5 lipoxygenase activating protein (ALOX5AP) and cyclooxygenase-2 (Cox-2) sug-
gests increase in prostaglandin metabolism, which may result in alterations of the
vascular tone and blood flow. Increased Cox-2 expression has been described in
rat endothelium during EAE, while increased Cox-1 expression was localized to
macrophages/microglial cells (Deininger and Schluesener, 1999). As we did not
detect regulation of Cox-1 in this present work, this underlines that we detected
upregulated genes in endothelial cells or closely related inflammatory cells. Also, al-
tered gene expression of extracellular matrix proteins found in both EAE models at
the vascular level emphasizes that molecular alterations in the BBB basal membrane
favoring inflammatory cell recruitment and BBB breakdown are not simply a con-
sequence of loss of certain extracellular matrix proteins due to enzymatic digestion,
but might additionally be influenced by reduced gene expression in cerebral endothe-
lial cells. Interestingly, tissue inhibitors of matrix metalloproteases (TIMP-1) was
found to be upregulated in both EAE models, suggesting that repair mechanisms
might be activated in parallel.
Additionally, genes coding for type 1 interferon regulated proteins, namely in-
terferon inducible protein 1 (IFI1), interferon stimulated gene 12 (ISG12) and
interferon-stimulated protein 15 kDa (ISG15) were found to be upregulated in both
EAE models. While not much is known about IFI1, neuroprotective functions of
ISG12 during viral infections have been shown (Labrada et al., 2002). ISG15 is
also known as ubiquitin cross reactive protein (UCRP) and has been described to
have ubiquitin-like functions by conjugating to other intracellular proteins (Loeb
and Haas, 1992). Recently, its involvement in JAK/STAT signaling has been sug-
gested (Malakhova et al., 2003; Malakhov et al., 2003). Such signaling events might
be involved in protective effects on the BBB, which have been described for human
recombinant interferon β-1a in chicken (Nico et al., 2000). As Type I interferon
stimulated genes have been suggested to be crucial players in viral infections of the
CNS (Akwa et al., 1998), our observations suggest that similar mechanisms are in-
volved in viral and autoimmune induced inflammation. This is supported by the
recent finding that systemic lack of interferon-β (IFN-β) leads to increased severity
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of EAE (Teige et al., 2003).
Regarding individual genes of which expression was differentially regulated com-
paring both EAE models, we considered the increased gene expression of beta-
galactosidase alpha-2,3-sialyltransferase 4A (SiaT4A) mRNA in cerebral microves-
sels in the MOG EAE model but not in the PLP EAE model as potentially in-
teresting. As neutrophils lacking beta-galactosidase alpha-2,3-sialyltransferase 4C
(SiaT4C) have been described to show reduced E- and P-selectin mediated rolling
in vitro (Ellies et al., 2002) and neutrophil infiltration is observed in MOG in-
duced EAE in C57Bl/6 mice but not in PLP induced EAE in SJL/N mice, SiaT4A
might be a potential regulator of neutrophil recruitment across the BBB. Another
sialyltransferase, CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase (SiaT9),
also known as ganglioside GM3 synthase, was found to be selectively downregu-
lated in the MOG EAE model. High GM3 synthase activity has been described
in bovine brain microvascular endothelial cells (Kanda et al., 1997). Involvement
of GM3 in modifying growth factor receptor functions has been suggested, as de-
scribed by inhibition of FGF receptor and FGF internalization in BHK cells as well
as EGF-dependent growth in A431 and KB cells (reviewed by Hakomori, 2000).
Additionally, there have been reports that low doses of GM3 may enhance activ-
ity of the fibronectin receptor α5β1-integrin while high doses result in inhibition of
α5β1-integrin activity in reconstituted membranes (reviewed by Hakomori, 2000).
Furthermore, GM3-dependent B16 melanoma cell adhesion to LacCer, Gb4 or Gg3
coated plates has been reported (reviewed by Hakomori, 2000). Therefore, as varia-
tions in GM3 expression have been described to result in altered cell-cell interactions,
maybe partially due to altered integrin activity, GM3 synthase may modify constitu-
tively expressed surface molecules, i. e. adhesion molecules at the BBB endothelium.
This might alter leukocyte adhesion and thereby leukocyte infiltration into the CNS.
While the gene array approach allowed highly sensitive identification of genes,
which were regulated in cerebral microvessels during EAE pathogenesis, it was lim-
ited to genes being presented on the chip and regulated more than 2-fold. A totally
different approach, SSH enriches genes, which are increased in one versus another
tissue sample. These genes can subsequently be identified by cloning and DNA se-
quencing, which allows identification of so far unknown genes. Multiple copies of
one given gene may result from more abundantly expressed genes. Hence, the clone
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number of a given gene does not correlate with its functional relevance, as high and
low level expressed genes may be very important. Comparing the results from these
different approaches, 13 genes were identified to be enriched by SSH/HTS, which had
as well been detected to be upregulated by gene array analysis, while no contradic-
tory results were observed. On a first glance, the number of genes identified by both
techniques in parallel was astonishingly low. To be able to predict this number, one
would have to assume that each gene is randomly and independently identified by
either gene array analysis or SSH/HTS, which is not the case. Nevertheless, under
this prerequisites, the following could be calculated: As 134 upregulated genes were
detected by gene array analysis in cerebral microvessels during EAE and the gene
array represented about 20 % of the mouse genome, assumably 670 genes should
have been regulated in total. SSH/HTS allowed identification of approximately 100
regulated genes, which represents about 15 % of 670 genes that had been regulated
in total. Therefore, 15 % of the 130 genes being identified by gene array analysis, 20
genes, should have been identified by both approaches in parallel, so that the actual
number of 13 genes should be less surprising and these two different techniques have
to be considered rather complementary than confirmative.
Although a different cerebral microvessel preparation method was used for the
SSH/HTS approach, as compared to the gene array analysis, mRNA derived from
inflammatory cells was contained in this preparation as well, as we found enrichment
of the macrophage-specific immune receptor gene CD14 and the T cell-specific im-
mune receptor CD52 / CAMPATH-1. Nevertheless, humanized antibodies directed
against CD52 have been described to result in T cell depletion, thereby ameliorat-
ing MS pathogenesis, while unfortunate side effects cause carbimazole-responsive
autoimmune hyperthyroidism (Coles et al., 1999). Thus, although we found non-
endothelial cell specific genes, these are of high functional importance for EAE
pathogenesis. Additionally, gp49A has been detected by SSH/HTS to be differen-
tially expressed. This gene has been identified before to be an either mast cells or
NK-cells expressed glycoprotein (Katz et al., 1989; Arm et al., 1991; Rojo et al.,
1997), which delivers inhibitory signals into the cells. Involvement of mast cells and
NK cells in EAE pathogenesis (Secor et al., 2000; Jahng et al., 2001) and multiple
sclerosis (reviewed in Zappulla et al., 2002) has been described before. Transfer of
bone marrow-derived mast cell into mast cell-deficient W/Wv mice did not restore
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mast cells within the CNS, lymph nodes and heart; but reconstituted mice exhibited
an EAE disease course equivalent to that induced in wild-type mice (Tanzola et al.,
2003). Thus, mast cells outside the CNS may influence EAE. However, the absence
of mast cells within the lymphoid system and the CNS may have more general ef-
fects, so that the potential role of mast cells located within the CNS during EAE
pathogenesis remains to be solved.
Regarding leukocyte recruitment into the CNS, additional adhesion molecules
were identified to be differentially expressed in cerebral microvessel preparation
during EAE pathogenesis. Down syndrome cell adhesion molecule-like protein 1
(DSCAML1) was detected to be enriched during EAE pathogenesis. While this
molecule has been suggested to be involved in axonal guidance during neural de-
velopment and homophilic adhesion (Agarwala et al., 2001), a potential function
in leukocyte recruitment across the endothelial BBB requires more detailed anal-
ysis. Furthermore, C-type lectin, superfamily member 10 (CLECSF10) / dectin-2
(Ariizumi et al., 2000; Okazaki et al., 2002) has been identified to be enriched in
the cerebral microvessel compartment during EAE pathogenesis. Dectin-2 was de-
scribed as undetectable in healthy brain and to be specifically expressed in dendritic
cells (DC), while not being expressed by other hematopoietic cell types (Ariizumi
et al., 2000), however, expression within the brain of mice afflicted with EAE has
not been analyzed yet. Therefore, further analysis is required to elucidate potential
involvement of dectin-2 in recruitment of i. e. dendritic cells in EAE pathogenesis.
Besides adhesion molecules, we found chitinase 3-like 1 (Chi3l1) and chitinase 3-
like 3 (Chi3l3) to be enriched in cerebral microvessel preparations during EAE
pathogenesis. As another chitinase-family member had been described as exhibit-
ing chemotactic properties and some homology to the chemokine family (Owhashi
et al., 2000), Chi3l1 and Chi3l3 might be involved in leukocyte recruitment. Further
studies suggested involvement of Chi3l1 in another autoimmune disease, rheumatoid
arthritis and in tissue remodeling (Volck et al., 1998) or mitogenic signaling processes
via mitogen-activated protein kinase and the protein kinase B (AKT) (Recklies et al.,
2002).
The Duffy antigen / receptor for chemokines (DARC) was identified by SSH/HTS
to be enriched during EAE pathogenesis in cerebral microvessels. This matches our
previous finding showing DARC upregulation in cerebral endothelial cells during
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EAE pathogenesis by in situ hybridization (Alt, 1999) and will be discussed in more
detail (see 4.4). Besides DARC, three additional serpentine receptors were found to
be enriched in cerebral microvessel preparations during EAE pathogenesis. Increased
expression of one of them, CD97, has been described in MS lesions in T lympho-
cytes, macrophages and microglial cells, while its ligand, CD55 was expressed by
endothelial cells. The two other receptors, one of them related to Homo sapiens
seven transmembrane domain protein (NIFIE14) and vomeronasal 1 receptor, A2
(V1RA2) require detailed analysis, as their functional role has not been described
yet.
Two enriched genes might be involved in junctional integrity. One of them,
axin, had been originally identified as a negative regulator of wnt-signaling path-
ways (Zeng et al., 1997), while additionally interacting with β-catenin (Ikeda et al.,
1998). Furthermore, IQ motif containing GTPase activating protein 1 (IQGAP1)
has been suggested to be involved in E-cadherin – β-catenin interactions during
murine preimplantation development (Natale and Watson, 2002). Therefore, both
genes could potentially be involved in modifying junctional properties during EAE
pathogenesis.
Another very interesting finding was enrichment of neuropilin-2 (NP-2) in cere-
bral microvessel preparations during EAE pathogenesis. NPs are cell surface gly-
coproteins with short cytoplasmic tails. They bind semaphorins, which are in-
volved in axonal guidance during neural development, as well as several vascular
endothelial growth factor (VEGF) family members (reviewed in Matsumoto and
Claesson-Welsh, 2001; Neufeld et al., 2002). NPs are non-signaling coreceptors for
semaphorins and require the presence of signal transducing receptors of the plexin
family to mediate their effects. NP-2 expression in lymphatic vessels has been shown,
while additionally NP-2–deficiency in mice results in severe reduction or complete
absence of lymphatic vessels during embryonic development, suggesting an impor-
tant role in lymphatic development (Yuan et al., 2002). As there are no lymphatic
vessels present within the CNS, several questions arise regarding the function of
NP-2 in the brain during EAE pathogenesis: Is expression of NP-2 accompanied
by induction of additional lymphatic endothelial cell marker molecules, potentially
due to edema formation during the disease? Does this result in a modified, rather
lymphatic phenotype of vascular endothelium in the CNS during EAE? Are known
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interaction partners of NP-2, i. e. plexins, semaphorins, PlGF or distinct VEGF-
isoforms, present at the CNS endothelium to interact with NP-2, and might this
result in a so far unknown function of these interactions?
After having found differentially expressed genes in cerebral microvessels during
EAE pathogenesis, a proteomics approach allowed to identify 6 differentially ex-
pressed proteins, of which 5 were found to be represented on the Affymetrix chip.
However, only one of them, fibroleukin was significantly upregulated in both, the
proteomics and oligonucleotide microarray screen. Such a low correlation between
protein and gene expression profiling has been described before (Anderson and Seil-
hamer, 1997; Gygi et al., 1999; Chen et al., 2002) and may result from several
technical problems: On the one hand, gene expression changes smaller than 2-fold
have to be considered not significant according to the manufacturer, nevertheless,
they may result in significant protein level changes detectable by proteomics. On
the other hand, proteomics approaches may have missed expression changes of very
small or very large, hydrophobic or secreted proteins, which may have been lost
during the tissue preparation. I. e. chemokines may have been lost during the tissue
preparation and are too small to be reliably quantified by the 2D-gelelectrophoresis.
Therefore, both techniques have to be considered rather complementary than con-
firmative.
We found strong upregulation of fibroleukin / fgl2, expression of which has been
described before in human endothelial, intestinal, trophoblast and cytotoxic T cells
and to be inducible in macrophages / monocytes (Liu et al., 2003). While acting as
an immune coagulant due to its prothrombinase activity (Parr et al., 1995), soluble
fgl2 has been described recently to suppress T cell and dendritic cell proliferation
and to polarize T cells towards a TH2 profile (Chan et al., 2003). This underlines
our gene array results, which suggest an important role of TH1 / TH2 equilibrium
in EAE pathogenesis. Additionally, upregulated protein expression of an acidic and
basic variant of heterogeneous nuclear ribonucleoprotein A2/B1, both involved in
RNA processing, was detected, suggesting modulatory effects on translation of other
proteins in inflamed cerebral microvessels during EAE. Another protein identified to
be upregulated was purine nucleosid phosphorylase (PNP) / inosine phosphorylase,
deficiency of which has been described to result in T cell depletion, while B cell
function remains mostly intact (Stoop et al., 1977). Also, guanine nucleotide-binding
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protein subunit-like protein 12.3 / receptor of activated protein kinase C 1 (RACK-1)
could be identified to be upregulated. Involvement of RACK-1 in integrin mediated
adhesion, protrusion and chemotactic cell migration has been described in vitro
(Cox et al., 2003). Considering its multiple functional domains, RACK-1 might
act as a scaffolding protein, which is underlined by observations demonstrating its
interaction with other WD40 domain containing proteins, i. e. G-protein β subunits
(Dell et al., 2002). The additionally observed downregulation of the WD40 domain
containing guanine nucleotide binding protein beta subunit 2 (GBB2) suggests that
modifications in RACK-1 scaffolding with different other proteins might either play a
potential role in lymphocyte migration across the endothelial BBB or in endothelial
cells allowing lymphocytes to transmigrate. Along the same lines, the observed
upregulation of tailless complex polypeptide 1 (TCP-1), a chaperon suggested to be
involved in the folding of actin and tubulin, points to increased actin remodeling in
inflamed cerebral microvessels during EAE.
In conclusion, all three techniques allowed to discover new molecules which are
regulated in the cerebral microvessel compartment during EAE providing new in-
sight into the disease pathogenesis and raising the exciting possibility to target new
molecules for the therapy of human inflammatory demyelinating diseases of the CNS.
4.3 Gene expression profiling of encephalitogenic
T cells
PLP-specific T cell lines established from SJL/N mice are referred to as either en-
cephalitogenic or non-encephalitogenic depending on their ability to transfer clinical
EAE into na¨ıve syngeneic recipients. While some T cell lines are never encephal-
itogenic, others lose their encephalitogenicity after several in vitro restimulation
steps. The question by what molecular means this functional difference is caused
has been addressed in our laboratory and by others before. Different cytokine and
α4-integrin expression have been suggested to be critically involved in encephali-
togenicity (Tokuchi et al., 1990; Baron et al., 1993; Kuchroo et al., 1993). How-
ever, such results were never observed when comparing encephalitogenic vs. non-
encephalitogenic T cell lines in our laboratory (Engelhardt et al., unpublished data).
Thus, we applied molecular screening techniques to analyze potential differences.
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Comparing encephalitogenic with non-encephalitogenic T lymphoblasts by gene
array analysis, only few molecules being possibly directly involved in leukocyte re-
cruitment were altered. While there was a decent number of cytokines, chemokines
and their receptors mostly decreased in encephalitogenic T cells as compared to non-
encephalitogenic T cells, only one adhesion related molecule was regulated, CD81.
CD81 belongs to the tetraspanin family, which has been described to regulate α4-
integrin mediated adhesion strengthening under shear (Feigelson et al., 2003). As
α4-integrin involvement in recruitment of encephalitogenic T lymphoblasts across
the endothelial BBB has been shown in our laboratory in vivo (Vajkoczy et al.,
2001), this strongly suggests an important role of CD81 in lymphocyte recruitment.
Cytoskeleton related proteins are predominantly increased in encephalitogenic
versus non-encephalitogenic T lymphoblasts, of which calcium binding protein p22
is the most prominent regulated one. Involvement of this gene in directed vesicular
transport and association with the microtubular cytoskeleton has been described
(Barroso et al., 1996; Timm et al., 1999), suggesting a possible role in motility and
thereby transmigration of lymphocytes across vascular walls. Thus, encephalitogenic
T lymphoblasts might be more motile than non-encephalitogenic T lymphoblasts.
Furthermore, there were significant differences in genes being involved in signal
transduction and transcription. The proto-oncogene and receptor tyrosine kinase
c-fes was decreased in encephalitogenic versus non-encephalitogenic T cell lines. As
c-fes has been shown to be involved in IL-4 mediated signaling events (Izuhara et al.,
1996), one might suggests, that non-encephalitogenic T cells have been shifted to-
wards a TH2 specific immune response. Although TH2 lymphoblasts are able to
induce EAE as well (Lafaille et al., 1997), such a TH1 / TH2 dysbalance might
result in loss of encephalitogenicity. Additionally, strongly decreased c-fos in en-
cephalitogenic versus non-encephalitogenic T lymphoblasts has been observed in
this present thesis. c-fos overexpression has been described to result in increased
collagenase-1 expression by T cells (Gack et al., 1994). This would suggest de-
creased collagenase-1 expression, which has to be considered inconclusive at present.
Another transcription related gene, chop-10, was massively decreased in encephal-
itogenic versus non-encephalitogenic T cells. As chop-10 binds to leucine zipper
type transcription factors, but lacks DNA binding properties, it may function as a
negative regulator of other transcription factors (Ron and Habener, 1992). How-
142 CHAPTER 4. DISCUSSION
ever, its role in T cell function has not been described yet. Another significant
difference in signaling events might result from the fact, that we detected highly in-
creased amounts of ATPase-2 A2 (ATP2A2) / sarcoplasmic/endoplasmic reticulum
Ca2+-activated adenosine triphosphatase 2 / SERCA-2 in encephalitogenic versus
non-encephalitogenic T cells, which maintains the intracellular Ca2+ stores. Re-
duced activity of this transporter may therefore result in reduced Ca2+ signaling
events.
Besides these regulated genes, genes being upregulated in encephalitogenic versus
non-encephalitogenic T cells were identified by SSH and subsequent sequencing. The
most interesting one was hook homolog 1, which has been described as a linker of
the microtubular manchette and flagellum to cellular structures in spermatozoa,
suggesting a possible role in T lymphoblast diapedesis across the endothelial BBB
(Mendoza-Lujambio et al., 2002).
Taken together, these two approaches allowed to discover molecules differentially
expressed in encephalitogenic versus non-encephalitogenic T lymphoblasts, thereby
being of potentially high relevance for encephalitogenic T lymphoblast function and
proposing new target molecules for treatment of inflammatory demyelinating dis-
eases of the CNS.
4.4 Involvement of DARC in T cell recruitment
into the CNS during EAE pathogenesis
In this present thesis, the Duffy Antigen / Receptor for Chemokines (DARC), which
is a blood group antigen presented on erythrocytes, was detected by SSH/HTS
to be upregulated in cerebral microvessel preparations during EAE. This nicely
confirms our previous in situ observations, that DARC is induced in cerebral venules
during clinical EAE (Alt, 1999). DARC expression has been described before in
kidney, lung, spleen and thyroid endothelial cells (Hadley et al., 1994; Peiper et al.,
1995; Chaudhuri et al., 1997) and in Purkinje cells within the brain parenchyma
(Horuk et al., 1996), while expression in brain endothelial cells has not been reported
yet. Nevertheless, DARC involvement has been suggested in autoimmune responses,
such as crescentic glomerulonephritis and rheumatoid arthritis (Segerer et al., 2000;
Patterson et al., 2002), while two studies with DARC-deficient mice described its
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involvement during inflammatory responses in vivo (Dawson et al., 2000; Luo et al.,
2000, 2003).
Regarding the functional role of DARC, it has been proposed to fulfill one or
multiple different tasks: On the one hand, endothelial cell expressed DARC may
be involved in chemokine transcytosis to and presentation at the luminal surface
of endothelial cells (reviewed in Middleton et al., 2002). On the other hand, ery-
throcyte expressed DARC may remove chemokines from the bloodstream (“sink”)
(Dawson et al., 2000). This local “sink” function might have to be extended by a
systemic “reservoir” function, as it has been described, that DARC delays the disap-
pearance of systemically administered chemokines from the blood plasma, thereby
maintaining plasma chemokine concentrations (Fukuma et al., 2003).
In this present thesis, EAE in DARC-deficient mice resulted in a delayed onset of
disease, while clinical severity of the disease was increased as compared to wild type
mice. These surprising results allow different explanations. First of all, experiments
were performed in mice which had been backcrossed into the C57Bl/6 background
for only 4 generations. However, as wildtype littermates were used as a control, it
is unlikely that diversity in genetic background influences the experiments. Rather,
lack of DARC expression on endothelial cells and erythrocytes results in beneficial
and detrimental effects, antagonizing each other. Hence, we would like to suggest the
following: Initial recruitment of T lymphoblasts mediated by CCL19 is unaffected
by DARC absence, as CCL19 has been described not to bind to DARC (Kashiwazaki
et al., 2003). Subsequently, inflammatory chemokines which are produced within the
CNS parenchyma cannot be transported across the endothelial BBB to be presented
at the luminal surface. Thus, onset of disease is delayed. However, after onset of
disease and breakdown of the endothelial BBB, inflammatory chemokines might
diffuse across the leaky BBB and reach reach the luminal surface of the endothelial
cells. Due to the absence of DARC on erythrocytes, chemokines are not removed
and therefore, increased amounts of secondary inflammatory cells are attracted to
the CNS, resulting in more severe clinical symptoms. To distinguish these different
effects, bone marrow chimeras will have to be established, which possess either
DARC-deficient endothelial cells or erythrocytes.
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4.5 Model for chemokine involvement in lympho-
cyte recruitment into the CNS
In conclusion, we would like to suggest the model shown in Figure 4.5.1.
Figure 4.5.1: Model showing the potential involvement of lymphoid (quadrangles), inflammatory
DARC-binding (circles) and non-DARC-binding (hexagons) chemokines in lymphocyte recruitment
into the CNS. A: At the healthy BBB, initial T lymphoblast recruitment is mediated by CCL19,
which is presented on the luminal surface of endothelial cells, while CXCL12 is expressed by
astrocytes but cannot pass the endothelial BBB. B: During inflammation, CCL21 expression is
induced in endothelial cells, so it is presented on the luminal surface and directly affects lymphocyte
recruitment into the CNS. Induced expression of DARC allows transport of a distinct inflammatory
chemokines, which are expressed within the brain parenchyma, across the endothelial BBB to the
luminal surface. Further effector functions are fulfilled by chemokines located within the CNS.
C: During severe inflammation and after BBB breakdown, additional chemokines can reach the
luminal surface of the endothelial cells and further increase CNS inflammation.
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B Summary
Migration of autoaggressive T cells across the blood-brain barrier (BBB) is critically
involved in the initiation of multiple sclerosis (MS) and its animal model experimen-
tal autoimmune encephalomyelitis (EAE). The direct involvement of chemokines in
this process was suggested by our recent observation that G-protein-mediated sig-
naling is required to promote adhesion strengthening of encephalitogenic T cells on
BBB endothelium in vivo. For chemokines to be involved in this process, they have
to be either expressed by BBB endothelial cells themselves or would require a yet
unknown transport mechanism from the central nervous system (CNS) parenchyma
across the endothelial BBB to the luminal surface of the endothelial cells. To search
for chemokines expressed by the endothelial BBB itself, in situ hybridizations and
immunohistochemistry were performed and expression of the lymphoid chemokines
CCL19 and CCL21 was found in venules surrounded by inflammatory cells. Their
expression was paralleled by the presence of their common receptor CCR7 in in-
flammatory cells in brain and spinal cord sections of mice afflicted with EAE. En-
cephalitogenic T cells showed surface expression of CCR7 and the alternative re-
ceptor for CCL21, CXCR3. They specifically chemotaxed towards both CCL19 or
CCL21 in a concentration dependent and pertussis toxin-sensitive manner compa-
rable to na¨ıve lymphocytes in vitro. Functional involvement of CCL19 and CCL21
in adhesion strengthening of encephalitogenic T lymphocytes was demonstrated by
binding assays on frozen brain sections of mice afflicted with EAE in vitro and pre-
liminary by intravital fluorescence videomicroscopy in spinal cord of healthy mice
in vivo. The moderate effect observed suggests additional, potentially unknown
chemokines to be involved in lymphocyte recruitment across the endothelial BBB
into the immunoprivileged CNS. Such chemokines, receptors as well as unknown
molecules were identified at the level of the endothelial BBB by oligonucleotide
microarrays, subtractive suppression hybridization (SSH) and proteomics. Besides
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the upregulation of expected genes and proteins described to be involved in leukocyte
recruitment during EAE pathogenesis before, unexpected genes and proteins were
identified. The latter included increased Duffy antigen / receptor for chemokines
(DARC) expression suggesting its involvement in lymphocyte recruitment during
EAE pathogenesis, which was proven as in DARC-deficient mice, disease onset was
delayed, while clinical severity was increased. This may be explained by an ambigu-
ous DARC function in EAE pathogenesis. Either endothelial cell expressed DARC
“shuttles” chemokines to the luminal surface of the endothelial cells or erythrocyte
expressed DARC removes chemokines by its “sink”-like function. This results in ei-
ther increased or decreased chemokine concentrations accessible to encephalitogenic
T lymphoblasts. Their encephalitogenicity was addressed by gene array analysis and
SSH of encephalitogenic versus non-encephalitogenic T lymphoblasts identifying 79
differentially expressed genes.
Based on the results obtained during this thesis, we would like to suggest the
lymphoid chemokines CCL19 and CCL21 to be critically involved in lymphocyte
recruitment across the endothelial BBB during EAE pathogenesis, while the chemo-
kine receptor DARC may provide a “shuttle” mechanism for inflammatory chemo-
kines from the CNS parenchyma across the endothelial BBB to the luminal surface of
the endothelial cells during EAE. A large number of additional genes and proteins
was identified to be differentially expressed in either endothelial cells or T lym-
phoblasts pointing to new mechanisms involved in leukocyte trafficking across the
BBB.
C Zusammenfassung
Die Wanderung autoaggressiver T-Zellen durch die Blut-Hirn-Schranke (BHS) ist
am Ausbruch der Multiplen Sklerose (MS) und ihres Tiermodells, der Experi-
mentellen Autoimmunen Enzephalomyelitis (EAE), entscheidend beteiligt. Un-
sere ku¨rzlich gemachte Beobachtung, daß G Protein-vermittelte Signale fu¨r die
Adha¨sionsversta¨rkung enzephalitogener T-Zellen an BHS-Endothel in vivo beno¨tigt
werden, macht eine direkte Beteiligung von Chemokinen an diesem Vorgang
wahrscheinlich. Um direkt an der Lymphozytenrekrutierung beteiligt zu sein,
mu¨ssen Chemokine entweder von BHS-Endothelzellen exprimiert werden oder
sie wu¨rden einen bisher unbekannten Transportmechanismus vom Parenchym
des Zentralen Nervensystems (ZNS) durch die endotheliale BHS auf die lumi-
nale Oberfla¨che der Endothelzellen beno¨tigen. Von der endothelialen BHS ex-
primierte Chemokine wurden mit Hilfe von in situ Hybridisierungs- und im-
munhistochemischen Methoden identifiziert, wodurch die Expression der lym-
phoiden Chemokine CCL19 und CCL21 in Venolen gezeigt wurde, die von in-
flammatorischen Zellen umgeben waren. Gleichzeitig wurde die Expression ihres
gemeinsamen Rezeptors, CCR7, in inflammatorischen Zellen in Gehirn- und
Ru¨ckenmarkgewebeschnitten an EAE erkrankter Ma¨use detektiert. Enzephalito-
gene T-Zellen wiesen sich durch Oberfla¨chenexpression von CCR7 und des alterna-
tiven Rezeptors fu¨r CCL21, CXCR3, aus. In vitro zeigten sie eine Konzentrations-
und Pertussis Toxin-abha¨ngige, chemotaktische Reaktion, die mit der naiver Lym-
phozyten vergleichbar war. Die funktionelle Beteiligung von CCL19 und CCL21 an
der Adha¨sionsversta¨rkung enzephalitogener T-Lymphozyten wurde in vitro durch
Bindungsversuche auf Gefrierschnitten an EAE erkrankter Ma¨use und in vivo durch
vorla¨ufige Ergebnisse intravitaler Fluoreszenzvideomikroskopie im Ru¨ckenmark
gesunder Ma¨use gezeigt. Die teilweise Hemmung der Bindung enzephalitogener T-
Lymphoblasten, die beobachtet wurde, legt die Beteiligung weiterer, mo¨glicherweise
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unbekannter Chemokine an der Rekrutierung von Lymphozyten durch die BHS
in das immunprivilegierte ZNS nahe. Derartige Chemokine, Rezeptoren, sowie
weitere Moleku¨le wurden in BHS-Endothelzellen mit Hilfe von Oligonukleotid-
Mikroarrays, subtraktiver-Unterdru¨ckungshybridisierung und Proteomik Ansa¨tzen
identifiziert. Abgesehen von der versta¨rkten Expression von Genen und Proteinen,
deren Einfluß auf die Leukozytenrekrutierung wa¨hrend des Krankheitsverlaufs der
EAE bereits gezeigt wurde, wurden weitere Gene und Proteine identifiziert, deren
Beteiligung am Krankheitsverlauf der EAE bisher nicht beschrieben war. Zu den
letzteren geho¨rte der Duffy Antigen / Rezeptor fu¨r Chemokine (DARC), dessen
Beteiligung an der Lymphozytenrekrutierung wa¨hrend des EAE Krankheitsver-
laufs daher nahe liegt. Dies wurde mit Hilfe DARC-defizienter Ma¨use bewiesen,
da deren Krankheitsausbruch verzo¨gert, aber die klinischen Symptome wa¨hrend
der EAE versta¨rkt waren. Dies kann durch eine doppelte Funktion von DARC
wa¨hrend des EAE Krankheitsverlaufs erkla¨rt werden. Entweder transportiert auf
Endothelzellen exprimiertes DARC Chemokine auf die luminale Seite der En-
dothelzellen (,,Pendelverkehr-Funktion”) oder auf Erythrozyten exprimiertes DARC
entfernt die Chemokine (,,Abfluß-Funktion”). Somit ergeben sich entweder erho¨hte
oder gesenkte Chemokinkonzentrationen, die fu¨r enzephalitogene T-Lymphozyten
zuga¨nglich sind. Deren Enzephalitogenita¨t wurde mit Hilfe von Oligonukleotid-
Mikroarrays und subtraktiver-Unterdru¨ckungshybridisierung durch Vergleich en-
zephalitogener und nicht-enzephalitogener T-Lymphoblasten untersucht, wodurch
79 unterschiedlich exprimierte Gene identifiziert wurden.
Die in dieser Dissertation erhaltenen Ergebnisse legen nahe, daß die lymphoiden
Chemokine CCL19 und CCL21 maßgeblich an der Lymphozytenrekrutierung durch
die BHS wa¨hrend des EAE Krankheitsverlaufs beteiligt sind, wa¨hrend der Che-
mokinrezeptor DARC einen Transportmechanismus fu¨r inflammatorische Chemo-
kine vom ZNS-Parenchym durch die endotheliale BHS auf die luminale Oberfla¨che
der Endothelzellen wa¨hrend des EAE Krankheitsverlaufs darstellt. Weitere Gene
und Proteine, die entweder in Endothelzellen oder T-Lymphoblasten unterschiedlich
exprimiert wurden, weisen auf neue Mechanismen wa¨hrend der Leukozytenrekru-
tierung u¨ber die BHS hin.
D List of abbreviations
β-ME . . . . . . . β-mercaptoethanol
3H-dT . . . . . . . 3H-deoxy thymidine
aa . . . . . . . . . . . amino acid
ab . . . . . . . . . . . antibody
aEAE . . . . . . . active experimental autoimmune encephalomyelitis
AEC . . . . . . . . 3-amino-9-ethyl-carbazol
APC . . . . . . . . antigen presenting cell
ATP. . . . . . . . . adenosine triphosphate
BBB . . . . . . . . blood-brain barrier
BCA . . . . . . . . bicinchoninic acid
BLAST. . . . . . basic local alignment search tool
bp . . . . . . . . . . . base pair
BPB . . . . . . . . bromphenol blue
BSA. . . . . . . . . bovine serum albumine
CCD . . . . . . . . charged coupled device
cDNA . . . . . . . copy desoxyribonucleic acid
CFA. . . . . . . . . complete Freund’s adjuvant
CHAPS . . . . . 3-((3-cholamidopropyl)dimethylammonio)-1-
propanesulfonate
CNS. . . . . . . . . central nervous system
CS . . . . . . . . . . calf serum
ConA. . . . . . . . concanavalin A
ConAS . . . . . . concanavalin A supernatant
CTrG . . . . . . . Cell Tracker Green
CTrO. . . . . . . . Cell Tracker Orange
179
180 D LIST OF ABBREVIATIONS
CTP . . . . . . . . cytidine triphosphate
depc . . . . . . . . . diethylpyrocarbonate
DMEM. . . . . . Dulbecco’s modified eagle medium
DMSO . . . . . . dimethyl sulfoxide
dATP . . . . . . . deoxy-adenosine triphosphate
dCTP . . . . . . . deoxy-cytidine triphosphat
dGTP . . . . . . . deoxy-guanosine triphosphat
dTTP . . . . . . . deoxy-thymidine triphosphat
DNA . . . . . . . . desoxyribonucleic acid
dNTPs . . . . . . mixture of dATP, dCTP, dGTP, dTTP
DC . . . . . . . . . . dendritic cells
DTT . . . . . . . . dithiotreitol
EAE . . . . . . . . experimental autoimmune encephalomyelitis
EDTA . . . . . . . ethylen-diamine-tetra-acetic acid
ESI-MS/MS . electrospray ionization tandem mass spectrometry
EST . . . . . . . . . expressed sequence tag
FCS . . . . . . . . . fetal calf serum
FITC. . . . . . . . fluorescein isothiocyanate
GFAP . . . . . . . glial fibrillary acidic protein
GSLI . . . . . . . . Griffonia simplicifolia lectin I
GTP . . . . . . . . guanosine triphosphate
HBSS . . . . . . . Hank’s balanced salt solution
HEPES. . . . . . 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HEV . . . . . . . . high endothelial venule
HRP . . . . . . . . horseradish peroxidase
HTS. . . . . . . . . high-throughput sequencing
IEF . . . . . . . . . isoelectric focusing
IL-2 . . . . . . . . . interleukin-2
IPG . . . . . . . . . immobilized pH gradient
IPTG . . . . . . . isopropylthiogalactoside
IU . . . . . . . . . . . International Unit
181
LB . . . . . . . . . . Luria-Bertani
LPS . . . . . . . . . lipopolysaccharide
MALII . . . . . . Maackia amurensis lectin II
MALDI . . . . . Matrix assisted laser desorption/ionization
MBP . . . . . . . . myelin basic protein
MHC . . . . . . . . major histocompatibility complex
MOG. . . . . . . . myelin oligodendrocytic glycoprotein
MOPS. . . . . . . morpholinopropanesulphonic acid
MTX . . . . . . . . mutant pertussis toxin
MS . . . . . . . . . . multiple sclerosis
Mr . . . . . . . . . . molecular weight
mRNA . . . . . . messenger ribonucleic acid
NGS. . . . . . . . . normal goat serum
NK cell . . . . . . Natural Killer cell
NMS . . . . . . . . normal mouse serum
NP . . . . . . . . . . neuropilin
NP40 . . . . . . . . nonidet P-40
NRbS . . . . . . . normal rabbit serum
O/N. . . . . . . . . over night
PAGE . . . . . . . polyacrylamide gel electrophoresis
PBS . . . . . . . . . phosphate buffered saline
PCI . . . . . . . . . phenol:chloroform:isoamyl alcohol
PCR . . . . . . . . polymerase chain reaction
PE . . . . . . . . . . phycoerythrin
PEG 6000 . . . polyethylene glycol 6000
PFA. . . . . . . . . paraformaldehyde
pI . . . . . . . . . . . isoelectric point
PLP. . . . . . . . . proteolipid protein
PMSF . . . . . . . phenylmethylsulfonyl fluoride
PPD . . . . . . . . purified protein derivate from Mycobacterium tuberculosis
PTX . . . . . . . . pertussis toxin
182 D LIST OF ABBREVIATIONS
pymT . . . . . . . polyoma middle T oncogene
RIPA. . . . . . . . radio immuno precipitation assay
RPMI . . . . . . . Roswell Park Memorial Institute
RT . . . . . . . . . . room temperature
rpm . . . . . . . . . rounds per minute
rzpd . . . . . . . . . Deutsches Ressourcenzentrum fu¨r Genomforschung GmbH,
Berlin, Germany
RNA . . . . . . . . ribonucleic acid
SA . . . . . . . . . . streptavidin
SA/HRP . . . . streptavidin/horseradish peroxidase
SDS . . . . . . . . . sodiumdodecylsulfate
SNL . . . . . . . . . Sambucus nigra lectin
SSP . . . . . . . . . sample spot
Taq . . . . . . . . . Thermophilus aquaticus
tEAE. . . . . . . . transfer experimental autoimmune encephalomyelitis
TBE . . . . . . . . Tris-borate-EDTA
TESPA. . . . . . 3-aminopropyltriethoxysilane
TNF-α . . . . . . tumor necrosis factor α
TOF-MS . . . . time-of-flight mass spectrometry
Tris . . . . . . . . . Tris(hydroxymethyl)aminomethane
tRNA . . . . . . . transfer ribonucleic acid
TJ . . . . . . . . . . tight junction
UTP . . . . . . . . uraciltriphosphate
UTPαS. . . . . . uraciltriphosphate-α-S
VEGF. . . . . . . vascular endothelial growth factor
wt . . . . . . . . . . . wildtype
X-gal . . . . . . . . 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside
E List of figures
1.1.1 Cellular components of the blood-brain barrier . . . . . . . . . . . . 3
1.3.1 Schematic description of the multistep model . . . . . . . . . . . . . 7
1.4.1 Schematic description of chemokine subfamilies . . . . . . . . . . . . 9
2.2.1 active EAE in C57Bl/6 and SJL/N mice . . . . . . . . . . . . . . . . 31
3.1.1 cDNA inserts encoding CC chemokines . . . . . . . . . . . . . . . . . 68
3.1.2 cDNA inserts encoding CXC chemokines and chemokine receptors . . 69
3.1.3 CXCL12 expression in healthy brain of SJL/N mice . . . . . . . . . . 71
3.1.4 CCL19 expression in healthy brain of SJL/N mice . . . . . . . . . . . 72
3.1.5 CCL19 and CCL21 expression in inflamed brain of SJL/N mice . . . 73
3.1.6 Detection of CCL19 and CCL21 on the protein level in healthy and
EAE brain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
3.1.7 Immunoblot of whole brain lysates with CCL19 and CCL21 antisera 75
3.1.8 CCR7 and CXCR3 are present on encephalitogenic T cell blasts . . . 77
3.1.9 L-selectin expression of CTrG labeled encephalitogenic T lym-
phoblasts in vivo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
3.1.10 Encephalitogenic T cells specifically chemotax towards CCL19 and
CCL21 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
3.1.11 Combination of CCL19, CCL21 and CXCL12 does not increase spe-
cific chemotactic efficacy . . . . . . . . . . . . . . . . . . . . . . . . . 81
3.1.12 Transmigration of encephalitogenic T cells across bEnd5 cells towards
CCL21 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
3.1.13 CCL19 and CCL21 are involved in adhesion strengthening of en-
cephalitogenic T cells to inflamed vessels in EAE brain . . . . . . . . 83
183
184 E LIST OF FIGURES
3.1.14 Firm adhesion of encephalitogenic T lymphoblasts after CCL19 de-
sensitization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.2.1 Cluster Analysis of Microarrays . . . . . . . . . . . . . . . . . . . . . 86
3.2.2 In situ hybridization and immunohistochemistry of adhesion
molecules and chemokines in brain sections . . . . . . . . . . . . . . 97
3.2.3 Inflammation of Gr-1 expressing cells during EAE in C57Bl/6 but
hardly in SJL/N mice . . . . . . . . . . . . . . . . . . . . . . . . . . 99
3.2.4 MALII binding on brain sections of EAE afflicted C57Bl/6 mice . . . 100
3.2.5 Lectin binding to bEnd5 endothelioma cell lines . . . . . . . . . . . . 101
3.2.6 Comparison of RNA yield resulting from enzymatic and mechanic
microvessel preparations . . . . . . . . . . . . . . . . . . . . . . . . . 102
3.2.7 2D gel electrophoresis maps showing identified proteins of cerebral
microvessels from EAE afflicted and healthy SJL mice . . . . . . . . 113
3.4.1 Active EAE in C57Bl/6 wildtype and DARC-deficient mice . . . . . 121
3.4.2 Comparison of DARC-deficient and C57Bl/6 mouse brain during EAE122
3.4.3 Proliferation of C57H.MOG T lymphocytes . . . . . . . . . . . . . . 123
3.4.4 DARC-deficient endothelioma line cells . . . . . . . . . . . . . . . . . 124
3.4.5 Full-length DARC cDNA sequence . . . . . . . . . . . . . . . . . . . 124
4.5.1 Model for chemokine involvement in lymphocyte recruitment into the
CNS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
F List of tables
1.4.1 Systematic nomenclature for CXC, CC, C and CX3C chemokines . . 10
2.3.2 Primary antibody, blocking reagent, secondary antibody combinations 39
2.4.1 Plasmids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.1.1 Semiquantitative analysis of the expression of chemokine mRNA dur-
ing EAE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
3.2.1 Regulated genes in cerebral microvessel preparations of C57Bl/6 and
SJL/N mice during EAE . . . . . . . . . . . . . . . . . . . . . . . . . 87
3.2.2 cDNA libraries of cerebral microvessels . . . . . . . . . . . . . . . . . 103
3.2.3 Enriched genes in cerebral microvessel preparations during EAE as
detected by SSH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
3.2.4 Differentially regulated genes during EAE as detected by gene array
analysis and SSH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
3.2.5 Protein expression analysis . . . . . . . . . . . . . . . . . . . . . . . 114
3.3.1 Altered mRNA levels in encephalitogenic vs. non-encephalitogenic
T cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
3.3.2 cDNA libraries of encephalitogenic and non-encephalitogenic T cells . 119
3.3.3 Genes being expressed at higher mRNA levels in encephalitogenic T
lymphoblasts in comparison to non-encephalitogenic T lymphoblasts 120
185
G Lebenslauf
Carsten Alt
Geboren 20. November 1973 in Friedberg/Hessen, Deutschland
Staatsbu¨rgerschaft deutsch
Familienstand ledig
Privatanschrift Feldbergstrasse 5
61200 Wo¨lfersheim
Tel.: 0 6036 982488
Dienstanschrift Max-Planck Institut fu¨r Vaskula¨re Biologie
Abteilung fu¨r vaskula¨re Zellbiologie
c/o ZMBE
Von-Esmarch-Strasse 56
48149 Mu¨nster
Tel.: 0 251 83 57179 (Bu¨ro)
Tel.: 0 251 83 52224 (Labor)
Fax.: 0 251 83 58616
E-Mail: alt@mpi-muenster.mpg.de
1980 – 1983 Grundschule So¨del
1983 – 1984 Mittelpunktschule Wo¨lfersheim
1984 – 1993 Augustinerschule Friedberg
16.06.1993 Allgemeine Hochschulreife
1993 – 1994 Wehrdienst in Stadtallendorf
186
187
1994 – heute Studium der Humanbiologie an der Philipps-
Universita¨t, Marburg
15.10.1996 Vordiplom in Humanbiologie
1998 – 1999 Diplomarbeit am Max-Planck Institut fu¨r physiologis-
che und klinische Forschung / W. G. Kerckhoff Institut
in Bad Nauheim unter Leitung von Prof. Dr. Werner
Risau † / Prof. Dr. Britta Engelhardt
Thema: ”Die Rolle von Chemokinen bei der Rekru-
tierung von T-Lymphozyten durch die endotheliale
Blut-Hirn-Schranke.”
30.09.1999 Diplom in Humanbiologie
1999 – heute Doktorarbeit am Max-Planck Institut fu¨r physiologis-
che und klinische Forschung / W. G. Kerckhoff Institut,
Bad Nauheim und Max-Planck Institut fu¨r vaskula¨re
Biologie, Mu¨nster unter Leitung von Prof. Dr. Werner
Risau † / Prof. Dr. Dietmar Vestweber / Prof. Dr. Britta
Engelhardt
Thema: ”Die Rolle von Chemokinen bei der Rekru-
tierung von Leukozyten durch die Blut-Hirn-Schranke.”
H Akademische Lehrer
Meine akademischen Lehrer in Marburg waren die Damen und Herren:
Aurich, Beato, Braun, Clauss, Daut, Dressler, Elbel, Elsa¨sser, Engelhardt, Feuser,
Fruhstorfer, Garten, Habermehl, Hasilik, Hartmann, Heeg, Kern, Kindl, Kirch-
ner, Klenk, Koolman, Lill, Lo¨ffler, Lu¨hrmann, Mazumdar, Mu¨eller, Risau, Ro¨hm,
Scha¨fer, Schulz, Schwee, Seitz, Seitz, Steinmetz, Suske, Thomas, Voigt, von Lo¨w,
Weihe, Westphal.
188
I Danksagung
An allererster Stelle gilt mein Dank Frau Prof. Dr. Britta Engelhardt fu¨r die Betreu-
ung meiner Doktorarbeit. Ihre sta¨ndige Bereitschaft, Probleme zu analysieren und
Ergebnisse zu diskutieren, sowie ihre motivierende Art, haben entscheidend zum
Erfolg dieser Arbeit beigetragen.
Herrn Prof. Werner Risau † gilt mein Dank fu¨r das Schaffen der exzellenten
Laborbedingungen, unter denen diese Arbeit durchgefu¨hrt werden konnte. Deswei-
teren gilt mein Dank Herrn Prof. Dietmar Vestweber, daß ich sie in seinem Labor
beenden durfte.
Fu¨r die großartige Zusammenarbeit mit den Mitarbeitern des Labors in Bad
Nauheim bedanke ich mich bei Gabi Hoch, Katharine Ling und Ruth Lyck. Ins-
besondere gilt mein Dank Irene Ku¨chenmeister fu¨r ihre enorme Geduld bei den
Injektionen; Monika Rieschel, dafu¨r, daß in der Zellkultur immer alles mit rechten
Dingen zuging und ich immer wußte, welcher Tag es war; Veronika Schmidt fu¨r das
gute Ru¨cken-an-Ru¨cken Arbeiten, Martina Schulz fu¨r ihre Hilfe in allen histologis-
chen Fragen und Silke Tauber fu¨r die Einfu¨hrung in den Umgang mit transgenen
Ma¨usen. Den Ma¨dels aus dem Labor Breier gilt mein Dank fu¨r die freundliche
Aufnahme als Gastarbeiter wa¨hrend der in situ Hybridisierungen.
Bei denjenigen, die den Umzug nach Mu¨nster mitgemacht haben, bedanke ich
mich bei Jo¨rg Kraus dafu¨r, daß mir sein su¨dla¨ndisches Temperament bis nach
Mu¨nster erhalten blieb, bei Stefanie Merfeld-Clauss fu¨r die angenehme Gesellschaft
wa¨hrend diverser Wochenendheimfahrten und bei Melanie Laschinger fu¨r die vielen
konstruktiven Diskussionen.
In Mu¨nster gilt mein Dank Axinia Do¨ring, Anne Erpenbeck-Leuer, Birgit
Kleingers, Carsten Minten, Brit Neuhaus, Irene Patzak, Chiara Uboldi, Gaby Ver-
berk und Barbara Waschk fu¨r die gelungene Zusammenarbeit.
Allen weiteren Mitarbeitern, die ich nicht namentlich erwa¨hnen konnte, sei an
189
190 I DANKSAGUNG
dieser Stelle mein Dank ausgesprochen.
Astra-Zeneca gilt mein Dank fu¨r die Unterstu¨tzung dieser Arbeit, insbesondere
sei die konstruktive Zusammenarbeit mit Maria Anvret, Kristina Duvefelt, Anders
Ericsson-Dahlstand, Bosse Franze´n und Dan Sunnemark erwa¨hnt.
Ebenso mo¨chte ich mich bei Herrn Dr. Peter Vajkoczy fu¨r die gemeinsame
Durchfu¨hrung der intravitalmikroskopischen Versuche bedanken.
Herrn Dr. Urban Deutsch gilt mein Dank dafu¨r, daß er stets ein offenes Ohr
fu¨r Fragen hatte und mich an seinem schier unbegrenzten molekularbiologischem
Wissen teilhaben ließ.
Herrn Dr. Hannes Drexler sei an dieser Stelle mein Dank dafu¨r ausgesprochen,
daß er immer bereit war, biochemische Fragen zu diskutieren und half, mo¨gliche
Lo¨sungen zu finden.
Bei Herrn Dr. Friedemann Kiefer mo¨chte ich mich fu¨r viele ertragreiche Diskussio-
nen bedanken, insbesonders sei hier die Hilfe in RNA-pra¨parativen Fragestellungen
erwa¨hnt.
Zu guter Letzt gilt mein Dank meinen Eltern, ohne deren Unterstu¨tzung es mir
niemals mo¨glich gewesen wa¨re, diese Arbeit durchzufu¨hren.
J Ehrenwo¨rtliche Erkla¨rung
Ich erkla¨re ehrenwo¨rtlich, daß ich die dem Fachbereich Medizin Marburg zur
Promotionspru¨fung eingereichte Arbeit mit dem Titel ,,Die Rolle von Chemokinen
bei der Rekrutierung von Leukozyten durch die Blut-Hirn Schranke” in dem Max-
Planck-Institut fu¨r klinische und physiologische Forschung / Kerckhoff-Institut, Bad
Nauheim unter Leitung von Prof. Dr. Werner Risau † und dem Max-Planck-Institut
fu¨r vaskula¨re Biologie, Mu¨nster unter Leitung von Prof. Dr. Dietmar Vestweber
mit Unterstu¨tzung durch Prof. Dr. Britta Engelhardt ohne sonstige Hilfe selbst
durchgefu¨hrt und bei der Abfassung der Arbeit keine anderen als die in der
Dissertation angefu¨hrten Hilfsmittel benutzt habe. Ich habe bisher an keinem
in- und ausla¨ndischen Medizinischen Fachbereich ein Gesuch um Zulassung zur
Promotion eingereicht noch die vorliegende oder eine andere Arbeit als Dissertation
vorgelegt. Auszu¨ge aus der vorliegenden Arbeit wurden, bzw. werden wie folgt
vero¨ffentlicht:
Original-Publikationen:
Alt, C. & Laschinger, M. & Engelhardt, B., 2002, ,,Functional expression of the
lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier
suggests their involvement in G-protein-dependent lymphocyte recruitment into
the central nervous system during experimental autoimmune encephalomyelitis”,
Eur. J. Immunol., 32(8), 2133-2144.
Alt, C. & Duvefelt, K. & Franze´n, B. & Yang, Y. & Engelhardt, B., 2003,
,,Gene and protein expression profiling of cerebral microvessels in experimental au-
toimmune encephalomyelitis in C57Bl/6 and SJL mice”, zur Publikation eingereicht.
,,Abstract”-Publikationen:
Alt, C. & Engelhardt, B., ,,Expression of ELC (CCL19) and SLC (CCL21) at the
191
192 J EHRENWO¨RTLICHE ERKLA¨RUNG
blood-brain barrier during experimental autoimmune encephalomyelitis suggest
their involvement in lymphocyte recruitment into the central nervous system”, Im-
munobiology, 204(1–2), 32, zum Postervortrag ausgewa¨hlt auf der 32. Jahrestagung
der Deutschen Gesellschaft fu¨r Immunologie in Dresden vom 26. – 29. September
2001.
Alt, C. & Engelhardt, B., ,,Distinct expression patterns of chemokines in the
CNS during active experimental autoimmune encephalomyelitis”, Immunobiol-
ogy, 206(1–3), 157, zum Postervortrag ausgewa¨hlt auf der 33. Jahrestagung der
Deutschen Gesellschaft fu¨r Immunologie in Marburg vom 25. – 28. September 2002.
Vortra¨ge und Poster:
Alt, C. & Engelhardt, B., ,,Involvement of chemokines in the recruitment of T cells
across the endothelial blood-brain barrier”, pra¨sentiert auf dem 8th Symposium of
the Adhesion Workshop / German Society for Immunology in Mu¨nster vom 17. –
18. Juli 2000.
Alt, C. & Laschinger, M. & Engelhardt, B., ,,Expression of the lymphoid chemo-
kines CCL19 (ELC) and CCL21 (SLC) at the blood-brain barrier suggests their
involvement in G-protein-dependent lymphocyte recruitment into the CNS during
experimental autoimmune encephalomyelitis”, pra¨sentiert auf der Gordon Research
Conference on Chemotactic Cytokines in South Hadley, MA, USA vom 7. – 12. Juli
2002.
Alt, C. & Duvefelt, K. & Franzen, B. & Engelhardt, B., ,,Gene and protein
expression profiling of blood-brain barrier microvessels during active experimental
autoimmune encephalomyelitis in C57Bl/6 and SJL/N mice”, zum Postervortrag
ausgewa¨hlt auf der 5th International Conference of Cerebral Vascular Biology in
Amarillo, TX, USA vom 15. – 19. Juni 2003.
Alt, C. & Duvefelt, K. & Franzen, B. & Engelhardt, B., ,,Gene and protein
expression profiling of cerebral microvessels during active experimental autoimmune
encephalomyelitis in C57Bl/6 and SJL/N mice”, zum Postervortrag ausgewa¨hlt auf
dem 3rd Symposium on Vascular Biology in Mu¨nster vom 08. - 10. Oktober 2003.
So¨del, den 10.12.2003 Carsten Alt
